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Steroid hormones, acting via their cognate receptors, are key players in
fundamental reproductive events: implantation and endometrial bleeding. To
understand local mechanisms regulating function and the effect of pharmacologic
modulation it is essential to have an understanding of factors regulating ligand
availability and steroid receptor expression in the physiological state and after
pharmacologic manipulations.
This thesis encompasses studies analysing expression of steroid metabolising
enzymes (intracrinology) and steroid receptor expression in human endometrium
after three different pharmacologic manipulations.
1. Endometrium exposed to a GnRH antagonist during controlled ovarian
hyperstimulation
Mid-luteal phase endometrial biopsies were obtained from oocyte donors
undergoing ovarian stimulation and from control women with regular
periods. Immunohistochemistry and real-time quantitative polymerase chain
reaction (QRT-PCR) were used to compare protein and mRNA expression
of sex steroid receptors and steroid metabolising enzymes. Significant
alterations in the expression of sex-steroid receptors and their metabolizing
enzymes were demonstrated. These changes may lead to alterations in the
activity and intracellular availability of estrogens, progestogens and
androgens in endometrium of women treated with a GnRH antagonist
during controlled ovarian hyperstimulation. Their impact on embryo
implantation merits further evaluation.
2. Endometrium exposed to hormone replacement therapy (HRT)
Endometrial biopsies from postmenopausal women not using HRT and
from HRT users were collected during and outside unscheduled bleeding
episodes. Immunohistochemical analysis of endometrial sex steroid
receptors was performed and the relationship between expression and
bleeding patterns studied. Despite the predominantly progestational effect
of continuous combined HRT used in the study, the steroid receptor
expression in the postmenopausal endometrium differed from that seen in
the premenopausal secretory phase of menstrual cycle and after long-term
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progestogen-only administration, suggesting that different local
mechanisms are involved in HRT-related unscheduled bleeding.
3. Endometrium exposed to intrauterine delivery of a progesterone receptor
antagonist
Women were randomised to intrauterine administration of either the
antigestogen, ZK230211 (ZK-IUS) or Levonorgestrel (LNG-IUS) prior to
hysterectomy. Endometrium was obtained from hysterectomy specimens.
Bleeding patterns, endometrial morphology and content of ZK230211 were
evaluated. Expression of sex steroid receptors, proliferation markers;
phosphorylated Histone 3 (PH3) and Ki-67, and Insulin-like Growth Factor-
Binding Protein-1 (IGFBP-1) were evaluated by immunohistochemistry
(IHC). Administration of the antigestogen demonstrated novel effects such
as an absence of IGFBP-1 and increase in progesterone receptor expression.
These results suggest that intrauterine administration of an antigestogen is
feasible and trials need to be undertaken to test clinical efficacy.
These studies, in pre and postmenopausal women, demonstrate that endometrial
sex steroid receptor expression and enzymes determining intracellular steroid
(ligand) availability are modulated by exogenous steroid manipulation.
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The endometrium is a target organ for steroid hormones such as estrogens and
progesterones. These regulate the development and function of the human
endometrium. There is an increasing appreciation of the fact that other steroid
hormones such as androgens and glucocorticoids play important roles in the varied
functions of the endometrium such as menstruation and repair and embryo
implantation. It is also being recognised that the activity of the various steroid
hormones is directly or indirectly responsible for endometrial pathology that is
likely to be the underlying cause for a variety of clinical conditions inter alia
infertility, breakthrough bleeding and recurrent miscarriages. This thesis mainly
describes data relating to steroid receptor expression after pharmacological
manipulation of the endometrium in the context of three clinical scenarios namely
embryo implantation in assisted conception cycles, effects of postmenopausal
hormone replacement therapy and use of a progesterone antagonist for the
treatment of heavy menstrual bleeding. Through a summary of the published data
and new results based on our studies, we hope to gain further understanding of the
effects of steroid hormones and the modulation of steroid receptor expression on
human endometrium.
For successful conception, embryo implantation requires the presence of an
optimum state of endometrium. This optimum state is believed to occur during a
short window of time in the mid-secretory phase; commonly described as the
'window of implantation'. The endometrial characteristics that are present in this
crucial window are a result of a complex interplay of multiple factors. Because of
extensive circumstantial evidence, there is little doubt in stating that the sex
steroids and their receptor modulation play a central role in the processes involved
leading up to the ideal conditions required for successful implantation. With the
onset of IVF/ICSI treatments in the last three decades, an understanding of this
topic has no longer remained an academic necessity but an urgent clinical need. A
clear understanding and then a beneficial manipulation of the endometrium at this
crucial time could, potentially, lead to improved pregnancy rates. Chapter 4 of this
thesis details the current understanding of the endometrial intracrinology and its
relationship to steroid receptor expression and, based on new data, proposes further
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explanations of their role in embryo implantation in the context of use of
Gonadotrophin Releasing Hormone antagonists (GnRHantag).
Menopause in women leads to wide ranging changes involving all body systems.
Postmenopausal hormone replacement therapy (HRT) was, until recently, thought
by some to be a panacea for all menopausal problems in women. Increasing
experience with current HRT regimes has proved this to be far from the truth. An
increasing awareness of the various side effects of HRT use has provoked a
complete rethink on the role of HRT in managing menopause. Nonetheless, there is
little doubt that in carefully selected women HRT use can significantly alleviate the
menopausal vasomotor symptoms and provide other benefits such as bone
protection and cardiovascular protection. However a significant proportion of
women on HRT will suffer from breakthrough bleeding forcing them to stop the
use of HRT. A clear understanding of the mechanisms involved in postmenopausal
breakthrough bleeding could not only help us devise better treatment regimes but
could also help solve a long standing biological and clinical conundrum - that of
progesterone related breakthrough bleeding. Chapter 5 describes our current
understanding of processes related to steroid hormone expression with a special
focus on their relationship to postmenopausal breakthrough bleeding.
Among all gynaecological outpatient referrals, the commonest reason is for
treatment of heavy menstrual bleeding and other menstrual disorders. Among the
range of medical therapies developed, progestogens, plays a major part in treating
menstrual disorders. Whilst oral progestogens have been shown to be less effective
in reducing menstrual blood loss, the Levonorgestrel - releasing Intra Uterine
System (LNG-IUS) has shown excellent results in treating heavy menstrual
bleeding. Initially introduced as a contraceptive, currently, in Europe, more women
use it for relief of menstrual disorders. However just like any progesterone
derivative, breakthrough bleeding remains a clinically significant side effect.
Progesterone antagonists (PA) have been known to cause amenorrhoea without the
unwanted side effects of breakthrough bleeding. Whilst oral Mifepristone has been
tested in humans, a Progesterone Antagonist - IUS (PA-IUS) has, till date, not
been trialled. Animal studies have shown promising results with several PAs and
for the first time, a proof of concept study using a PA-IUS was performed in
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women suffering from menstrual disorders. Chapter 6 describes the background
understanding of this emerging area of high clinical importance with a special
emphasis on endometrial markers in the presence of a PA-IUS.
The literature review that follows will expand on the background and the published
data relevant to these three clinical scenarios with a particular emphasis on
endometrial steroid receptor modulation. It will also propose avenues of future
research and possible clinical applications.
1.2 Hypothalamo-Pituitary-Ovarian axis
Neurons that produce the Gonadotrophin Releasing Hormone (GnRH) originate in
the olfactory area and during embryogenesis migrate along cranial nerves to finally
reside in the arcuate nucleus of the hypothalamus (Speroff and Fritz, 2005). GnRH
is secreted in a pulsatile manner by these neurons from the hypothalamus.
Feedback from target gland hormones, pituitary hormones and from GnRH itself,
modify the release of further GnRH through an array of neurotransmitters including
dopamine, norepinephrine, epinephrine, endorphin, serotonin and melatonin. Once
released it is then transported through the hypophyseal portal circulation to reach
the putative target sites on the gonadotrope cells in the anterior pituitary. GnRH has
a half-life of 2-4 minutes. Because of this rapid degradation, combined with the
enormous dilution on entry into the peripheral circulation, biologically effective
amounts of GnRH do not escape the portal system. Therefore, control of the
reproductive cycle depends on constant release of GnRH (Speroff and Fritz, 2005).
GnRH acts on the gonadotrope cells of the pituitary. In the gonadotrope cells,
GnRH binds to G protein coupled receptors and initiates a series of physiological
events leading to the synthesis and release of gonadotrophins; Follicle Stimulating
Hormone (FSH) and Luteinizing Hormone (LH) in a highly coordinated fashion
(Ramakrishnappa et al., 2005). The GnRH receptors are regulated by many agents
including GnRH itself, inhibin, activin and sex steroids (Kaiser et al., 1997).
Binding of GnRH to its receptor in the pituitary activates multiple messengers and
responses. The immediate response is the secretion of gonadotrophins while the
delayed response is partly responsible for the large surge of gonadotrophins at
midcycle. The delayed response, which ultimately leads to a surge in
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gonadotrophins midcycle, requires estrogen exposure and can be augmented by
progesterone (Speroff and Fritz, 2005). Both FSH and LH are released from the
gonadotrope cells in a pulsatile manner into the systemic circulation. They in turn
control the processes of gametogenesis and steroidogenesis in the ovary as detailed
in section 1.2.2.
Negative feedback loops ensure control of further hormone secretions. Estrogen
and high levels of progesterones inhibit GnRH pulses in the hypothalamus. In the
proliferative phase, estradiol and inhibin - B suppress the release of FSH. In the
luteal phase; progesterone, estradiol and inhibin-A act centrally to suppress
gonadotrophins and new follicular growth (Speroff and Fritz, 2005) (Figures 1.1 (a)
& (b)).
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Figure 1.1(a) Schematic representation of the crucial events in the Hypothalamo-
Pituitary-Ovarian (HPO) axis.
(B) Events in ovary Ovulation Corpus luteum
(C) Ovarian hormones Progesterone
0 5 10 15 20 25
Day of menstrual cycle
FSH - mlU/ml; LH - mlU/ml; Estrogen - pg/ml; Progesterone - ng/ml
Figure adapted from DevBio - A companion to Developmental Biology
(2006) (8th Ed), by Scott F Gilbert




1.2.1 Role of Gonadotrophin Releasing Hormone
Human Gonadotrophin Releasing Hormone (GnRH) is a decapeptide with 10
amino acids. GnRH acts through the GnRH receptor. Three types of GnRH
receptors have been identified in the vertebrates (Troskie et al., 1998). GnRH
receptor Type II is found in the humans and is widely expressed in the central
nervous system and in reproductive tissues. It is also present in the gonadotropes in
the anterior pituitary and hence it is believed that most of the GnRH mediated
reproductive functions are modulated through this receptor type (Millar et al.,
2001). GnRH is also known to have an autocrine - paracrine function throughout
the body.
In relation to the reproductive system, GnRH receptors have been found in several
extra-pituitary sites like the ovary, breast, placenta, fallopian tubes and human
endometrium (Ramakrishnappa et al., 2005). Because of its widespread presence, it
is believed that GnRH has a role to play in wide ranging clinical situations like
reproductive cancers, infertility and potentially in male and female contraception.
The principal function of GnRH involves the stimulation of gonadotrope cells in
the anterior pituitary leading to the secretion of FSH and LH. GnRH is known to
stimulate the secretion of both FSH and LH, but there is ongoing debate regarding
the exact mechanisms involved in the way one releasing hormone leads to the
secretion of two gonadotrophins. One possible mechanism is related to the pulse
frequencies of GnRH release. High GnRH pulse frequencies (one pulse every 30
minutes) favour LH synthesis whereas low GnRH pulse frequencies (one pulse
every 120 minutes) favour FSH synthesis (Kaiser et al., 1997). Whilst other
mechanisms to explain this phenomenon have been proposed, it is interesting to
note that a possibility of a separate FSH releasing factor has been postulated
(Padmanabhan and McNeilly, 2001).
1.2.1.1 GnRH and Infertility
Pulsatile GnRH is used for ovulation induction in women with hypogonadotrophic
hypogonadism. However it is the use of GnRH analogues, GnRH antagonists and
gonadotrophins that has revolutionized the treatment protocols in assisted
conception. Continuous stimulation with GnRH analogues leads to an initial flare
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up followed by prolonged suppression of gonadotropins and this in turn leads to a
fall in levels of sex steroids.
Premature LH surges were responsible for the cancellation of a large number of In-
vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) treatment cycles.
With the introduction of treatment strategies to prevent premature LH surges, the
cycle cancellation rate has been significantly reduced and IVF/ICSI success rates
have significantly improved (Hughes et al., 1992). GnRH analogues (Hughes et al.,
1992) and more recently GnRH antagonists (Albano et al., 2000) have been shown
to reliably prevent premature LH surges and these have been increasingly
employed to achieve this goal. As described later, in comparison to the use of
GnRH analogues, there are several advantages of using GnRH antagonists for this
purpose. However, with the use of GnRH antagonists, there are concerns of
reduced pregnancy rates (Al-Inany et al., 2006).
The clinical pregnancy rates in IVF/ICSI treatment cycles are approximately 25%.
A recent meta-analysis comparing (calculated) live birth rates in GnRH agonist and
GnRH antagonist treated cycles found a non-significant drop of 2.7% in the live
birth rates in GnRH antagonist cycles. However the study authors did conclude that
'If the observed non-significant difference in live birth rates of 2.7% represents the
true difference present in the population, it is likely that this will become significant
CP < 0.05) with the addition of more comparative studies' (Kolibianakis et al.,
2006). The reasons for this putative drop in pregnancy rates are unclear. Whilst
GnRH analogues and GnRH antagonists influence steroidogenesis through their
suppression of gonadotrophin levels, it is possible that they have some direct
effects through their actions on the GnRH receptor. Not surprisingly, a possible
role of the GnRH receptor in embryo implantation related processes has been
postulated (Casan etal., 1998).
1.2.2 Role of Gonadotrophins
FSH and LH are hormones released from the gonadotrope cells of the anterior
pituitary. In the human preantral and antral follicles, LH receptors are present only
on the theca cells and FSH receptors only on the granulosa cells (Kobayashi et al.,
1990; Yamoto et al., 1992). The sequence of events responsible for follicular
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growth, maturation, ovulation and the development and regression of corpus
luteum are complex. As per the widely accepted two-cell two-gonadotrophin
hypothesis, FSH stimulates the granulosa cells in the developing follicle in the
ovary and through aromatization of androgens, leads to the synthesis and secretion
of estrogen (Figure 1.2). FSH stimulation propels the primordial follicle to the
preantral stage. LH stimulates the theca cells in the ovarian follicle. The cholesterol
within the theca cells is then converted to androgens. The androgens produced
within the theca cells then diffuse into the granulosa cells where, through FSH-
induced aromatization, they are converted to estrogens (Erickson, 1996; Kobayashi
et al, 1990). The FSH and LH activity is mediated through their respective
receptors. In the preantral and antral follicle, FSH receptors are only present on the
granulosa cells and LH receptors are only present in the theca cells (Kobayashi et
al., 1990; Yamoto et al., 1992). As the granulosa cells respond to FSH, further
proliferation and growth of the granulosa cells is associated with an increase in
FSH receptors. With progressive maturation of the follicle, the preovulatory follicle
produces increasing amounts of estrogen. During the late proliferative phase,
estrogens rise rapidly, reaching a peak approximately 24-36 hours prior to
ovulation (Pauerstein et al., 1978). The onset of the pre-ovulatory LH surge occurs
when the peak levels of estradiol are achieved (Fritz et al., 1992). Ovulation is
thought to occur about 34-36 hours after the onset of the LH surge and about 10-12
hours after the LH peak. Following ovulation, continued LH stimulation is
responsible for the maintenance of the corpus luteum, with corpus luteum being the
main source of progesterone.
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Figure 1.2 Diagram illustrating the activity of the gonadotropins on the ovarian
follicle
(Adapted from Speroff and Fritz, 2005)
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1.2.3 Controlled Ovarian Hyperstimulation
Although the first conception through IVF was in a natural cycle (Steptoe and
Edwards, 1978) it soon became evident that this strategy was a very inefficient way
of achieving significant pregnancy rates (Jones et al., 1982). Successful in-vitro
fertilization (IVF) requires the generation of a number of healthy embryos plus
adequate priming and maintenance of a receptive endometrium. Both of these
factors are influenced by ovarian stimulation regimes and are responsive to
endocrine manipulation. Exogenous gonadotrophins are essential for standard
ovulation induction as well as controlled ovarian hyperstimulation in IVF. The first
available preparation was human menopausal gonadotrophin (hMG) that contained
75 IU follicle stimulating hormone (FSH) and 75 IU luteinizing hormone (LH), but
the majority (> 90%) of the protein content of these preparations consisted of
gonadotrophin-unrelated urinary proteins. Thus, during a typical ovarian
stimulation cycle with hMG, several milligrams of non-relevant proteins are
administered that can result in unwanted side effects including allergic or other
hypersensitivity reactions. The next generation of gonadotrophins were the purified
urinary FSH or urofollitrophins containing very little LH and non-relevant proteins.
This was followed by highly purified urinary FSH containing only traces ofLH and
finally by the 'pure' preparation of recombinant human FSH. HMG, urinary FSH
(uFSH) and recombinant FSH (rFSH) preparations have been used successfully for
controlled ovarian hyperstimulation in IVF cycles. Although the fast introduction
of rFSH was market driven, its purity, batch-to-batch consistency and availability
made it an attractive alternative to the urinary FSH products (Macklon et al., 2006).
The purity and batch-to-batch consistency achieved with rFSH had raised hopes of
improved outcomes in IVF but disappointingly this has not been proven by trials.
Furthermore rFSH is more expensive than uHMG. Hence many units are reverting
to the uHMG in IVF cycles. Introducing controlled ovarian hyperstimulation
resulted in multi-follicular development and the numbers of retrieved oocytes
increased. Premature LH surges during natural or stimulated IVF cycles were
responsible for a significant proportion of cycle cancellations. Hence strategies had
to be developed to reliably prevent premature LH surges. With the introduction of
GnRH agonists in IVF cycles, the incidence of premature LH surges reduced
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drastically. This led to a rise in the numbers of retrieved oocytes, number of
embryo transfers and evidently in better pregnancy rates (Droesch et al., 1989). For
many years GnRH agonists remained the preferred agents for suppression of
premature LH surges but more recently GnRH antagonists have been introduced in
clinical practice and the diagram below depicts their mechanism of action (Figure
1.3). Various treatment regimes have been evaluated but the one most widely used
is the so called 'long protocol' with the use of a GnRH analogue (Figure 1.4).
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Figure 1.3 Schematic diagram demonstrating activity of GnRH, GnRH agonist and
antagonist on the pituitary gonadotroph cells
A: Effects of GnRH stimulation on release of gonadotrophins
B: Effects of GnRH agonist stimulation on release of gonadotrophins

































This protocol involves starting a GnRH agonist in the mid-luteal stage of a cycle
followed by daily administration for approximately 12-14 days. Once pituitary
downregulation is achieved, daily injections of urinary or recombinant FSH are
commenced. Serial scans are carried out to monitor follicular growth and once at
least 3 follicles reach a size of 17 to 18mm, follicular maturation is triggered by a
single injection of hCG. Oocytes are retrieved after a period of 34 to 35 hours and
IVF/ICSI is carried out. Fertilized embryo(s) or blastocyst(s) are replaced into the
endometrial cavity, 2 to 3 days or 5 days after oocyte retrieval respectively. With
the use of a GnRH agonist, the average length of a treatment cycle is longer, the
amount of gonadotrophins used is higher (Ben-Rafael et al., 1991) and the risk of
ovarian hyperstimulation syndrome is greater (Rizk and Smitz, 1992). Furthermore
during the phase of pituitary desensitization, there is a period of estrogen
deprivation leading, in some women, to menopausal side effects like hot flushes,
vaginal dryness and headaches. GnRH antagonist use bypasses some of these
disadvantages.
1.2.3.1 Gonadotrophin Releasing Hormone Antagonists (GnRH antag)
As described in section 1.2.1, GnRH is a 10 amino acid peptide secreted in a
pulsatile manner by the hypothalamus. GnRH binds to a specific receptor in the
pituitary cells to regulate the secretion of FSH and LH. After binding with the
receptor, the GnRH-receptor complex elicits several (calcium-dependent) reactions
to release FSH and LH (Olivennes et al., 2002).
Recently available GnRH antagonists are GnRH molecules with amino acid
modifications at positions 1, 2, 3, 6 and 10. They immediately block the GnRH
receptor in a competitive fashion and hence reduce LH and FSH secretion within a
period of 8 hours (Olivennes et al., 2002). The inhibition of LH secretion is more
pronounced than that of FSH, this being most likely due to the different forms of
gonadotrophin regulation, the prolonged FSH half-life or the immunoactive and
bioactive forms of FSH (Matikainen et al., 1992).
GnRH antagonists were introduced in clinical practice in the early 1990's
(Frydman et al., 1992). They were shown to reliably prevent premature LH surges.
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Cetrorelix was the first clinically available GnRH antagonist (Reissmann et al.,
2000).
In a GnRH antagonist treatment cycle, urinary or recombinant FSH is started in the
early follicular phase. Follicular growth is monitored by serial ultrasound scans. In
the mid-follicular phase, once the follicles reach a size of 11 or 12mm, GnRH
antagonist is commenced to suppress premature LH surge. Once the follicles reach
a size of 17 or 18mm, maturation of the follicles is triggered by a single injection of
hCG. Oocytes are retrieved after a period of 34 to 35 hours and IVF/ICSI is carried
out. Fertilized embryo(s) or blastocyst(s) are replaced into the endometrial cavity 2
to 3 days or 5 days respectively, after oocyte retrieval (Figure 1.5).
There are several advantages with the use of GnRH antagonists over GnRH
agonists. These are namely; shortened duration of treatment cycle, reduction in the
amount of gonadotrophins used, avoidance of hypo-estrogenic side effects and a
likely reduction in the incidence of ovarian hyperstimulation syndrome (Al-Inany
et al., 2006). However, with the use of GnRH antagonists, there are concerns of
reduced pregnancy rates (Al-Inany et al., 2006). Hence before GnRH antagonists
can replace GnRH agonists in IVF/ICSI treatment cycles, it is vital that we
understand the impact of GnRH antagonists on the endometrium in relation embryo
implantation. A thorough understanding of the endometrial characteristics under
the influence ofGnRH antagonists would not only help us understand the processes
related to embryo implantation but may also help us devise treatment strategies to
reduce the detrimental effects of the hormonal manipulation on the endometrium
during IVF/ICSI cycles.
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1.2.4 Steroidogenesis and Steroid Hormones Mechanism of action
The ovary and the adrenals are the classical steroidogenic organs. The steroid
hormones and particularly the sex steroids, estrogen and progesterone are released
from the ovary. The ovary and the adrenals are the source of the androgens. These
hormones in turn act on the endometrium which is the main steroid responsive
tissue.
Within the ovary, the theca and the granulosa cells in the developing ovarian
follicle are the steroid producing cells. The ovarian steroidogenesis and its control
are described in section 1.2.2.
Adrenal glands are the main source of androgens. The adrenal gland is divided into
the medulla and cortex. The adrenal cortex is further divided into 3 zones; the outer
zona glomerulosa, the zona fasciculate and the inner reticularis. Adrenal androgens
are thought to be secreted from the reticularis zone. The adrenal androgens include;
testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone
(DHEA) and DHEA-sulphate (DHEAS). The mechanism of control of androgen
secretion is unknown but is thought to be partly related to the Adrenocorticotrophic
Hormone (ACTH) secretion (Mckenna and Cunningham, 1991).
The glucorticoids e.g. Cortisol and corticosterone are secreted from the inner 2
zones. Cortisol secretion from the adrenals is controlled by ACTH. ACTH is
known to be under very sensitive negative feedback control from Cortisol, but no
such mechanism is thought to exist for adrenal androgens. Therefore it would
appear that ACTH plays a role in regulation of adrenal androgens secretion but in
conjunction with other factors including prolactin, growth hormone, insulin, sex
steroids and a cortical androgen stimulating hormone has been proposed (McKenna
etal., 1997).
1.2.4.1 Steroid Hormones Mechanism of Action
The steroid ligands classically bind to nuclear receptors, initiating a genomic
response (Figure 1.6). The nuclear receptors are principally ligand-inducible
transcription factors whose primary function is to mediate the transcriptional
response in target cells to hormones such as sex steroids (androgens, estrogens and
progestins), adrenal steroids (glucocorticoids, mineralocorticoids) and a variety of
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other hormones and metabolic ligands. These protein receptors constitute the
Nuclear Receptor Superfamily (Aranda and Pascual, 2001). Members of the
Nuclear Receptor Superfamily are divided into 3 subclasses: Type I ('Classical'
receptors including AR, PR, ER, GR and Mineralocorticoid receptor), Type II
(Thyroid, Retinoic acid and Vitamin D3 receptors) and Orphan receptors with
unknown ligands (Aranda and Pascual, 2001). The effects of nuclear receptors on
transcription are mediated through recruitment of co-regulators. A subset of
receptors binds co-repressor factors and actively represses target gene expression in
the absence of ligand. However, upon ligand binding, the receptors undergo a
conformational change that allows the recruitment of multiple co-activator
complexes. Recruitment of co-activator complexes to the target promoter causes
chromatin decompactation and transcriptional activation (Aranda and Pascual,
2001). The characterization of co-repressor and co-activator complexes, in concert
with the identification of the specific interaction motifs in the receptors, has
demonstrated the existence of a general molecular mechanism by which different
receptors elicit their transcriptional responses in target genes.
More recently a further non-genomic action for sex steroids has been recognised. In
contrast to genomic responses, non-genomic responses are rapid and their response
is not inhibited by agents that inhibit transcription or translation e.g. actinomycin-D
or cyclohexamide.
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1.3 Intracrinology
Human endocrinology traditionally describes the effects of hormones in relation to
their source and their sites of actions. This complex system is controlled by
endocrine, paracrine, autocrine and the most recently described intracrine
regulation. Classic endocrine systems secrete steroid hormones from the endocrine
glands and these are then transported through the systemic circulation to target
cells in peripheral tissues. Paracrine systems cause hormone activity on adjacent
cells after the release of hormone in the extra cellular space. Autocrine effects refer
to actions of the hormone on the same cell as it was released from. Intracrinology
refers to the influence of the hormone within the same cell without release into the
extra cellular space.
The term Tntracrinology' was first coined by Labrie and colleagues (Labrie el al.,
1988). This important phenomenon conceptualises that the peripheral target tissues
such as the endometrium have autonomous control over sex steroid formation and
metabolism as per their requirements. Figure 1.7 highlights the intracellular
metabolic pathways in the production of sex steroids and the enzymes responsible
for their production. In the female, estrogen and progesterone are the main
biologically active sex steroids with androgens of presumed secondary importance.
The main source of these sex steroids is the ovary, the cyclical production in the
ovary being under the control of FSH and LH. After release from the ovary sex
steroids are transported to their target site, the endometrium. Whilst some of the
intracellular sex steroids in the endometrium could be sourced from the ovary, it is
interesting to note that the most abundant sex steroids in the systemic circulation,
dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEA-S)
are both synthesised in large quantities by the adrenal glands under the effect of
ACTH. It is these large reservoirs of inactive sex steroids that provide the
precursors for conversion into biologically active sex steroids, estrogen and
progesterone within the target cell. The target cell responses to steroid hormones
are dependent on the target cell concentration of steroid and their binding affinity
to the respective receptors. After binding of the ligand, gene transcription is
activated thereby leading to the effects of the steroid hormones. Apart from
receptor concentration, a key regulatory factor in steroid action is the intracellular
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steroid concentration. A significant factor that could affect intracellular steroid
concentration is the level and localisation of steroid metabolising enzymes.
Hydroxysteroid dehydrogenases (HSDs) regulate ligand access to nuclear receptors
in steroid target tissues. This is often achieved by HSDs working in pairs to convert
potent steroid hormones to their inactive metabolites and vice versa (Penning et al.,
2007). The key enzymes involved in the intracrine metabolism of sex steroids
include the isozymes of 17p-hydroxysteroid dehydrogenase (17PHSD), 3p-
hydroxysteroid dehydrogenase (3pHSD), 5a-reductase (5aR) and Aromatase.
Positional specific HSD pairs have also been proposed to regulate the action of the
androgen receptor, the estrogen receptor and the progesterone receptor (Penning,
2003). Whilst the intracrine sex steroid metabolism phenomenon has found
effective clinical applications in patients with hormone responsive malignancies
like prostate and breast cancers, its role, in another steroid responsive pathology
such as endometriosis is only just beginning to receive more attention. It has been
proposed that, in endometriotic tissue, a stromal cell defect blocks formation of
progesterone-dependent production of factors leading to 17PHSD2 deficiency in
turn responsible for a defective estrogen metabolism (Cheng et ah, 2007).
Matsuzaki and colleagues have found a significantly higher aromatase mRNA
expression in epithelial cells than in stromal cells in both eutopic and ectopic
endometrium obtained from endometriosis patients. They also observed that in
eutopic endometrium from endometriosis patients, 17(!HSD2 expression in
epithelial cells was significantly increased during the early, middle and late
secretory phases compared with the late proliferative phase, whereas no significant
cyclical difference was detected in normal endometrium. These findings led them
to conclude that local estrogen concentration may be much higher in epithelial cells
than in stromal cells in deep endometriotic tissue (Matsuzaki et al., 2006). Studies
so far suggest an important role for aromatase inhibitors in the treatment of
endometriosis but their exact clinical application in treating endometriosis is yet to
be clearly defined (Attar and Bulun, 2006). In the study included in this thesis the
endometrial intracrine metabolism of sex steroids in relation to embryo
implantation was evaluated.
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Figure 1.7 General steroid pathway showing sex steroid synthesis
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1.3.1 17 beta hydroxysteroid dehydrogenases
The 17P-hydroxysteroid dehydrogenases (17[3HSD) are a group of enzymes that
catalyze the last steps in the activation and inactivation of estrogens and androgens;
the reduction of the 17-keto group to the 17P-hydroxyl on the steroid nucleus,
increasing the affinity of the steroids to their cognate receptors (Peltoketo et al.,
1996) (Figure 1.8). Type 1 17PHSD, which is abundantly found in the human
placenta, was the first isoform to be purified (Karavolas et al., 1970). Since then
several isoforms have been identified in various species and currently, there are at
least fourteen known isoforms of the 17pHSD enzymes with twelve found in
humans (Jansson et al., 2006). In humans they are widely distributed in the body
(Labrie et al., 1997). Over and above the classical steroidogenic tissues such as the
human placenta, ovary and testis, the 17PHSD enzymes are also found in
peripheral intracrine tissues (Martel et al., 1992) including endometrium (Casey et
al., 1994) and adipose tissues (Labrie etal., 1997).
The enzymes 17PHSD2 and 17PHSD5 are found in the human endometrium. The
enzyme 17PHSD2 is a member of the short chain alcohol dehydrogenase/reductase
(SDR) family but 17pHSD5 is a member of the aldoreductase (AKR) protein
family (Dufort et al., 1999). The different 17PHSD enzymes, despite catalysing
similar reactions often with the same substrates, only share in the region of 20%
homology in their gene sequence (Labrie et al., 1997). Estrogens are interchanged
by two enzymes, 17PHSD types 1 and 2; type 1 converts Estrone to Estradiol, and
type 2 does reverse actions. 17PHSD5 catalyzes the reduction of androstenedione
to testosterone and it also converts estrone to estradiol. 17PHSD2 expression was
decreased through normal endometrium, hyperplasia and carcinoma accordingly.
There was a significant inverse correlation between intratumoral E2 concentration
and the level of 17PHSD2 mRNA in endometrial carcinoma. 17PHSD5 expression
was significantly increased through normal endometrium, hyperplasia and
carcinoma accordingly. These results indicated that 17PHSD types 2 and 5 play an
important role in the regulation of in situ estrogen production in endometrial
carcinoma (Ito et al., 2006). With the significant effects on intracellular estrogen,
progesterone and androgen regulation, a possible role of 17PHSD enzymes in
embryo implantation has been explored in animal models (Wu and Matsumoto,
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1985; Kreitmann et al., 1980) however till date there are scanty data on human
implantation.
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Figure 1.8 Biochemical reactions catalysed by the enzymes of the 170-



















The type 2 17(3HSD cDNA encodes a predicted protein of 387 amino acids with a
molecular mass of 42,782 Da (Wu et al., 1993). The gene is comprised of seven
exons which give rise to the types 17pHSD2a and 17pHSD2b proteins. The type
17pHSD2a, but not type 17pHSD2b, has been shown to catalyse the conversion of
estradiol to estrone, testosterone into androstenedione and androstenediol into
DHEA. It has also shown 20a-hydroxysteroid dehydrogenase activity i.e. the
conversion of 20a-dihydroprogesterone to the more active progestin, progesterone
(Wu et al., 1993). The function of the 17pHSD2b protein is unknown but it is
hypothesized that the type 2b protein might regulate 17pHSD2a activity by forming
heterodimers with 17pHSD2a (Labrie et al., 1995). The remaining discussion in
this thesis will refer to 17pHSD2a.
The enzyme is a member of the short-chain alcohol dehydrogenase super family. It
utilizes NAD as cofactor and preferentially catalyzes the oxidative reaction (Labrie
et al., 1997). In the humans it is principally expressed in the placenta (Drolet et al.,
2007) but it is also expressed in several other tissues including the endometrium
(Maentausta et al., 1991). Gurpide and colleagues first demonstrated the temporal
variation in the endometrial expression of 17PHSD2 enzyme. It was shown that the
action of progestins up-regulated the activity of enzyme 17PHSD leading to
increased conversion of estradiol to estrone in human secretory phase endometrium
(Tseng and Gurpide, 1975; Gurpide et al., 1977). More recently it has been
demonstrated that this activity is present even in the endometrial epithelial cells
and is mediated through a paracrine mechanism from stromal PRs (Yang et al.,
2001). In the endometrium, immunostaining of 17HSD appeared in the cytoplasm
of surface epithelial and gland cells during the early and midluteal phase with
predominant activity in the glandular cells (Maentausta et al., 1991; Scublinsky et
al., 1976). During the late luteal phase, it gradually disappeared. No
immunostaining was observed in the endometrium during the follicular phase of
the menstrual cycle (Maentausta et al., 1991). The highest levels of 17PHSD2
mRNA were found in endometrial tissues obtained during the mid- to late secretory
phase of the ovarian cycle (i.e., during the time of high plasma levels of
progesterone). 17PHSD2 mRNA levels were much greater in glandular epithelium
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than in the stromal cells isolated from secretory phase endometrium (Casey et al.,
1994).
The precise function of 17(3HSD2 in human endometrium is unknown. It is
hypothesized that the effects during the luteal phase are not only aimed at the
down-regulation of estrogen action but also to up-regulate progesterone action
(Tseng and Gurpide, 1975; Mustonen et al., 1998). Furthermore through its effects
on the androgen regulation it is likely to have a significant impact on the
intracellular steroid milieu predominantly in the mid-luteal phase of the menstrual
cycle. Hence it is vital, particularly in relation to embryo implantation, to gain a
clear understanding of the role of 17(3HSD2 in human endometrium.
1.3.1.2 17pHSD5
In contrast to the other 17-hydroxysteroid dehydrogenases, 17PHSD5 belongs to
the aldo-keto reductase family. It was originally cloned from the human liver but
was then demonstrated in multiple organs like brain, kidney, testis and placenta.
During the earlier stages of its discovery it was labelled as 3a-hydroxysteroid
dehydrogenase type 2 (Khanna et al., 1995). However Dufort and colleagues
established that human 3a-HSD2 was not the predominant activity and a higher
percentage conversion of androstenedione to testosterone and progesterone to 20a-
hydroxyprogesterone occurred when a stably expressed enzyme was studied. It was
felt from this and prior studies that homogenization protocols had destroyed much
of the 17P-HSD activity of the enzyme, suggesting that it was highly labile (Dufort
et al., 1999). Therefore it is now recognised as 17PHSD5.
The 17PHSD5 activity of the enzyme converts androstenedione to testosterone and
the 20a-hydrogenase activity will inactivate progesterone to 20a-
hydroxyprogesterone (Penning et al., 2001; Dufort et al., 1999). The double
activity of type 5 17pHSD in the female reproductive tissues is probably necessary
for the control of optimal level of progesterone and sex steroids (Luu-The et al.,
2001). Human 17PHSD5 possesses a high 20a-HSD activity that inactivates
progesterone, whereas the monkey and mouse enzymes do not have such high 20a-
HSD activity (Luu-The et al., 2001) and hence some of the activities of the enzyme
appear to be species specific.
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In the female 17(3HSD5 has been localised in the ovary, breast and the uterus
(Pelletier et al., 1999). In the uterus, 17(1HSD5 was localised to the endometrium,
the myometrium being completely unlabeled. Surface epithelial cells and glandular
cells were strongly reactive. The endometrial stroma was devoid of labelling
(Pelletier et al., 1999). The endometrial AR is predominantly stromal (Burton et
al., 2003) and hence it is possible that the 17(5HSD5 androgen production produces
a paracrine effect. Alternatively, its role may relate to its 20a-HSD activity,
inactivating progesterone. As has been suggested, the activity of type 5 17PHSD in
the female reproductive tissues is probably necessary to control optimal levels of
progesterone and sex steroids, changes in this enzyme could potentially alter the
mid-luteal availability of ligands thereby affecting implantation. Hence further
clarification of 17PHSD5 activity in the mid-luteal stage is vital.
1.3.2 3 beta Hydroxysteroid Dehydrogenases
The enzyme 3P-hydroxysteroid dehydrogenase/A5-A4-isomerase (3PHSD) is
involved in the biosynthesis of all classes of active steroids namely progesterone,
glucocorticoids, mineralocorticoids, androgens and estrogens (Mason et al., 1997;
Labrie et al., 1992) (Figure 1.8). Two isozymes are present in the humans and both
are encoded by two distinct genes. The 3PHSD1 gene encodes an enzyme of 372
amino acids predominantly expressed in the placenta and peripheral tissues, such as
the skin, mammary gland, prostate, endometrium and several other normal and
tumour tissues (Thomas et al., 2001; Simard et al., 2005). The type 2 gene, which
encodes a protein of 371 amino acids, shares 93.5% identity with the type 1 enzyme
and is predominantly found in the adrenals and the gonads (Thomas et al., 2001;
Simard et al., 2005). The human 3PHSD1 cDNA was first isolated and
characterized by Luu-The and colleagues (Luu-The et al., 1989). The second
human 3PHSD isoenzyme, chronologically designated as type 2, was isolated from
a human adrenal cDNA library (Rheaume etal., 1991).
3pHSD activity has been described in the human endometrium (Tang et al., 1993).
Its role in human embryo implantation has been proposed but there are few data in
relation to human pregnancy (Rhee et al., 2003). Immunohistochemistry has shown
that in the secretory phase 3PHSD is moderately expressed in the glandular
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epithelium of the endometrium with very little expression in the proliferative phase
(Rhee et al., 2003). In the human endometrium 3J3HSD is thought to catalyze the
reaction that converts pregnenolone to progesterone (Figure 1.8) and it has been
postulated that the de novo synthesis of progesterone in the endometrium might be
crucial for implantation and maintenance of pregnancy. The type of 3PHSD found
in the endometrium is type 1, the same type that is predominantly localised in the
placenta (Rhee et al., 2003).
1.4 The human uterus and endometrium
The uterus is a dynamic endocrine organ derived from the mullerian duct. Grossly
it is divided into 3 anatomical parts: the body of the uterus, the isthmic portion and
the cervix. It is a flbro-muscular organ that is essential for reproduction. It is
composed of an outer layer made up of smooth muscle and the inner cellular layer,
the endometrium. The smooth muscle cells of the uterus undergo hypertrophic and
hyperplastic changes under the effect of sex hormones.
At various stages in life, in response to sex hormones, the uterus undergoes
periodic changes. Pre-pubertal, the body of the uterus is in equal proportion to the
size of the cervix. With the onset of puberty and with the cyclical changes in the
female hormones, the body of the uterus enlarges to double the size in relation to
the cervix. Ultrasound based studies have shown that the uterine size and the
ovarian volume increase before the onset of clinical puberty and these processes
continue well into the second decade (Holm et al., 1995). Pregnancy leads to
considerable changes in the uterus. The smooth muscle cells of the myometrium
undergo significant hypertrophy, hyperplasia and remodelling under the influence
of ovarian and placental steroids ensuring the implantation of the embryo and then
the growth of the fetus. With the depletion of the sex steroids during menopause,
the smooth muscle cells undergo atrophy leading to shrinkage in the size of the
uterus.
The endometrium is the most dynamic hormone responsive element of the uterus. It
lines the body of the uterus and it must cyclically undergo regeneration and
remodelling in each menstrual cycle in preparation for possible embryo
implantation. Histologically, human endometrium can be identified as 3 layers: the
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superficial zona compacta, the intermediate zona spongiosa and an inner basal
layer. The inner basal layer is in contact with the myometrium. It is not shed during
menstruation and from this layer starts the regeneration of the endometrium during
each menstrual cycle. The superficial layers i.e. zona compacta and spongiosa, are
referred to as the functional layers of the endometrium. The cellular compartments
that can be identified in the endometrium are the superficial epithelium, the stroma,
the glands, the vascular endothelium and the perivascular cells. The ovarian
steroids act on the cells of these compartments to effect the cyclical changes
throughout the menstrual cycle.
1.4.1 Endometrial morphology during the menstrual cycle
The first half of the menstrual cycle is referred to as the proliferative phase and this
is predominantly estrogen driven. After ovulation the progesterone driven phase
starts which leads to secretory differentiation i.e. the secretory phase, of the
endometrium. In the absence of conception, following luteolysis, shedding of the
functional layers of the endometrium occurs against a background of falling levels
of progesterone and estrogen as a consequence of luteal regression. This is referred
to as the menstrual phase.
Noyes et al., in their seminal paper, described the endometrial morphology at each
stage of the menstrual cycle. They divided the proliferative and secretory phases
further into early, mid and late categories and produced a guide for dating the
endometrium. Even today this system forms the basis of dating the endometrium
(Noyes et al., 1950). Relevant details of the characteristics of endometrium at each
stage of the cycle are mentioned below (Noyes et al., 1950; Speroff and Fritz,
2005; Buckley and Fox, 1989).
Proliferative Phase
This stage is characterised by regenerating columnar surface epithelium. Initially
the glands are narrow and tubular. Then mitoses become prominent, pseudo
stratification is observed and by linking one gland segment with another a
continuous epithelial lining facing the endometrial cavity is formed (Speroff and
Fritz, 2005). The spiral vessels course through the stroma to reach a point
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immediately beneath the epithelial binding membrane where they form a loose
capillary network. All the tissue components (glands, stromal cells and endothelial
cells) demonstrate proliferation, which peaks on days 8-10 of the cycle,
corresponding to peak estradiol levels in the circulation and maximal estrogen
receptor concentration in the endometrium (Bergeron et al., 1988).
Secretory Phase
The appearance of subnuclear glycogen-rich vacuoles in the glandular epithelium
of at least 50% of cells is a prominent feature of early secretory phase endometrium
(Buckley and Fox, 1989). Epithelial proliferation ceases after ovulation and this
inhibitory effect is believed to be under the influence of progesterone. Mitoses
cease to be seen. Glands become more tortuous and intra-luminal secretions reach a
peak. Stromal oedema is marked. The spiral arterioles become much more
prominent with intensified coiling. These changes are the first signs of
decidualization. In the absence of conception, in late secretory phase, there is
marked physiological leucocyte infiltration. There is a stromal regression and loss
of endometrial height. The gland secretion diminishes to a variable extent and the
involution of gland epithelium occurs. The epithelium is thrown into tufts giving
rise to the characteristic saw-toothed effect.
Menstrual Phase
The withdrawal of estrogen and progesterone initiates important endometrial events
which culminate in menstruation. The most prominent effects of the hormone
withdrawal are evident on the spiral arterioles. With progressively prolonged and
profound arteriolar spasms, endometrial ischaemia results followed by breakdown
and shedding of the superficial layer, upper two thirds, of the endometrium. The
endometrium at this stage exhibits focal areas of sub-epithelial necrosis with
subsequent glandular collapse and necrosis. The basal layer of the endometrium
remains and repair recommences from this layer.
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1.4.2 Endometrial morphology during mid-secretory phase (window of
implantation)
During the secretoiy phase, the endometrium is predominantly influenced by the
progesterone produced by the corpus luteum in the ovary. The changes in the
endometrium are tightly regulated and it is generally accepted that optimum
conditions need to be in place during a definite period commonly referred to as the
'window of implantation' for successful implantation of the embryo. This putative
'window' is thought to extend from days LH+6 to LH+10.
The most profound and documented effects are seen in the endometrial glands but
all cell types undergo significant changes. On day LH+5, mitoses have ceased in
the endometrial glandular cells but are still occasionally evident in the stroma.
Endometrial glands during the window ofimplantation (Glasser et al., 2002):
The secretory products in the glands increase and the secretory apparatus increases
to a maximum by LH+6. The glands become more tortuous. On day LH+7 the
gland cells contain little secretory material and have acquired a low columnar to
cuboidal appearance and this contributes to the saw tooth appearance of the glands.
Endometrial blood vessels during the window of implantation (Glasser et al.,
2002):
At this stage the spiral vessels are prominent and densely coiled. Progesterone is
responsible for an increase in the dilatation of endometrial subepithelial blood
vessels. The significance of this vascular dilatation is uncertain. Morphometric
analysis has shown that between LH+6 and LH+12, the proportion of endometrium
made up of blood vessels remains constant (Rogers et al., 1993). Electron
microscopy of endothelial cell profiles in small blood vessels demonstrated that
their nuclear diameter did not change but the proportion of rough endoplasmic
reticulum, secretory apparatus and mitochondria increased between LH+6 and
LH+10.
Endometrial stroma during the window of implantation (Glasser et al., 2002; Neill,
2006):
The endometrial stromal cells are now thought to arise from the primitive uterine
mesenchymal stem cells. Around the time of implantation, the stromal cells
become large and polyhedral. Beginning on day LH+6 and thereafter in the cycle,
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changes in the stroma become prominent. Stromal changes include stromal edema,
increased capillary permeability, stromal mitoses, endothelial cell proliferation and
coiling of the spiral arterioles. Maximal capillary permeability and stromal edema
occur on day LH+10 and are prerequisites for predecidual transformation of
endometrial stromal fibroblasts.
Endometrial luminal epithelium during the window ofimplantation (Neill, 2006):
The predominant feature on the endometrial epithelium is the appearance and then
disappearance of pinopodes. These structures, visualised through electron
microscopy, are important for embryonic attachment. During the window of
implantation, they persist for 1-2 days and their presence positively correlates with
implantation sites. Continuing pregnancy rates are high for embryos that implant
between Post Ovulation Days 8-10 (84%) compared to 18% when implantation
occurs 11 days or more after ovulation (Wilcox et al., 1999).
1.4.3 Endometrial morphology of the postmenopausal endometrium
There are limited data on the histology of the postmenopausal endometrium. A
likely cause may be the difficulty in obtaining sufficient tissue for analysis.
However Archer et al, in their study that analysed 801 endometrial biopsies from
asymptomatic perimenopausal and postmenopausal women found that the
endometrium was atrophic in 373 (46.9%), proliferative in 133 (16.7%), secretory
in 54 (6.8%), and hyperplastic in 41 (5.2%). Insufficient tissue for diagnosis was
obtained in 195 (24.5%) (Archer et al., 1991). Another larger study that included
endometrial biopsies from 2964 perimenopausal and postmenopausal women prior
to starting HRT, showed 68.7% were atrophic, 23.5% were proliferative, 0.5%
were secretory, 0.6% were hyperplastic, 0.07% were adenocarcinoma, and 6.6%
were insufficient for classification (Korhonen et al., 1997). Noci et al, in a small
study, observed a discrepancy between the morphology and the
immunohistochemical analysis of postmenopausal endometrium. Whilst the
morphological pictures suggested an involution of this tissue according to the
increase in collagen fibres, the decrease in vascular distribution and the frequent
atrophic patterns, on the other hand, data from steroid receptors and the cell
proliferation index suggested that post-menopausal endometrium is an active
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structure. So they conclude that the endometria from normal post-menopausal
women appear to be in a more quiescent state than in a really atrophic condition
(Noci et al., 1996).
Postmenopausal endometrium, especially in the absence of abnormality, is a
challenging area for research, not least because of a significant proportion of
endometrial biopsies not yielding sufficient tissue for analysis.
1.5 Endometrial Expression of Steroid Receptors, Proliferation
Markers and Decidualisation Markers
The endometrial proliferation, secretory transformation, shedding and repair are all
processes under the control of steroid hormones. The steroid hormones act through
their cognate receptors. In an attempt to unravel the specific functions of each
steroid hormone, research has been directed at elucidating the temporal and spatial
expression of the receptors of these hormones in the endometrium. The endometrial
expression of estrogen and progesterone receptors have been best characterised.
Expression patterns of AR and GR have only been studied more recently.
Furthermore with increasing interest in the field of endometrial biology, subtypes
and variants of the well characterised ER and PR have been identified. Hence
further studies will be needed to clarify their distribution and ultimately their
effects on endometrial physiology and pathology.
The endometrium is a very dynamic tissue undergoing cyclical shedding and
repair. This involves processes of cellular proliferation and apoptosis. Markers to
study these processes are increasingly being recognised but their exact roles in
various endometrial functions are yet to be understood. Current understanding
regarding the endometrial function of 3 such markers; Ki-67, phosphorylated
Histone-3 (PH3) and Insulin like Growth Factor Binding Protein -1 (IGFBP-1) is
presented below.
1.5.1 Estrogen and Progesterone Receptor Expression and Regulation
Since the ER and PR expression is interlinked, these are reviewed together in this
section. With the development of specific monoclonal antibodies to ER and PR and
with improved antigen retrieval techniques, progress has been made in
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immunolocalisation of these receptors. Immunohistochemistry has been
extensively used for studies to determine the receptor distribution in the
endometrium. The ER and PR are immunolocalised to the nuclear compartments of
the cells. Their spatial localisation is broadly described in relation to the superficial
and basal layers and further categorised into the epithelial, stromal, glandular,
vascular endothelial and perivascular regions.
There are several isoforms of human PR (Taylor et al., 2006). In relation to the
human endometrium, the two classical isoforms of PR are PR-A and PR-B. These
are known to arise from the same gene (Graham and Clarke, 1997). The A isoform
which is 769 amino acids (aa) in length is a truncated version of the B isoform that
is 933 aa in length, the truncation of 164 aa being from the N terminal end of the
protein (Sartorius et al., 1994). With the development of two anti-progesterone
receptor antibodies, a specific polyclonal raised against PR-B and the other a
commercially available monoclonal raised against PR subtype A+B, it has been
possible to refine the cellular localization of PR subtype A and B in the normal
endometrium throughout the menstrual cycle. Since PR-A is a shorter splice variant
it is not possible to raise a specific antibody to this isoform alone. Hence
immunohistochemical analysis of PR-A may be further determined by subtractive
inference (Wang et al., 1998).
In relation to the ER, two distinct isoforms, ERa and ERp have been identified.
Whilst the two isoforms of PR arise from the same gene, the 2 identified isoforms
of ER, ERa and ERP, arise from two different genes (Koike et al., 1987; Kuiper et
al., 1996, Enmark et al., 1997). The recently discovered ERP was initially cloned in
the rat but has since been cloned in the humans with the classical ER now
designated ERa (Mosselman et al., 1996).
By comparing monoclonal antibody immunolocalisation with ligand binding
studies, Lessey et al described the temporal expression ofER and PR (Lessey et al.,
1988). These data showed an increase in the concentration of ER throughout the
proliferative phase with a peak in the early secretory phase. Thereafter the ER
concentrations decline. The expression of PR, and therefore sensitivity to
progestins, is under the control of estrogen, which increases, and progesterone,
which decreases PR expression in most target tissues (Graham and Clarke, 1997).
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Concentrations of PR increase in a parallel fashion, albeit somewhat delayed, with
a decline in the secretory phase of the cycle. The nuclear localisation of ER and PR
in the endometrial compartments has been demonstrated by immunohistochemical
studies. In the stromal and glandular compartments, ER expression was maximal in
the late proliferative phase. However, in the secretory phase, ER expression
declined in the stromal and glandular compartments. It is also possible to localise
ERa and ERp using monoclonal antibodies. ERa and ER(3 are both localised in the
nuclei of the glandular compartment and stromal cells of functional and basal
endometrium in the proliferative phase. The expression of ERa declines in the
glands and stroma of the functional layer while expression of ERP declines in the
glands, but not the stroma, during the secretory phase. Levels of expression ofERa
and ERp in all cellular compartments remain unchanged in the basal layer
(Critchley et al., 2001). Marked PR expression is observed in the nuclei of glands
and stroma during the proliferative phase. In the secretory phase this
immunoreactivity declines in the glandular cells with a modest expression in
stromal cells (Lessey et al., 1988; Snijders et al., 1992; Critchley et al., 1993). In
the glands, PRA and PRB were expressed before subnuclear vacuole formation and
glycogenolysis, implicating both isoforms in this process, whereas persistence of
PRB during the midsecretory phase suggested its significance in glandular
secretion. In the stroma, the predominance of PRA throughout the cycle implicates
this isoform in post-ovulatory progesterone-mediated events. These results support
the view that PRA and PRB mediate distinct pathways of progesterone action in the
glandular epithelium and stroma of the human uterus throughout the menstrual
cycle (Mote et al., 1999). Using subtractive inference it was determined that the
isoform of PR that mainly persists in the secretory phase stroma is PRA (Wang et
al., 1998). A study by Brosens and colleagues provides further support to this
observation but they also demonstrated that whilst PRA was the predominant
isoform in differentiating endometrial stromal cells, its abundance decreased
markedly during the course of the decidualization response (Brosens et al., 1999).
In relation to endometrial vascular function, ER and PR expression show some
interesting features. Both PRA and PRB are present in a perivascular location in
the secretory phase, but not in the proliferative phase. The presence of PRA and
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PRE in the secretory phase makes it likely that progesterone action either directly
or indirectly influences growth, development and function of the spiral arterioles in
this phase of the menstrual cycle (Koji et al., 1994; Wang et al., 1998). It appears
that the estrogen mediated regulation of the endometrial vasculature and
angiogenesis may be mediated via binding to ER(3. This is because only ERp, and
not ERa, is present in the nuclei of the endothelial cells of most blood vessels
including spiral arterioles, capillaries and veins. The intensity of immunoreactivity
of ERp in the endothelial cells shows little change throughout the proliferative and
secretory phases (Critchley et al., 2001).
1.5.1.1 Estrogen receptor regulation
ER and PR regulation is closely interlinked. Estradiol stimulates ER expression and
ER levels are highest in the proliferative phase (Lessey et al., 1988). ER expression
decreases after ovulation, reflecting the suppressive effects of progesterone on ER
expression. Two forms of ER are now recognised, ERa and ERp. The functional
significance of ER is gradually being unravelled with the generation of ER knock
out (ERKO) mouse models. At the time when the first ER knock out mouse was
generated (Lubahn et al., 1993), the only ER isoform known was ERa. The initial
studies on aERKO mice showed interesting features. Both male and female
animals survived to adulthood with normal gross external phenotypes. Females
were infertile; males had a decreased fertility. Females had hypoplastic uteri and
hyperemic ovaries with no detectable corpora lutea (Lubahn et al., 1993). ERp
knock out mice were generated 5 years later by which stage the second ER isoform
had been recognised. In the initial studies involving PERKO mice it was observed
that ERP was essential for normal ovulation efficiency but not essential for female
or male sexual differentiation, fertility or lactation (Krege et al., 1998).
In the endometrium, ERp expression is lower than ERa and in the ERa null mouse,
ERp does not compensate for ERa (Couse and Korach, 1999). This suggests that
ERa is the predominant ER in the endometrium. However only ERP, but not ERa,
is present in the endometrial vascular endothelium (Critchley et al., 2001) and
hence the vascular effects of estrogens are directly mediated via this receptor
isoform.
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Estradiol action on the endometrium is direct, through its cognate receptor and
indirect, by induction of growth factors in either target cells or by inducing growth
factors as paracrine modulators. In relation to cell-cycle regulation, estradiol
complexed with ER leads to up-regulation of cell cycle proteins. In the proliferative
phase, an increase in ERa expression is correlated with cyclins and cyclin-
dependant kinases. Furthermore, the transcription factors c-fos and c-jun, mediators
of estradiol action, are highly expressed in the proliferative phase (Neill, 2006).
1.5.1.2 Progesterone receptor regulation
The PR is controlled by both estrogen and its own ligand progesterone. In the
proliferative phase, which is predominantly estrogen dominated, PR is upregulated
secondary to the estradiol up regulation of PR mRNA. This effect occurs as a result
of an estrogen response element that results in increased PR protein synthesis
(Clarke and Sutherland, 1990). In the secretory phase, which is progesterone
dominated, progesterone itself initiates down regulation at both the transcriptional,
via the same estrogen response element (Savouret et al., 1991), and post
transcriptional levels (Chauchereau et al., 1992).
Just as in ER, two isoforms of PR are currently recognised, PRA and PRB. While
progesterone action on target genes is conferred primarily by PRB homodimers,
truncated PRA acts as a repressor of PRB function (Neill, 2006).
To better understand the functional significance of PR, PR knock out (PRKO) mice
were generated. Initial studies on these mice demonstrated that male and female
embryos homozygous for the PR mutation developed normally until adulthood.
However, the adult female PR mutant displayed significant defects in all
reproductive tissues. These include an inability to ovulate, uterine hyperplasia and
inflammation, severely limited mammary gland development and an inability to
exhibit sexual behaviour. Collectively, these results provided direct support for
progesterone's role as a pleiotropic coordinator of diverse reproductive events that
together ensure species survival (Lydon et al., 1995). Estradiol treatment of the
PRAKO mouse results in endometrial epithelial hyperplasia and progesterone
treatment had no subsequent effect, suggesting that PRA mediates progesterone
inhibition of estradiol stimulated endometrial epithelial growth. Ablation of PRB
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protein (PRBKO mice) does not affect biological responses of the ovary or uterus
to progesterone but results in reduced pregnancy-associated mammary gland
morphogenesis (Mulac-Jericevic and Conneely, 2004). The use of mifepristone, a
progesterone receptor antagonist has further elucidated progesterone regulated
events in the endometrium. Mifepristone given early in the secretory phase in
humans prevents progesterone-induced down-regulation of PR and ER (Cameron et
al., 1996; Maentausta et al., 1993).
1.5.2 Androgen Receptor Expression and Regulation
Two isoforms of AR have been proposed. An AR-A isoform (ARA) with an
apparent molecular mass of 87 kDa, which is an NH2-terminally truncated form of
a major AR-B isoform (ARB), was reported (Wilson and McPhaul, 1996; Gao and
McPhaul, 1998). Although the study suggested that the use of initiation methionine
at amino acid 188 would yield the ARA isoform, the possibility that the ARA
isoform might be a proteolyzed product of AR could not be ruled out. As no follow-
up studies were reported about the N-terminally truncated isoform of AR, the
concept of AR isoforms is not widely accepted (Lee and Chang, 2003). This is in
contrast to other steroid receptors, such as PR and ER.
In comparison to ER and PR, in the human endometrium, AR has been less
extensively studied. This may be partly related to the fact that there are a variety of
antibodies and immunohistochemical techniques employed to study AR in the
human endometrium. Initially, the presence of an androgen receptor in the human
endometrium was shown with ligand binding studies (Muechler, 1987). However
subsequent immunolocalisation studies using the mouse monoclonal antibody
(F39.4) localised AR in a variety of human tissues, but no receptors were identified
in the uterus (Ruizeveld de Winter et al., 1991). Horie et al, using the rat anti-
human monoclonal antibody, found the AR to be present in endometrial glands and
stroma throughout the menstrual cycle (Horie et al., 1992). The immunoreactivity
was mainly localised to the functional layer with less in the basal layer (Horie et
al., 1992). Other studies have found immunoreactivity in the endometrial stroma
and glands (Kimura et al., 1993; Takeda et al., 1990) but the level of glandular
expression has been variable with Takeda et al reporting some expression and
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Chadha et al reporting no expression in the endometrial glands (Takeda et al.,
1990; Chadha et al., 1994). Mertens et al localised the receptor in the stromal cells
with the most profound immunoreactivity in the basal layer and only minimal
immunoreactivity in the glandular epithelium. In this study and in the one by
Slayden and colleagues, AR immunoreactivity was not observed in the late
secretory phase indicating there may be temporal variation in expression within the
menstrual cycle (Mertens et al., 1996; Slayden et al., 2001b).
1.5.2.1 Androgen receptor regulation
The functional significance of the androgen receptor pathway in the male
reproductive system is well studied. However, until the recent past in the absence
of a proper model system, the AR pathway in the female is unclear. Recently, AR
knockout (ARKO) mice have been successfully generated (Yeh et al., 2002). The
study demonstrated that the average number of pups per litter in homologous and
heterozygous ARKO female mice was lower than in wild type female mice,
suggesting potential defects in female fertility and/or ovulation (Yeh et al., 2002).
It has also been reported that the ovaries from sexually mature ARKO female mice
exhibited a marked reduction in the number of corpora lutea. During the
periovulatory period, in the ARKO female mice, an intensive granulosa apoptosis
event occurs in the preovulatory follicles, concurrent with the down-regulation of
p21 and progesterone receptor expression. In addition to insufficient progesterone
production, the diminished endometrial growth in uteri in response to exogenous
gonadotropins indicates that ARKO females exhibit a luteal phase defect (Hu et al.,
2004).
Mertens et al observed AR downregulation in the late secretory phase (Mertens et
al., 1996; Mertens et al., 2001). Since this downregulation was observed in a
progesterone dominated phase, it may be suggested that the downregulation is
secondary to a progesterone mediated mechanism. Fujimoto et al studied women
given an intramuscular injection of estradiol dipropionate (ED) with or without
testosterone cypionate (TC) 1 week prior to hysterectomy. ED alone was
responsible for a significant increase in AR mRNA and testosterone binding sites
but when administered with TC the testosterone binding sites were significantly
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reduced and the AR mRNA level showed a non significant increase suggesting that
while TC significantly reduced testosterone binding sites it had no significant effect
on AR mRNA levels (Fujimoto et al., 1995). Iwai et al studied endometrial stromal
cell cultures and found that progesterone and testosterone independently were able
to decrease ER mRNA, PR mRNA and AR mRNA in a dose dependent manner
(Iwai et al., 1995). There are scanty data in the field of AR regulation and indeed
further work is required in this field.
1.5.3 Glucocorticoid Receptor Expression
Glucorticoids exert their effects on human tissues through the GR. In humans, two
receptor isoforms, hGRa and hGR(3, have been identified. These originate from the
same gene by alternative splicing (Encio and Detera-Wadleigh, 1991). The two
receptor isoforms are identical between amino acid 1-727 and then diverge. hGRa
contains 50 specific C-terminal amino acid residues that form two helical structures
that play an important role in ligand binding, whereas the C terminus of hGRP
contains 15 specific nonhomologous amino acids which are largely disordered
(Yudt et al., 2003). Until now, hGRP has been only found in the humans and hence
no animal models were available for further studies. Recently, hGRP has been
reported in other species potentially providing animal models for further studies on
GR mediated effects (Schaaf et al., 2008).
Glucocorticoids have been shown to exert specific effects on endometrial cells
(Hoffman et al., 1984; Bigsby, 1993; Jo et al., 1993) but their role in endometrial
physiology is not defined (Jabbour et al., 2006). There are very limited data
regarding GR expression in the endometrium. The GR is almost exclusively
expressed in the stromal compartment including the endothelial and lymphoid cells
(uterine Natural Killer cells) (Henderson et al., 2003; Bamberger et al., 2001).
Expression of GR was low in glandular epithelium across the cycle however there
was a significant increase in expression in decidual glands. There was high
expression of GR in the endothelium in both functional and basal layers of the
endometrium throughout the menstrual cycle and in first trimester decidua.
Expression of GR protein increased across the cycle in the surface epithelium, from
negligible expression in the proliferative and early secretory phases to weak
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expression in the late secretory phase (McDonald et al., 2006). It has been
demonstrated that uterine Natural Killer (uNK) cells express GR (Henderson et al.,
2003). GR mRNA expression is not cycle-dependent as shown by the recent data
on endometrial mRNA levels across the cycle (Vienonen et al., 2004). GR mRNA
was present in normal endometrium at low levels across the cycle and in similar
amounts in the first trimester decidua (McDonald et al., 2006).
Numerous studies have suggested roles for inflammatory markers, cytokines,
prostaglandins and other agents in processes related to embryo implantation and
endometrial shedding and repair, both pre and post menopausal (Salamonsen et al.,
2007; Henderson et al., 2003; Lea and Sandra, 2007; Hickey et al., 2005).
Glucocorticoids could potentially influence these processes and hence a clear
definition of the receptor expression and its effects are crucial to better understand
these processes.
1.5.4 Ki-67 marker expression
The Ki-67 protein was originally defined by the prototype monoclonal antibody Ki-
67 which was generated by immunizing mice with nuclei of the Hodgkin
Lymphoma cell line L428 (Gerdes et al., 1983). A detailed cell cycle analysis
revealed that the antigen was present in the nuclei of cells in the Gi, S and G2
phases of the cell division cycle as well as in mitosis. Quiescent or resting cells in
the Go phase did not express the Ki-67 antigen (Gerdes et al., 1984) (Figure 1.9).
Because the Ki-67 antigen was present in all proliferating cells (normal and tumour
cells), it became evident that the presence of this protein could constitute an
excellent operational marker to determine the growth fraction of a given cell
population (Scholzen and Gerdes, 2000).
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Since the Ki-67 antigen is expressed during several phases of the cell cycle e.g. Gl,
S, G2 and M (Gerdes et al., 1984), counts of Ki-67 positive nuclei in paraffin
sections are numerically far higher than the mitotic counts in the same sections,
though the Ki-67 index is usually well correlated with the mitotic index. However,
this correlation does not always hold. For example, in endometria of estrogenized
macaques treated with either vehicle or antiprogestin for 2 weeks, the antiprogestin
caused a dramatic suppression in the mitotic index but no suppression of the Ki-67
index (Slayden et al., 2001a). Therefore, counts of Ki-67-stained cells failed to
reveal that the antiprogestin treatment had suppressed estrogen-dependent
proliferation. Presumably, the cells were blocked at a stage during which Ki-67
protein was continually expressed but from which cells could not progress through
mitosis. In such cases, only the mitotic index accurately reflects the number of cells
that complete the cell cycle (Brenner et al., 2003b). Despite some of these
drawbacks, Ki-67 remains a useful marker of cellular proliferation.
The Ki-67 expression correlates well with estrogen stimulation. The Ki-67
expression increases in the epithelial, glandular and stromal cells in the
proliferative phase and decreases after ovulation in the secretory phase (Mertens et
al., 2002; Jones et al., 1998; Maia et al., 2004). Dahmoun and colleagues observed
that the Ki-67 index increased in the stroma during the last 3 days of the secretory
phase, parallel with an increasing progesterone receptor score and peaking at the
onset of menstruation. These findings concur with high proliferation at the end of
the menstrual cycle and high cell turnover during menstruation, suggesting the
participation of stroma in the renewal process of endometrium (Dahmoun et al.,
1999). Furthermore, compared to normal endometrium, increased Ki-67 expression
has been observed in endometrial polyps suggestive of progressive endometrial
proliferative activity (Maia et al., 2004). Ki-67 immunostaining is thought to be a
satisfactory technique in evaluating the effects of hormone therapy even in
postmenopausal endometrium (Daij et al., 1995). In postmenopausal endometrium,
Ki-67 immunostaining was significantly increased in stromal as well as glandular
cells after estrogen-only treatment but these effects were clearly counterbalanced
by the addition of Medroxyprogesterone Acetate (Klaassens et al., 2006).
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1.5.5 Phosphorylated Histone 3 (PH3) marker expression
Accurate measurement of cell proliferation in histological sections of endometrium
is an important parameter in the assessment of hormone action, menstrual cycle
stage and neoplastic growth (Brenner et al., 2003b). These proliferative activities in
endometrial cells have been studied in various ways including
immunohistochemical analysis of cell cycle restricted proteins - proliferating cell
nuclear antigen and the Ki-67 antigen (Hayama et al., 2002). Direct counting of
mitotic cells in haematoxylin and eosin (H&E)-stained sections is a time-
consuming process that requires highly skilled observers (Hall and Levison, 1990).
It is especially difficult to distinguish between cells in prophase and cells
undergoing pycnosis or apoptosis in H&E-stained sections. Relatively high
magnifications have to be used to distinguish the cycle phases and large numbers of
cells must be counted to obtain statistical validity (Brenner et al., 2003b). Therefore
mitotic markers that can be easily studied are required and PH3 serves as a reliable
marker for assessing cellular mitosis in various body tissues including the
endometrium. The PH3 antibody has been used to identify chromosomes during
mitosis in cultured cells (Brenner et al., 2003b). It is expressed only in the M phase
of the cell cycle (Chadee et al., 1999) (Figure 1.9).
Eukaryotic cells must possess mechanisms for condensing and decondensing
chromatin. Chromatin condensation is particularly evident during mitosis and cell
death induced by apoptosis, whereas chromatin decondensation is necessary for
replication, repair, recombination and transcription. Histones are among the
numerous DNA-binding proteins that control the level of DNA condensation, and
post-translational modification of histone tails plays a critical role in the dynamic
condensation/decondensation that occurs during the cell cycle (Prigent and
Dimitrov, 2003). Histone phosphorylation was first observed in the sixties
(Gutierrez and Hnilica, 1967). Histone phosphorylation is believed to play a direct
role in mitosis, cell death, repair, replication and recombination (Ito, 2007). During
mitosis, histone H3 is phosphorylated at SerlO in all eukaryotes (Prigent and
Dimitrov, 2003) and with the development of an antibody against histone H3-
phospho SerlO, it was established that there is a strong correlation between SerlO
phosphorylation and chromosome condensation during cell division (Hendzel et al.,
61
1997). However it has been suggested that Histone H3 phosphorylation is only
required for initiation but not maintenance of mammalian chromosome
condensation (Van Hooser et al., 1998).
Endometrial epithelial cells and stromal cells proliferate briskly during the
proliferative phase of the menstrual cycle, but their proliferation is less marked
during the secretory phase. Since the anti-PH3 antibody has only recently been
introduced, there are very limited data regarding PH3 expression in the
endometrium. Brenner and colleagues evaluated the mitotic index and the PH3
expression in human and Rhesus macaque endometrium. In the human
endometrium, the mitotic index and PH3 expression correlated well with increased
evidence of mitosis in the proliferative phase and reduced expression in the
secretory phase. In the macaque endometrium they further evaluated the PH3
expression in the functional and the basal layers after treatment with estrogen
and/or progesterone. After treatment with estrogen, abundant PH3 positive cells
were seen in the functional layer and the counts sharply decreased after addition of
progesterone. However in the basal layer, the mitotic counts were very low during
treatment with estrogen but they increased after treatment with progesterone
suggesting that progesterone stimulates proliferation in the basal zone but
suppresses it in the functional layer (Brenner et al., 2003b). Narvekar and
colleagues observed significant PH3 expression in the proliferative phase in the
endometrial glands and stroma suggestive of active mitosis consistent with
endometrial proliferation (Narvekar et al., 2004). However PH3 expression was
suppressed after treatment with mifepristone (Narvekar et al., 2004). Compared to
normal endometrium in proliferative phase, endometrium from PCOS women
showed higher mitotic activity in the glands, whereas postmenopausal women had a
significantly lower mitotic activity in the stroma. The mitotic activity in the stromal
compartment (PCO group) and glands (postmenopausal group) was not
significantly different from that in proliferative samples (Narvekar et al., 2004).
1.5.6 Insulin like Growth Factor Binding Protein -1 (IGFBP-I) expression
Insulin-like Growth Factor-I (IGF-I) and IGF-II are polypeptides that stimulate
cellular proliferation and differentiation (Baxter, 1986). Endometrial stromal cells
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produce Insulin-like growth factors I and II (IGF-I and IGF-II) as well as the high-
affinity IGF binding proteins (IGFBPs), whereas epithelial cells and, in a lesser
amount, also stromal cells contain cell membrane receptors for IGFs (Rutanen,
1998). The biological actions of IGFs are mediated through cell membrane
receptors (Rechler and Nissley, 1985). In serum and some other media, IGFs are
bound to binding proteins (BPS) (Baxter and Martin, 1989) and the BPS are
believed to modulate the availability of the IGFs to their target cell thereby acting
as regulators of IGF actions (Baxter and Martin, 1989; Elgin et al., 1987; Busby et
al., 1988; Rutanen et al., 1988; Ritvos et al., 1988).
Although three distinct IGF binding proteins (IGFBPs) have been characterized in
the human endometrium (Rutanen et al., 1986; Giudice et al., 1991), the most
abundant is IGFBP-I (Rutanen, 2000). IGFBP-1 is synthesized and secreted by
human secretory phase and pregnancy endometrium, and progesterone induces its
synthesis in endometrial explant cultures (Rutanen et al., 1986; Rutanen et al.,
1985). The precise role of the IGFs and their BPS in the endometrium is not fully
understood. Insulin-like growth factors, IGF-I, IGF-II, and IGF binding protein
(IGFBP-1) appear to play major roles in endometrial development during the
menstrual cycle and in the process of implantation. The mitogenic, differentiative
and anti-apoptotic properties of these growth factors as well as their spatial and
temporal expression in cycling endometrium suggest that they may participate in
endometrial growth, differentiation, inhibition of apoptosis, and perhaps
angiogenesis (Giudice et al., 1998). IGFBP-1 is a major protein product of non¬
pregnant endometrium during the mid-late secretory phase and occurs in
abundance in decidua. Its roles as an IGF-binding protein and as a trophoblast
integrin ligand suggest that it may have multiple roles in endometrial development
and in interactions between the decidua and the invading trophoblast (Giudice et
al., 1998). It is therefore studied as a marker of decidualisation. Estrogen stimulates
IGF-I gene expression in the endometrium and IGF-I is assumed to mediate
estrogen action. In contrast, progesterone stimulates the secretion of IGFBP-1 from
the predecidualized/decidualized endometrial stromal cells in late secretory phase
endometrium and pregnancy deciduas, thus counteracting the effects of the
estrogen mediated stimulation of IGF-1 (Rutanen, 1998). The primary negative
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regulator of IGFBP-1 expression is insulin, by inhibiting IGFBP-1 transcription.
IGFBP-1 inhibits the receptor binding and biological actions of IGF-I in the
endometrium and in cultured human trophoblastic cells. These findings support the
view that the IGF system has autocrine and paracrine functions in the regulation of
endometrial proliferation and differentiation (Rutanen, 1998). After treatment with
the LNG-IUS, strong cytoplasmic staining for IGFBP-1 was detected in
decidualized endometrium in women. Simultaneously oestrogen receptors were
present, while progesterone receptors were hardly detectable in the endometrium
by immunohistochemistry. The latter findings suggest that suppression of IGF-I
action by IGFBP-1 may be one of the molecular mechanisms accounting for
progestagenic and anti-oestrogenic effects of LNG-IUS in the endometrium
(Rutanen, 2000).
1.6 Implantation
Despite multiple advances in assisted conception, the pregnancy rates continue to
remain low. As a part of assisted conception treatment regimes, GnRH analogues
and more recently GnRH antagonists are commonly used. Controlled ovarian
stimulation leads to supraphysiological levels of ovarian steroids and hence
concern has been raised as to the adverse impact of this on successful implantation
(Nikas et al., 1999; Papanikolaou et al., 2005). There is some evidence suggesting
endometrial histological advancement at the time of oocyte pick up in women
treated with rFSH and GnRHantag (Kolibianakis et al., 2002; Kolibianakis et al.,
2003). However there are limited data on the state of the endometrium during the
crucial window of implantation. Although not clearly defined, the window of
implantation is thought to extend from day 6 to day 10 after the luteinizing
hormone (LH) surge.
In the endometrium, several molecules/factors that might affect implantation have
been identified (Sharkey and Smith, 2003; Lessey, 1998) but so far there is limited
understanding about the mechanisms involved. The actual process of implantation
is thought to be an interaction between the endometrium and the embryo that is
mediated by soluble growth factors (Yoo et al., 1997; Bausero et al., 1998),
hormones, adhesion molecules (Home et al., 2001; Lessey, 2002a), the
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extracellular matrix (ECM) (Jokimaa et al., 2002), cytokines and prostaglandins
(Kelly et al., 2001). GnRHantag. may impact the processes of implantation through
sex steroids or through direct effects via the GnRH receptors in the endometrium.
Sex steroids; estrogens (Lessey et al., 2002b), progestogens (Lessey, 2003), and
likely also androgen (Apparao et al., 2002), are thought to play a vital but as yet
not fully defined role in the complex mechanisms underlying endometrial
development leading up to and after embryo implantation. These hormones act via
their cognate receptors. After binding to the nuclear receptors, steroid receptors
activate gene transcription. With the advent of microarray technology, the focus
has shifted to trying to understand the endometrial gene profile in the mice (Wang
and Dey, 2006) and even in humans (Kao et al., 2002). Several genes have been
recently identified and alteration in their expression is thought to have a major
impact on implantation. Recent studies have analysed the gene expressions in
physiological mid-luteal endometrium and in stimulated IVF/ICSI treatment cycles
including in treatment cycles involving use of GnRH antagonists (Horcajadas et al.,
2008; Macklon et al., 2008). These studies have described patterns of up-regulation
and down-regulation of different sets of genes but it does appear that with further
studies recognisable patterns of expression will become clearer. Attention can then
be focussed on trying to establish the functional significance of these patterns of
gene expression. The gene expression is partly thought to be under the control of
estrogen and progestogens (Borthwick et al., 2003). Further, it is recognised that
elevated AR level during the window of implantation is associated with a decrease
in a well-characterized biomarker of endometrial receptivity, the avp3 integrin
(Apparao et al., 2002).
The cellular and molecular expression of PR, ER and AR during the window of
implantation in rFSH and GnRHantag treated endometrium has not yet been
reported. Furthermore, the endometrial intracellular ligand availability and changes
if any have not yet been evaluated in the context of embryo implantation.
1.7 Postmenopausal Endometrial Breakthrough Bleeding
Postmenopausal hormone replacement therapy (HRT) use is a common cause of
breakthrough bleeding (BTB). It can occur in upto 60% of HRT users. Most
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women will undergo investigations such as outpatient biopsy, ultrasound or
hysteroscopy but in the majority, no cause is found (Elliott et al., 2003). Majority
of women on HRT, use a continuous combined preparation of estrogen and
progestogen; the so-called bleed free HRT. In those on combined, sequential HRT
regimens, both breakthrough and prolonged withdrawal bleeding contain
morphological and presumably molecular alterations of the endometrium similar to
those seen and described in oral contraception (OC) users. The histology of the
endometrium exposed to combined, continuous HRT (cc-HRT) regimens is more
variable than that of OC users. This is probably due to the lower dose of sex
steroids used in the fonner than in the latter regimens (Ferenczy., 2003).
The exact cause of HRT related BTB is unknown. Changes in endometrial blood
vessels, uterine natural killer cells, matrix metalloproteinases (MMP's) and their
tissue inhibitors (TIMPs) have all been studied in women with BTB on HRT
(Hickey et al., 2005; Hickey et al., 2006; Hickey et al., 2008). There are few data
on the steroid receptor expression in postmenopausal endometrium. Dahmoun and
colleagues obtained endometrial biopsies from postmenopausal women before and
12 months after using cc-HRT. They observed that the PR expression in epithelium
and stroma remained unchanged. After treatment with PORT, ER expression in
epithelium and stroma was reduced and Ki-67 index in stroma was increased. They
proposed that the increased stromal proliferation may be of importance for stromal
support of the veins and for decreasing breakthrough bleeding during HRT. The
increased stromal proliferation, as well as the decreased ER expression both in
epithelium and stroma, could be an effect of progesterone (Dahmoun et al., 2004).
1.8 Effects of Levonorgestrel - releasing Intra Uterine System on
the Endometrium
The levonorgestrel - releasing intrauterine system (LNG-IUS) affords effective
contraception and reduces menstrual blood loss and dysmenorrhoea. The system
releases levonorgestrel at a slow rate of 20pg over 24 hours into the uterine cavity
(Luukkainen et al., 1990). Initially it was introduced as a contraceptive but now
heavy uterine bleeding is a primary indication for use of the LNG- IUS in Europe
(Jensen, 2002). The LNG-IUS also provides endometrial protection in combination
66
with oestrogen as a mode of post-menopausal hormonal replacement (Jensen,
2002). The main side effect of steroid contraception including LNG-IUS is
irregular or unscheduled breakthrough bleeding. This leads to discontinuation in a
proportion of users (Moller et al., 2005). The mechanisms underlying BTB remain
poorly understood but there is likely involvement of angiogenic factors (Roopa et
al., 2003), Matrix Metallo-Proteinases (MMP) activation (Skinner et al., 1999) and
altered haemostatic factors that result in increased endometrial vessel fragility
(Hickey and Fraser, 2002). The presence of this side effect in up to 53% of women
after 3 months' use of LNG-IUS provides justification to develop compounds that
are more effective but with an improved side effect profile. Intra-uterine delivery of
the Progesterone Antagonist (PA) ZK230211 is one such compound under
evaluation.
The endometrium is a target tissue for steroid hormones and PAs. The intrauterine
delivery of an androgenic progestogen, LNG, induces a dramatic transformation of
the endometrium characterised by extensive decidualisation (Critchley et al.,
1998a). There is a reduction in the cellular proliferative activity as evidenced by
the decrease in immunoreactivity of the cell proliferation marker Ki-67.
Additionally, the immunostaining scores of epithelial Progesterone Receptor (PR)
and stromal PR have been reported to be significantly lower after 6 months of
LNG-IUS use and there is a non-significant decline in the Estrogen Receptor (ER)
immunoreactivity in both the epithelial and stromal cells (Hurskainen et al., 2000).
In the normal cycle, Androgen Receptor (AR) has been spatially localised to the
endometrial stroma with up-regulation in the estrogen dominated proliferative
phase and down regulation in the late secretory phase. The presence of LNG-IUS
was associated with minimal AR immunoreactivity in the stromal compartment and
any duration of treatment with LNG-IUS caused a significantly lower production of
AR mRNA when compared to the levels in proliferative phase (Burton et al.,
2003). Table 1.1 summarises the endometrial effects on LNG-IUS (Adapted from




























The angiogenic factors in the endometrium are of great interest in relation to
understanding the mechanisms of action of the LNG-IUS. This is particularly
relevant since BTB is the main side effect responsible for patient requests for early
removal of the IUS (Moller et al., 2005). Histological sections of endometrium
from women using most of the long term progestin-only contraceptive (LTPOC)
options display abnormally enlarged blood vessels at bleeding sites. A paradoxical
observation is the reported trend toward reduced endometrial perfusion in LTPOC
users. Basic laboratory studies point to local changes in the endometrial
microvasculature following exposure to long acting progestogen, to be a
contributory cause for BTB. It has been suggested that the mechanisms controlling
endometrial angiogenesis could be altered with the use of long acting progestogen
contraceptives. A recent study showed that there was an increased mRNA
expression of the angiogenic growth factor VEGF in the endometrial tissues of
women exposed to LNG-IUS. The effects of VEGF seem to be exclusively on the
vascular endothelial cell. The study also noted a positive correlation between
endometrial VEGF levels and the number of bleeding/spotting days (Roopa et al.,
2003).
1.9 Effects of Progesterone Antagonists on the Endometrium
Progesterone antagonists (PAs) are compounds that bind to the progesterone
receptor and inhibit P-initiated gene transcription. With several compounds
synthesized and characterised, the PA's have been further classified on the basis of
their molecular actions. Some PA's have a partial agonistic/antagonistic activity on
the Progesterone receptor - the so called Progesterone Receptor Modulators
(PRM's), and some are thought to be pure antagonists that effect a progesterone
blocking action by binding to the PR. Since the introduction of RU486
(mifepristone), the first potent PA synthesized, studies have shown that PA's can
induce amenorrhoea, suppress ovulation, inhibit endometrial proliferation in
combination with oestrogen therapy and act as a contraceptive (Baird et al., 2003a;
Baird et al., 2003b).
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With such widespread effects the PA's have potential applications in the treatment
of heavy menstrual bleeding, fibroids, endometriosis, as a combination hormone
replacement therapy, in breast cancer and as a contraceptive.
The type III PA ZK230211 is a pure PA that does not display any PR agonistic
activity in-vivo or in-vitro. Since this is a relatively new compound (Fuhrmann et
al., 2000), virtually all the available data on local mechanisms of action come from
animal studies. It is a highly potent PA with reduced anti-glucocorticoid activity.
The effects ofZK230211 are thought to be species specific. For example in rodents
and guinea pigs it did not inhibit estrogen-induced uterine growth or endometrial
proliferation but enhanced it instead (Chwalisz et al., 2000). These effects were not
seen in the primate uterus. In the non-human primate uterus, subcutaneously
administered ZK230211, chronically at relatively low doses, inhibits mitotic
activity of endometrial epithelium and stromal compaction in spayed and intact
macaques indicating that it blocked both progesterone and estrogen responses in
the endometrium. Nevertheless there was no inhibition of the estrogen stimulation
of oviductal and vaginal growth or differentiation in monkeys (Slayden et al.,
2001a). Since the effect is specific to the primate endometrium, the term
'endometrial antiproliferative effect' has been suggested (Brenner et al., 2002). A
dose finding study tested different doses of ZK230211 given daily, subcutaneously
for 60 days in naturally cycling rhesus macaques. Doses of 0.016mg/kg body
weight and 0.05mg/kg suppressed all ovulation and menstruation cycle to
approximately 50 days. Flowever circulating estradiol concentrations were never
suppressed below normal, follicular phase concentrations at any dose. Therefore if
it is used to block menses, it is unlikely to cause any associated symptoms of
estrogen deprivation such as, hot flushes, vaginal atrophy or loss of bone density.
Following treatment with ZK230211, menstruation and ovulation were blocked in
the non-human primate. The endometrial immunohistochemistry displayed
interesting features. Treatment with higher doses (0.016 and 0.032mg/kg) blocked
progesterone suppression and led to increased ERa, PR and Ki-67 immnuostaining
in endometrial glands and stroma (Slayden et al., 2001a). In general, at least with
acute, short-term administration, PAs have been consistently shown to upregulate
ER and PR in various tissues of the female reproductive tract in all species. This is
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believed to be due to its antagonism of the PR. The action of PAs on the
endometrial stromal cell is poorly understood. It has been suggested that down
regulation of stromal growth factors may represent an important mechanism
contributing to the endometrial antiproliferative effects of PAs.
Breakthrough Bleeding, a common side effect with chronic progestin therapy, was
not observed with ZK 230211. In fact prolonged amenorrhoea lasting for many
months frequently occurred after treatment with ZK230211 (Slayden et al., 2001a).
The vascular features observed after prolonged treatment were quite striking
periarteriolar degeneration of endometrial spiral arteries leading in turn to their
atrophy. The mechanism of this effect is poorly understood but local vasoactive
factors including VEGF may play an important role (Chwalisz et al., 2000).
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CHAPTER 2
Hypothesis and Aims of Thesis
72
2 Hypothesis and Aims of Thesis
Endometrium is a vital steroid responsive target tissue that is involved in various
functions such as menstruation, embryo implantation and after menopause, the
cessation of cyclical shedding and repair. Previous sections in this thesis present
the current understanding of the sex steroid receptor profile in the endometrium in
relation to the above mentioned physiological events. However as is evident from
the discussion so far, a clear understanding of the complex set of events in each
situation is lacking.
In relation to embryo implantation, there are some available data regarding the
endometrial sex steroid receptor expression during the putative window of
implantation. However with the advent of assisted conception technologies and
with the very significant hormonal manipulation incumbent in these treatment
regimes, it is possible that the hormonal manipulation would have an impact,
probably adverse, on the mid-luteal endometrium. GnRH antagonists have been
introduced in IVF/ICSI treatment regimes within the last two decades. These
agents do lead to significant hormone fluctuations within a short period of time and
some studies have raised concerns about reduced pregnancy rates. Till date the
impact of GnRH antagonists on the mid-luteal endometrium has not been
adequately evaluated. The effects of GnRH antagonists could be mediated directly
through the GnRH receptor which has been localised in the endometrium or they
may be mediated indirectly via the steroid receptors or indeed through an alteration
in the intracrine modulation thereby affecting ligand availability within the
endometrial cell. The key enzymes involved in the intracellular ligand availability
are the 17p-hydroxysteroid dehydrogenases and the 3p- hydroxysteroid
dehydrogenases.
With progressive longevity, women spend increasing number of years post
menopause. For a significant proportion of women, menopause brings with it
troublesome complaints inter alia vasomotor symptoms and irregular vaginal
bleeding. HRT is commonly used to alleviate these troublesome symptoms. All
currently available HRT regimes have a common side effect - breakthrough
bleeding. The mechanisms of HRT related breakthrough bleeding are ill
understood. The steroid receptor expression at the time of a bleeding episode may
73
provide clues regarding the influence of HRT on human endometrium and
especially its relation to HRT related breakthrough bleeding.
Menstruation is a regular and frequent cyclical event in the female reproductive
life. Progestins and especially the levonorgestrel intra-uterine system (LNG-IUS)
are widely used in the treatment of menstrual problems. However as with other
progestins, breakthrough bleeding is a common side effect associated with the use
of LNG-IUS leading to discontinuation of use by some women. In comparison,
progesterone antagonists (PA) have shown encouraging results. They reduce
menstrual blood loss without leading to BTB. In primate studies, systemic
administration of a PA ZK230211 led to suppression of ovulation and
menstruation. Intra-uterine release of ZK230211 had an antiproliferative effect on
primate endometrium. Thus intrauterine release of PAs, especially ZK230211, may
make them useful in hormone therapy for various gynaecological indications in
humans. Specifically, endometrial suppression by means of PA-releasing IUS
might be effective in the treatment of heavy or prolonged uterine bleeding.
Moreover, an AP-IUS is likely to convert the endometrium into a non-receptive
state, which may be utilized in the development of novel contraceptive strategies.
Based on available data on the above conditions, the following hypotheses are
proposed:
1. Endometrial exposure to recombinant FSH and a GnRH antagonist alters
steroid receptor and the sex steroid hormone metabolizing enzyme
expression, thereby influencing the intracellular availability of sex
hormones within the endometrium. These alterations may contribute to
reduced pregnancy rates seen in women treated with recombinant FSH and
a GnRH antagonist as a part of IVF/ICSI treatment.
2. All HRT preparations have a common side effect - breakthrough bleeding.
In the pre-menopausal state, progesterone use leads to similar side effects.
Continuous combined HRT leads to progestational effects on the
endometrium. Hence, mechanisms of breakthrough bleeding should be
similar in pre-menopausal long term progestin users and in postmenopausal
continuous combined HRT users. The steroid receptor expression should
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therefore mimic the changes seen after pre-menopausal long term progestin
use.
3. Intrauterine delivery of progesterone antagonists causes endometrial
antiproliferative effects and amenorrhoea in primate models. With many
commonalities between primate and human endometrium, similar changes
should occur in human endometrium after long term administration of AP-
IUS.
The aims of this thesis thus were:
1. To study the midluteal phase endometrium during the putative window of
implantation after treatment with a rFSH and a GnRH antagonist as used in
an IVF/ICSI treatment cycle. The aim was also to determine the
endometnal intracrinology in relation to expression of sex-steroid receptors
and steroid metabolizing enzymes during the putative window of
implantation.
2. To investigate whether a relationship exists between endometrial steroid
receptor expression and bleeding patterns in HRT users.
3. To evaluate the endometrial effects of intrauterine release of the PA
ZK230211 versus progestin LNG in women with complaints of heavy or





3.1 Human Endometrial Tissue Collection
Endometrial tissue samples were obtained from women attending the gynaecology
departments of three hospitals for the respective studies presented in this thesis. All
women provided written informed consent and all studies were approved by the
local institutional ethics committees.
3.1.1 Endometrial specimens from women exposed to rFSH and GnRHantag
Women who took part in this study were recruited in the Royal Infirmary of
Edinburgh. For the entire study, endometrial tissue samples were obtained with a
Pipelle® endometrial sampling device (Pipelle de Cornier, Laboratoire CCD, Paris,
France) (Figures 3.1(a) and 3.1 (b)). After collection of endometrium, the tissue
was fixed in 4% paraformaldehyde and then embedded in paraffin for
immunohistochemical analysis. In addition, endometrium was also frozen at the
point of tissue collection in liquid nitrogen and stored at -70°C. RNA was extracted
from frozen endometrial tissue. All endometrial samples were histologically
classified as per the Noyes criteria (Noyes et al., 1950) to confirm the mid-luteal
stage of the cycle. All studies on the endometrial tissue were carried out in the
University of Edinburgh Centre for Reproductive Biology. The endometrial tissue
samples were subjected to Immunohistochemistry and Quantitative Real Time -
Polymerase Chain Reaction (QRT-PCR) as described in sections 3.2 and 3.3.
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Figure 3.1 (b) Endometrial biopsy sample using the Pipelle sampling device
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3.1.2 Endometrial specimens from postmenopausal women in the presence
or absence of Hormone Replacement Therapy
The endometrial samples for this study were obtained in the Menopause clinic at
King Edward Memorial Hospital, Perth, Western Australia. Endometrial biopsies
were obtained with the Pipelle* endometrial sampling device (Pipelle de Cornier,
Laboratoire CCD, Paris, France). After collection, biopsies were fixed immediately
in 10% formalin for 18 hours and tissue was then embedded in paraffin. Sections
were cut at 5 pm. The sections were dried at 37°C overnight. All biopsies had a
standard haematoxylin and eosin section submitted to an experienced
histopathologist for classification according to Noyes criteria (Noyes et al., 1950)
and for identification of any pathological features. The tissue sections were
subjected to immunohistochemical analysis (as described below) which was carried
out in the University of Edinburgh Centre for Reproductive Biology.
3.1.3 Endometrial specimens from women using an Antiprogestin -
Intrauterine System (AP-IUS)
The endometrial tissue samples were obtained from women at the Department of
Obstetrics and Gynaecology, Helsinki University Central Hospital, Finland.
Samples were obtained at the time of a hysterectomy. Following surgery and
collection of specimens for routine pathological examination, separate samples of
endometrium were collected from the fundal, mid-corpus and isthmic areas of the
uterus for haematoxylin and eosin staining and immunohistochemistry (IHC). For
the studies in this thesis, tissue samples from the fundus were used. The samples
were frozen and pre-prepared paraffin blocks were submitted to the University of
Edinburgh Centre for Reproductive Biology for immunohistochemical analysis.
Immunohistochemistry experiments for all markers except the decidualization
marker IGFBP-1 were conducted at the University of Edinburgh Centre for
Reproductive Biology. Immunohistochemistry for IGFBP-1 was conducted in the
University of Turku, Finland.
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3.2 Immunohistochemistry
Immunohistochemistry is the process of localization of antigens or proteins in cells
of a tissue section by the use of labelled antibodies as specific reagents through
antigen-antibody interactions that are visualized by a marker. A chromogen, e.g.
diaminobenzidine (DAB), used in all immunohistochemistry protocols included in
this thesis, is an example of one such marker. A standard Avidin-Biotin Complex -
Horseradish Peroxidase (ABC-HRP) method was employed in most of the studies.
Briefly, the primary antibody binds specifically to the protein of interest and the
biotinylated secondary antibody recognises and binds to the antigenic sites on the
primary antibody. An avidin-biotin-HRP complex binds to the biotin on the
secondary antibody and the marker DAB binds the HRP and is oxidised. This
causes a visible colour change which results in a brown staining of the tissue
sections at the sites of antibody interaction (Figure 3.2).
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Figure 3.2 Diagrammatic representation of ABC-HRP immunohistochemistry
method. Adapted from Dako UK Ltd. Handbook of Immunohistochemical staining
methods 3rd edition, (Boenisch, 2001).




For studies in this thesis, immunohistochemistry (IHC) was performed for the
localisation of several steroid receptors, steroid metabolizing enzymes and other
markers. The steroid receptors studied included Estrogen Receptor a (ERa),
Estrogen Receptor p (ERP), Progesterone Receptor (PR), Androgen Receptor (AR)
and the Glucocorticoid Receptor (GR). The steroid receptor metabolizing enzymes
studied included 3p-Hydroxysteroid Dehydrogenase (3PHSD) and 17P-
Hydroxysteroid Dehydrogenase Type 5 (17PHSD5). The currently available
3PHSD antibody recognizes both human 3pHSDl and 3PHSD2 enzymes. No
documented antibodies were commercially available for 17PHSD2 enzyme and
hence no immunochemistry was performed for this enzyme. The proliferation
markers studied included Ki-67 and Phosphorylated Histone 3 (PH3). The marker
of endometrial decidualisation, Insulin like Growth Factor Binding Protein - 1
(IGFBP-1) was also studied with IHC.
All protocols were optimized to achieve the best conditions for immunostaining.
The protocols are summarised below.
3.2.1 General Immunohistochemistry Protocol
Immunohistochemistry experiments were conducted by progressing through
sequential steps in the following order.
• Slide preparation
• Antigen retrieval - was carried out in some experiments. This step is
required to break the bonds created by fixation and to expose the antigen to
allow antibodies to bind.
• Endogenous peroxidase block - the endogenous peroxidases need to be
blocked to prevent excess background staining.
• Avidin-Biotin Block - endogenous avidin and biotin also need to be
blocked to prevent excess background staining.
• Non-immune block - background staining was further prevented by the
inclusion of a non-immune block.
• Primary antibodies - were diluted to the appropriate concentration
determined by titration in the serum used for blocking. Where possible, the
primary antibody was pre-absorbed against a blocking peptide for use as a
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negative control. Alternatively, pre-immune serum or generic
immunoglobulins from the same species at the same concentration as the
primary antibody was used. Positive controls were tissue sections known to
express high levels of the protein of interest.
• Secondary antibodies - biotinylated secondary antibodies raised against the
immunoglobulins of the species in which the primary antibody was raised
were diluted as described in the serum solutions used for the non-immune
block.
• Tertiary antibody- The ABC-Elite detection system (Vector Laboratories)
was used to amplify the signal from the biotinylated secondary antibody.
• Developing and counterstaining - slides were developed and staining was
observed after applying 3, 3'-diaminobenzidine (DAB; Dako, Cambridge,
UK).
An example of a general immunohistochemistry protocol is described below.
Paraffin block sections were cut to 5 microns thickness and were mounted on
superfrost glass slides (BDH, Merck House, Poole, Dorset, England). Slides were
dewaxed in histoclear for 10 min and then rehydrated in descending grades of
alcohol (100% ethanol for 2 minutes, 95% ethanol for 2 minutes, 70% ethanol for 2
minutes) to distilled water (dH20). The sections were washed in dH20 for 10
minutes. The slides were then washed in phosphate buffered saline (PBS, Sigma-
Aldrich Ltd. Poole, Dorset, England) for 10 minutes.
After this, an antigen retrieval step was performed if required. Endogenous
peroxidase activity was blocked. This was performed by incubating the sections in
3% hydrogen peroxide in dH20 for 10 min at room temperature. Tissue sections
were then washed for 10 min in PBS. This was followed by 15 min incubation with
avidin (Vector Laboratories Ltd, Peterborough, UK) at room temperature. After a
rinse in PBS for 2 min, the sections were incubated with biotin (Vector
Laboratories Ltd) for a further 15 min at room temperature. Following a 2-min
wash in PBS, normal horse serum (NHS, Vectastatin, Vector Laboratories) was
applied to each tissue section. This was followed by incubation for 20 min in a
humidified chamber at room temperature. The excess serum was removed and the
primary antibody was applied. The negative control for the primary antibody was
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substituted with mouse immunoglobulin G (mlgGl, Sigma) or rabbit pre-immune
serum at the same concentration. After the primary antibody incubation, the
sections were washed between each stage for 10 min in PBS+Tween 20. The
secondary antibody was then applied. To identify positive staining, the peroxidase
substrate diaminobenzidine (Dako, Cambridge, UK) was used as chromogen for
demonstration of epitope. Tissue sections were washed in dH20 and counterstained
with Harris's haematoxylin (a non-specific purple nuclear stain), dehydrated in
ascending grades of alcohol and mounted from xylene using pertex mounting
medium. A similar protocol was used for immunostaining of all receptors. Specific
incubation conditions for immunolocalization of each of the epitopes studied are
described here and are summarized in sections 4.2, 5.2 and 6.2 respectively.
BOND® Automated Immunohistochemistry
For the study examining HRT exposed endometrium, the BOND® (BOND system,
Vision Biosystems, UK) automated system was used for IHC. Separate IHC runs
were carried out for each steroid receptor. An antigen retrieval step was carried out
as described previously and then the tissue sections were placed in the BOND®
automated IHC machine for the remainder of the steps in the protocol. The sections
were then removed from the machine, washed in dH20 and counterstained with
Harris's Haematoxylin, a non-specific purple nuclear stain. They were then
dehydrated in ascending grades of alcohol and mounted from xylene using pertex
mounting medium.
3.2.2 Androgen Receptor (AR) Immunohistochemistry Protocol
AR IHC was performed on paraffin sections (5 microns in thickness). These were
dewaxed in histoclear for 10 minutes and rehydrated in descending grades of
alcohol to distilled water ((IH2O) as described in section 3.2. The sections were
then washed in dH20, after which a pressure cook antigen retrieval step was
performed. The sections were heated in 0.01M sodium citrate buffer (pH6) for 5
minutes at setting 2/high in Tefal Clipso pressure cooker, followed by 20 minutes
incubation in the pressure cooker. Following a lOminute wash in 0.01M Phosphate
Buffered Saline pH 7.4 (PBS, Sigma, Dorset, UK), endogenous peroxidase activity
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was blocked by incubating the sections in 3% hydrogen peroxide in dH20 for 10
minutes at room temperature. Sections were then washed for 10 minutes in PBS
followed by 15 minutes incubation with avidin (Vector Laboratories Ltd,
Peterborough, UK) at room temperature. Following a 2 minute wash in PBS,
normal horse serum (NHS, Vectastatin, Vector Laboratories, Peterborough, UK)
was applied to each tissue section and incubated for 20 minutes in a humidified
chamber at room temperature. The excess serum was carefully blotted off and 70pi
of a monoclonal mouse anti-AR antibody (Biogenex, CA, USA), at a dilution of
1:240 in PBS/l%BSA/0.1%Gelatin (Sigma, Dorset, UK) was applied. Coverslips
were placed over the tissue sections to minimise antibody evaporation and the
sections were incubated overnight at 4°C. The primary antibody was substituted
with mouse immunoglobulin G (MigGl, Sigma, Dorset, UK) at a matched
concentration (1:300), to the androgen receptor antibody for the negative control
sections.
After the primary antibody incubation, the sections were washed between each
stage for 10 minutes in PBS + Tween 20 (PBST). The sections were incubated with
biotinylated horse-anti mouse IgG and then with an avidin-biotin peroxidase
detection system, ABC-Elite (Vectastatin, Vector Laboratories Ltd, Peterborough,
UK), both for 60 minutes at room temperature. To identify positive staining, the
peroxidase substrate diaminobenzidine (DAB; Dako, Cambridge, UK) was applied
to the tissue sections; this forms a brown precipitate on contact with the antigen-
antibody complex. The sections were washed in cttUO and counterstained with
Harris's Haematoxylin, a non-specific purple nuclear stain, dehydrated in
ascending grades of alcohol and mounted from xylene using pertex mounting
medium.
3.2.3 Estrogen Receptor a (ERa) Immunohistochemistry Protocol
A protocol similar to AR IHC was used with the following exceptions. The
sections were not pre-treated with avidin and biotin. Prior to the endogenous
peroxidase block step, a microwave antigen retrieval step was necessary whereby
the sections were heated in 0.01M sodium citrate buffer (pH6) for 10 minutes at
high power followed by 20 minutes incubation in the oven. The primary antibody
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used was monoclonal mouse anti-ERa antibody (Dako, Cambridge, UK), at a
dilution of 1:400 in PBS. For the negative controls a 1:2400 dilution of MIgGI in
o
PBS was used. The primary antibody incubation was for 60 minutes at 37 C.
3.2.4 Estrogen Receptor P (ERP) Immunohistochemistry Protocol
A protocol similar to AR IHC was used with the following exceptions. The
sections were not pre-treated with avidin and biotin. The sections were washed in
Tris Buffered Saline (TBS) instead of PBS. The sections were heated in 0.05M
Glycine/0.01% EDTA buffer (pH8) for 7 minutes, setting 2/High in the pressure
cooker. The endogenous peroxide block was carried out using 3% H2O2 in
Methanol for 30 minutes at room temperature. A 1:5 dilution of normal rabbit
serum in TBS + 5% BSA (NRS/TBS/BSA) was used for the non-immune block.
The primary antibody used was monoclonal mouse anti-ERpi antibody (Serotec,
Oxford, UK), at a dilution of 1:40 in NRS/TBS/BSA. For the negative controls,
NRS/TBS/BSA was used. The secondary antibody was biotinylated rabbit anti-
mouse IgG (Dako, Cambridge, UK) at a concentration of 1:500, prepared in
NRS/TBS/BSA. ABC-Streptavidin (Dako, Cambridge, UK) was used in place of
ABC-Elite.
3.2.5 Progesterone Receptor (PR) Immunohistochemistry Protocol
A protocol similar to the AR IF1C was used with the following exceptions. The
sections were not pre-treated with avidin and biotin. Prior to the endogenous
peroxidase block step, a microwave antigen retrieval step was necessary whereby
the sections were heated in 0.01M sodium citrate buffer (pH6) for 10 minutes at
high power followed by 20 minutes incubation in the oven. The primary antibody
used was monoclonal mouse anti-PR antibody (Novocastra, Newcastle, UK), at a
dilution of 1:40 in NHS. For the negative controls a 1:800 dilution of MIgGI in
o
NHS was used. The primary antibody incubation was for 60 minutes at 37 C.
Incubations with the secondary antibody and ABC were for 30 minutes only.
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3.2.6 Glucocorticoid Receptor (GR) Immunohistochemistry Protocol
A protocol similar to that for AR IHC was used. The only exception was that the
primary antibody used was the monoclonal mouse anti-GR (Novocastra,
Newcastle, UK), diluted 1:40 in a 1:5 dilution of normal rabbit serum (Diagnostics
Scotland) in PBS + 5%BSA (NRS/PBS/BSA) and a 1:320 dilution of MigGl for
negative controls.
3.2.7 3p-Hydroxysteroid Dehydrogenase (3|3HSD) Immunohistochemistry
Protocol
A protocol similar to AR IHC was used with the following exceptions. No antigen
retrieval was performed. The primary antibody used was a polyclonal rabbit anti-
3PHSD (Professor J I Mason, University of Edinburgh), at a dilution of 1:500 in
NGS/PBS/BSA. The 3pHSD rabbit polyclonal antibody was raised against
recombinant human 3PHSD2 and recognizes both human 3PHSD1 and 3pHSD2
with similar affinity (McDonald SE, Mason JI, Critchley HOD; unpublished
observations). For negative controls, pre-immune serum at a dilution of 1:500 in
NGS/PBS/BSA was used.
3.2.8 17p-Hydroxysteroid Dehydrogenase Type 5 (17pHSD5)
Immunohistochemistry Protocol
A protocol similar to AR was used with the following exceptions. The primary
antibody used was monoclonal mouse anti-17pHSD5 (a generous gift from
Professor Trevor Penning, University of Pennsylvania, USA) at a dilution of 1:200
in NHS/PBS/BSA. For negative controls, a 1:300 dilution of MIgG in
NHS/PBS/BSA was used.
Although a mouse monoclonal antibody against human 17PHSD2 was used in an
earlier study (Burton et al., 2003), neither this nor any commercial 17PHSD2
antibody were currently available and hence no immunochemistry was performed
for this enzyme.
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3.2.9 Ki-67 Immunohistochemistry Protocol
A protocol similar to the AR IHC was used with the following exceptions. Prior to
the endogenous peroxidase block step, a microwave antigen retrieval step was
necessary whereby the sections were heated in 0.01M sodium citrate buffer (pH6)
for 10 minutes at high power followed by 20 minutes incubation in the oven. The
primary antibody used was monoclonal mouse anti-Ki67 antibody (Novocastra,
Newcastle, UK), at a dilution of 1:50 in PBS. For the negative controls a 1:500
dilution of MIgG in PBS was used. Incubations with the secondary antibody and
ABC were for 30 minutes only. ABC-HRP was used in place of ABC-Elite.
3.2.10 Anti-Phospho-Histone 3 (PH3) Mitosis Marker Immunohistochemistry
Protocol
A protocol similar to AR IHC was used with the following exceptions. The
sections were not pre-treated with avidin and biotin. The primary antibody used
was a rabbit anti-phospho-Histone (H3, Upstate Biotechnology, Buckingham, UK)
antibody at a dilution of 1:1000 in normal goat serum (Vector Laboratories Ltd,
Peterborough, UK). For the negative controls, a 1:1000 dilution of rabbit IgG
(rlgG) (Vector Laboratories Ltd, Peterborough, UK) was used. The secondary
antibody was biotinylated goat anti-rabbit IgG (Vector Laboratories Ltd,
Peterborough, UK). ABC-HRP (Vectastatin, Vector Laboratories Ltd,
Peterborough, UK) was used in place of ABC-Elite.
3.2.11 Insulin like Growth Factor Binding Protein - 1 (IGFBP-1)
Immunohistochemistry Protocol
This part of the study was carried out in the Department of Pathology, University
of Turku, Turku, Finland. The protocol used for IGFBP-1 immunostaining was as
described previously (Pekonen et al., 1992).
A protocol similar to the AR IHC was used with the following exceptions. The
sections were pre-treated with avidin and biotin using the Vectastatin ABC-Kit
(Vector Laboratories Inc., Burlingame, CA). The primary antibody used was
monoclonal mouse anti-IGFBP-1 antibody (MAb 6303, Medix Biochemica,
Kauniainen, Finland) at a dilution of 1:1000 in PBS containing 0.5% Tween. For
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the negative controls a 1:1000 dilution of MIgGI was used. The primary antibody
incubation was for 60 minutes. Incubations with the secondary antibody and ABC
were for 60 minutes. To identify positive staining, the peroxidase substrate 3-
amino-9-ethylcarbazole (lOmg/ml; red stain) in acetate buffer, pH5, and containing
0.03% hydrogen peroxide was applied.
3.2.12 Optimization of Immunohistochemistry Protocols
To ensure valid results from Immunohistochemistry experiments, optimization of
immunostaining protocols is a vital step. Local immunostaining protocols have
been optimized previously by other members of this laboratory prior to the start of
these studies. For optimization experiments, all antibodies were tested individually
at a range of dilutions and with different antigen retrieval conditions to determine
the protocol that gave the least background and highest specific signal before
additional optimization of double staining conditions (Henderson et al., 2003).
To ensure validity of results in each run, positive controls were included in each
immunostaining run. Endometrial tissue known to be positively stained for the
respective receptor types was used as positive control. The positive control slides
were stained along with the study slides and before analyzing the biopsies included
in the respective study, the positive control slides were checked to determine
appropriate staining.
Negative controls were also included in each run. These were stained by omitting
the primary antibody or by replacing the primary antibody with normal serum
preferably from the same species as the primary antibody. Absence of staining in
the negative control would confirm the specificity of the antibody.
3.2.13 Immunohistochemical Analysis and Statistics
Throughout the studies included in this thesis, protein expression has been studied
in 5 endometrial compartments i.e. Glands, Stroma, Surface Epithelium, Vascular
Endothelium and in Perivascular cells. It is considered that perivascular cells are
smooth muscle cells (rather than stromal cells), with separate functions and hence
they are assessed independently of the adjacent stromal cells.
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A semi-quantitative scoring system was utilised for all IHC experiments. In
examining the slides, immunostaining scores were allocated on the basis of staining
intensity. Examination of the slide was started at a low magnification to get a sense
of overall staining across the slide. Then moving to a higher magnification the
analysis focussed on the part of the slide representative of the overall staining.
Staining intensity in each compartment was evaluated. Each observer scored the
slides independently and then the scores were compared. Where there was
agreement in scoring, these were accepted as the final scores. Where observers
differed, a third observer, who was familiar with this scoring method, was asked to
see the slides and allocate scores. The score that was allocated by 2 out of 3
observers was taken as the final score.
The immunostaining intensity and localization of epitopes in whole tissue sections
was assessed in a semi-quantitative manner on a four point scale: 0 = no staining; 1
= mild/minimal immunostaining; 2 = moderate immunostaining and 3 = intense
immunostaining. All tissue sections were scored blind by at least two observers.
Because of the discontinuous nature of the semi-quantitative IHC data, the non-
parametric Mann-Whitney test was performed. Where comparisons between
groups were required, Dunn's multiple comparison correction was then applied to
the p values from each set of tests. Results with a p value <0.05 were considered to
be significant differences.
This scoring system has been previously validated in a study comparing
quantitative and semi-quantitative scores (Wang et al., 1998). In that study a high
correlation with a regression coefficient of 0.963 was found between the two
methods. This provides a high level of confidence in the semi-quantitative scoring
system and since it is much less time consuming than quantitative scoring methods,
the former was preferred in all the studies included in this thesis.
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3.3 Real Time Quantitative Reverse Transcription - PCR (QRT-
PCR)
3.3.1 RNA extraction
Endometrial tissue was collected either with a Pipelle* sampler or at hysterectomy
• . . 0
as described in section 3.1. Tissue was immediately frozen at -70 C. Endometrium
was homogenized and extraction was performed as detailed below. The tissue was
handled in such a manner to minimize possibility of RNAse contamination. All
instruments and disposables were certified RNAse free and sterile or were
autoclaved prior to use.
For RNA isolation, Trizol reagent (Invitrogen Life Technologies Ltd, Paisley, UK)
was used according to the manufacturer's instructions. This reagent is a
monophasic solution of phenol and guanidine isothiocyanate. During the process of
sample homogenization, Trizol maintains the integrity of the RNA while disrupting
cells and dissolving cell components. Chloroform is added followed by
centrifugation and this separates the solution into an aqueous phase and an organic
phase. RNA remains exclusively in the aqueous phase and after transferring the
aqueous phase, RNA is recovered by precipitation with isopropyl alcohol.
Using a hand-held homogenizer, 50-100mg of tissue was homogenized in 1ml of
Trizol reagent. Each homogenized sample was placed in a phase-lock gel heavy
o
tube and incubated for 5 minutes at 15-30 C to permit the complete dissociation of
nucleoprotein complex. Chloroform (0.2 ml per 1 ml of Trizol reagent) was added.
The sample tubes were capped, mixed by inversion for 15 seconds and incubated at
room temperature for 3 minutes. The samples were centrifuged at no more than
o
13000 rpm for 15 minutes at 4 C for separation of the mixture into two portions i.e.
the aqueous RNA containing phase above and the DNA/protein containing phase
below the gel in the phenol red layer.
The top portion, the aqueous phase, was transferred to 2 ml eppendorf tube. Then
0.5 ml of 100% isopropyl alcohol per 1 ml of Trizol reagent used for the initial
homogenization was added to allow precipitation of the RNA from the aqueous
phase. The samples were then incubated at room temperature for 10 minutes and
o
centrifuged at no more than 13000 rpm for 10 minutes at 4 C. The resulting
supernatant was removed leaving a pellet containing the RNA precipitate. The
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RNA pellet was washed once with 75% ethanol (by adding at least 1 ml of 75%
ethanol per 1 ml of Trizol reagent used for the initial homogenization) mixing the
samples by vortexing. The samples were then centrifuged at 7500 rpm for 10
minutes at 4 C. Finally, the RNA pellet was briefly air dried and then re-suspended
in RNA storage solution (Ambion, Austin, Texas, USA) and stored at -80°C until
required for Taqman PCR analysis.
3.3.2 RNA Quantitation
Optical density measurements were performed using the Genequant machine to
quantify the concentration of RNA. This machine automatically calculates the
concentration of RNA. A 1:10 dilution of RNA was made by dilution of 2 pi of
RNA in 8 pi of nuclease free H2O. An optical density ratio at a wavelength of
260nm to a wavelength of 280nm (260:280) was calculated. The sample was only
considered sufficiently pure for use in the studies if the ratio was greater than 1.6.
The concentration was then recorded.
3.3.3 Reverse Transcription
The reverse transcription polymerase chain reaction (RT-PCR) is a sensitive
method for the detection of low-abundance mRNA. RT-PCR assays are the most
common method for comparing mRNA levels in different sample populations
(Orlando et al., 1998). The first step in an RT-PCR assay is the reverse
transcription of the RNA template into cDNA. This is done since RNA cannot
serve as a template for PCR. The cDNA is exponentially amplified in a PCR
reaction. A further advantage of the RT step being carried out separately from the
PCR step is to facilitate the storage of the pool of cDNA for later use.
The genomic DNA was removed by subjecting the RNA to DNAse treatment, lpg
of each RNA was added to the individual mixtures containing lpl of DNAse buffer
and lpl of DNAse with the remaining volume being made up to 10 pi with
nuclease free water. The mixture was incubated at room temperature for 15 minutes
at which point lpl of 25 mM EDTA was added to stop the digestion reaction. Then
o
the mixture was incubated on a PCR block for 5 minutes at 99 C to denature the
DNAse. The mixture was then cooled on ice and samples were given a pulse
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centrifuge to collect any sample condensed on the eppendorf wall. Samples could
then be stored at -80 C until required for cDNA preparation.
The reverse transcription (RT) reaction was performed as described previously
(Henderson et al., 2003; McDonald et al., 2006). The RT-PCR reaction is
performed in a lOpl volume of reaction solution. 2 pi of DNAse treated mixture
containing 200 ng of RNA or RNA stock was diluted in nuclease free water to
prepare a concentration of 100ng/ pi from which 200ng (2 pi) of each sample RNA,
including a positive control, were added into 8 pi of master mix solution. The
master mix solution was made up of: lxTaqman RT buffer, magnesium chloride
(5.5 mmol/1), deoxyNTPs, random hexamers (2.5 pmol/1), multiscribe reverse
transcriptase (1.25 IU/ pi), RNAse inhibitor (0.40 IU/ pi) and nuclease-free water
(reagents from Applied Biosystems, Cheshire, UK). Each tube was mixed by
vortexing, pulse centrifuged and over-layered with mineral oil. PCR reactions were
carried out on a Hybaid Omn-E thermal cycler (Hybaid, Ashford, UK). The RT
reaction was conducted at 25 C for 60 min, 48 C for 45 min and 95 C for 5 min for
one cycle. An RT-negative control had template RNA but no multiscribe enzyme
included, and an RT H20 had template RNA replaced by nuclease-free water.
Negative controls were included in every run. The samples were then stored at -
20C.
3.3.4 Real Time RT-PCR
The Taqman assay (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA) is a
real time RT-PCR assay. It requires the use of the ABI Prism 7700 - a combined
thermal cycler/detector (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA)
which utilises sequential laser stimulation of its 96 reaction wells to detect
fluorescence between 500 nm and 660 nm. The fluorescence that is detected is then
analysed to quantify the amplicon of interest in the samples being analysed.
Presented below is a schematic diagram of the process involved.
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After completion of reverse transcription the assay requires the annealing of
specific oligonucleotide sequences to the cDNA under examination to be
successful. The endpoints of the amplicon are defined by two specific
oligonucleotide primers. This provides the first level of specificity with additional
specificity from the use of an oligonucleotide probe that hybridises to the amplicon
during the annealing/extension phase of the PCR. To avoid the amplification of
contaminant genomic DNA the primers should be designed to span an intron. This
is sometimes not possible and in such cases the RNA to be quantified should be
DNAse treated with RNAse free DNAse to minimise the potential for genomic
contamination of cDNA.
The assay utilises the 5'-3' nuclease activity of the DNA polymerase, Taq
polymerase, to hydrolyse a hybridisation probe that is bound to its amplicon. The
probe used for a Taqman assay is a 5'labelled FAM (6-carboxyfluorescene; a
fluorophore) 3'labelled TAMRA (6-carboxytetramethylrhodamine; a quencher)
FRET (Fluorescence Resonance Energy Transfer) probe. In FRET probes, the
fluorophore donor transfers its energy to the quencher suppressing fluorescence
due to its close proximity. In the absence of an amplicon complimentary to the
probe in the PCR, the probe remains unbound and its fluorescence cannot be
emitted for reporting. If the correct amplicon has been amplified, the probe can
hybridise to that amplicon after the denaturation step. It remains hybridised while
the polymerase extends the primers until it reaches the hybridised probes, when it
displaces its 5' end to hold it in a forked structure. The enzyme continues to move
from the now free end to the bifurcation of the duplex, where cleavage takes place.
This separates the FAM reporter and TAMRA quencher dyes meaning the
quencher can no longer suppress the reporter. Hence, the fluorescence is increased






















































3.3.4.1 Primer/Probe Design and Validation
The primers and probes used in the Taqman system need to be designed to very
exacting specifications. The Taqman system incorporates its own design program,
Primer express, to facilitate adherence to the design specifications for the Taqman
oligonucleotides that will in turn ensure successful hybridisation with the template
cDNA and efficient amplification. BLAST (Basic Local Alignment Search Tool)
searches were also conducted to determine the presence of sequences in the
scientific databases that are similar to those amplified by each set of primers.
Multiplexing is the use of more than one primer pair in the same tube. In the
experiments, a multiplexing strategy was utilised to allow relative quantitation of
cDNA between samples. In relative quantitation, one primer pair amplifies the
target and the other amplifies an endogenous reference in the same tube. An
endogenous reference is employed as there may be difference in the amount of
starting material between samples. The accepted method for minimising these
errors and correcting for sample-to-sample variation is to amplify, simultaneously
with the target, a cellular RNA that serves as an internal reference against which
other RNA values can be normalised (Karge et al., 1998). The ideal internal
standard should be expressed at a constant level among different tissues, at all
stages of development, and should be unaffected by any experimental treatment.
Currently three references are used; (3-Actin, GAPDH and ribosomal RNA (rRNA).
The endogenous reference used in these experiments was rRNA. It was used as it
constitutes 85-90% of cellular RNA, their levels are unlikely to vary under
conditions that may affect expression of mRNA (Barbu and Dautry, 1989) and it
has also been shown to be more reliable than the other two normalisation genes in a
comparison study of human malignant cell lines (Zhong and Simons, 1999).
VIC-labelled ribosomal 18s RNA probe and primers were used for normalisation in
this research project (Perkin-Elmer, Applied Biosystems, Warrington, UK). VIC is
an alternative fluorescent probe that is detected at a different wavelength from
FAM hence allowing discrimination between the two different labelled probes. To
prevent consumption of reagents by the abundant 18s within the tissue samples, the
concentration of 18s primers and probes were limited to the same degree in all
samples in accordance with the suggested protocol by applied biosystems.
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Prior to using the primers and probes for quantitation, the linearity of the response
was determined by serial dilutions of both measuring primer probe amplification
against a standard pool of RNA (cDNA) that expresses the target gene. The
dilutions were upto 1/64. The log of ng total RNA was plotted against the ACt. The
Ct is the cycle number at which the PCR signal crosses a designated threshold; and
the ACt is the difference between the Ct values for the specific amplicon and 18s.
The gradient of the best fit line through these points should be < 0.1.
3.3.4.2 Taqman Protocol
Real-Time quantitative RT-PCR was used to measure the levels of PR, ERa, ER0,
AR, 3PHSD types 1 and 2 and 17PHSD types 2 and 5 in the cDNA samples. A
reaction mixture containing Stratagene Taqman buffer, MgCh (5.5mmol/l), Sure
Start Taq DNA polymerase (0.025 IU/pl) (Stratagene, Amsterdam, Netherlands),
dATP (200 prnol/l), dCTP (200 pmol/1), dGTP (200 pmol/1), dUTP (200 pmol/1),
specific target amplicon forward and reverse probes (300 nmol/1) (Biosource,
Nivelles, Belgium) and specific probe (200 nmol/1) (Biosource, Nivelles, Belgium).
Additionally specific primer and probe for ribosomal 18s were also added at
50nmol/l (Perkin-Elmer; Applied Biosystems, Warrington, UK). The validated
primers and probes for 3PHSD1, 3pHSD2 and 17PHSD5 were 'Assay on Demand'
products supplied by PE Applied Biosystems and these primers were intron-
spanning.
The mixture was then aliquoted into separate tubes for each cDNA sample. An
amount of 2.5pl/replicate of 1:2.5 dilution cDNA was added to each tube. After
mixing, 23pl of each sample were added to the wells on a PCR reaction plate with
each sample being added and analysed in triplicate. Wells were sealed with optical
caps and the PCR reaction run on the ABI prism 7700 using standard conditions.
To assess if genomic DNA contamination was present, two negative controls were
added to the plate in triplicate. A no template (containing water) control and no
reverse transcriptase (containing RNA) control.
3.3.5 Taqman Analysis and Statistics
The PCR data was analysed using the formula 2"AACT (as described above the Ct is
the cycle number at which the PCR signal crosses a designated threshold). The
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ACT is the difference between the Ct value at the threshold for the target amplicon
and the internal normalisation control, 18S. AACT is the difference between the
ACT and the internal reference control, which all samples are compared to, thus
providing a relative value to the reference. Since each cDNA sample was analysed
in triplicate the mean ACT was used for each.
Statistical analysis was conducted using SPSS 11.0 for Windows. Since the number
of samples was small, the data were log transformed and then t-test was used to
evaluate whether there were significant differences in mean target mRNA
expression between samples. The error bars signify the standard error of the mean.
Results with a p value of <0.05 were considered statistically significant.
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CHAPTER 4
Midluteal endometrial intracrinology following controlled




Gonadotrophin-releasing hormone antagonists (GnRHantag), e.g. Cetrorelix and
Ganirelix, are now widely used in assisted conception treatments (Albano et al.,
2000; Olivennes et al., 2000; The European and Middle East Orgalutran Study
Group, 2001; The North American Ganirelix Study Group, 2001). They cause rapid
suppression of LH levels and have been found to reliably prevent premature LH
surges as a part of controlled ovarian hyperstimulation (COH) in IVF/ICSI
treatment (Albano et al., 2000). Their use shortens the treatment cycle and also
reduces the total amount of required gonadotrophins. Furthermore, they appear to
reduce the incidence of ovarian hyperstimulation syndrome (Ludwig et al., 2001;
Al-Inany et al., 2006). However, in comparison to the 'long protocol' with GnRH
agonists, with the use of GnRH antagonists there is an ongoing debate regarding
pregnancy rates. Whereas some studies have found similar pregnancy rates
(Ludwig et al., 2001), others have raised concerns about a drop in pregnancy rates
(Al-Inany et al., 2006).
Despite the advances in assisted conception practices, pregnancy rates are
approximately 20-25%. In stimulated cycles, the endometrium is exposed to
supraphysiological steroid hormone levels during the follicular phase and this
might be responsible for an altered steroid receptor expression profile in the early
luteal phase (Papanikolaou E, 2005). After treatment with recombinant FSH
(rFSH) and a GnRH antagonist, endometrial histological advancement at the time
of oocyte retrieval has been observed (Kolibianakis et al., 2002). There are limited
data however on the state of the endometrium during the putative window of
implantation with the use of the agents. Although not clearly defined, the window
of implantation is described as from Day 6 to Day 10 after the LH surge (Sharkey
and Smith, 2003).
GnRH antagonists and rFSH may impact the processes of implantation through
direct effects on the endometrium or indirectly through sex steroid availability and
activity. Estrogens (Norwitz et al., 2001; Ma et al., 2003), progestogens (Lessey,
2003) and probably also androgens (Apparao et al., 2002) are thought to play vital,
but as yet not fully defined, roles in the complex mechanisms underlying
endometrial development leading up to and after embryo implantation. These
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hormones act via their cognate receptors. An alteration of the receptor expression
profile could lead to changes in the function of the respective steroid hormone.
Intracellular ligand availability could also influence endometrial receptivity. The
enzyme 3|3-hydroxysteroid dehydrogenase/A5- A4-isomerase (3pHSD) is involved
in the biosynthesis of all classes of active steroids. Pregnenolone is converted to
progesterone under the effect of 3PHSD in the human endometrium and this might
be crucial for implantation and maintenance of pregnancy. In the secretory phase,
3PHSD is moderately expressed in the glandular epithelium of the endometrium
(Rhee et al., 2003). The enzymes 17PHSD2 and 17PHSD5 have been identified in
the human endometrium. The 17PHSD5 transforms not only androstenedione to
testosterone and estrone to estradiol (E2), but also progesterone to 20-
hydroxyprogesterone. In the endometrium, its expression has been localized to the
surface epithelium and the vascular endothelium (Pelletier et al., 1999). The
17pHSD2 has a major role in the inactivation of E2 to estrone. It is also responsible
for converting androgens to less potent forms, while also activating progesterone.
It is expressed in endometrial glandular epithelium, and is up-regulated by
progesterone (Maentausta et al., 1993). The availability of various androgenic
ligands to bind to the androgen receptor (AR) may be influenced by the local
presence of 17pHSD2 (Burton et al., 2003). The activity of 17PHSD2 has been
localized predominantly in the glandular epithelium but also in the endometrial
stroma. It has been postulated that the anti-estrogen action of progesterone in the
endometrial glands is mediated through this enzyme (Casey et al., 1994; Burton et
al., 2003).
The aim of this study was to compare the untreated mid-luteal endometrium with
the endometrium during the putative window of implantation after treatment with
rFSH and GnRH antagonists, by mimicking the exact conditions that would be
expected to occur in an IVF/ICSI treatment cycle. It was also to determine the
endometrial intracrinology in relation to expression of sex-steroid receptors and
steroid metabolizing enzymes during the putative window of implantation.
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4.2 Methods
First, the sex steroid receptor expression during the mid-secretory phase was
studied. Sex steroid receptor protein expression was studied with
immunohistochemistry (IHC) and the mRNA expression was studied with real time
quantitative - polymerase chain reaction (QRT-PCR). Second, the steroid
metabolising enzymes expression during the mid-secretory phase was evaluated.
Enzyme expression was studied with IHC and mRNA expression was studied with
QRT-PCR.
All endometrial samples were histologically classified as per the Noyes criteria
(Noyes et al., 1950) to confirm the mid-luteal stage of the cycle.
4.2.1 Patient characteristics:
Institutional ethical approval was obtained and all women gave informed written
consent. The study group consisted of parous women who had volunteered to
donate oocytes and women in the control group consisted of healthy parous women
with regular menses (25-35 days). The sample sizes and age demographics of the
women taking part in the respective parts of the study are presented in Tables
4.1(a) - (d). The women included in the study group, i.e. the oocyte donors,
underwent a cycle of ovarian stimulation as per the Edinburgh Assisted Conception
Unit's protocol (Thong et al., 2003). Recombinant-FSH (Gonal-F; Serono, UK)
was commenced on day 4 of the menstrual cycle. All donors commenced ovarian
stimulation at the dose of 150IU. Gonadotrophin releasing hormone antagonist,
Cetrorelix, was commenced at a dose of 0.25mg daily on day 7 or 8 of their cycle
once at least 2 or more follicles had reached the size of 11mm diameter. Ovarian
response was monitored by transvaginal ultrasound from day 4. When the three
largest follicles measured > 17mm, oocyte maturation was triggered by the
administration of a single subcutaneous injection of 10000U hCG (Profasi; Serono,
UK). Oocyte retrieval was performed 35-36 hours after hCG administration.
Progesterone (Cyclogest; Alpharma, UK) vaginal pessaries (200mg.) were
administered 12 hourly starting 2 days after oocyte retrieval and up to the day of
endometrial sampling. A pipelle endometrial biopsy (EB) was conducted 8-10 days
after hCG administration (Table 4.2(a)).
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Table 4.1 Age demographics of participants in respective parts of the studies
(a) - Sex steroid receptor protein expression
Immunohistochemistry study




Mean age (years) 38.0 ±2.7 31.0 ± 4.3 0.66
(b) - Sex steroid receptor quantitative mRNA expression
QRT-PCR study




Mean age (years) 41.4 ±2.4 31.0 ±4.9 0.92
(c) - Steroid metabolizing enzyme protein expression
Immunohistochemistry study




Mean age (years) 35.6 ±3.7 31.0 ±4.3 0.92
(d) - Steroid metabolizing enzyme quantitative mRNA expression
QRT-PCR study




Mean age (years) 41.7 ± 2.6 30.0 ±5.5 0.97
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Table 4.2 Biopsy timing in relation to hCG injection (study group) or urinary LH
surge (control group)








(b) Control Group (n=8)
Participant Biopsy day Progesterone










Note: The study design did not include taking blood samples for progesterone
levels from participants in the Study group. Women in the study group were oocyte
donors who were undergoing a cycle of ovarian stimulation and since they
underwent an oocyte retrieval, their 'ovulatory' status was not in doubt. While it is
recognised that this information would have been useful, it would have been
difficult to draw conclusions from progesterone levels when one group was more
likely to have uni-follicular ovulation (Control group) and the other group would
have had multi-follicular 'ovulation' (Study group).
The control group consisted of healthy parous ovulatory women with regular
menses (25-35 days) (Tables 4.1 (a) - (d)). Only parous women who attended the
gynaecology clinics with requests for sterilization or other complaints excluding
menstrual problems or infertility were included in the control group. Endometrial
biopsies from 8 of these women were available for the IHC studies. To help time
the endometrial biopsies, these women were asked to provide a urine sample on
alternate days from day 10 of their last menstrual period. Urinary LH levels were
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measured. An EB was performed 6-10 days (Table 4.2(b)) after the peak of a
urinary LH surge i.e. in the mid-luteal stage of the cycle (Figure 4.1). For
confirmation of ovulation a blood sample was obtained on the day of their
endometrial biopsy and the progesterone values observed are presented in Table
4.2 (b).
In a urine sample, an LFI surge would be detected a day after it has actually
occurred. Hence to ensure all suitable control women could be included in the
study we have 2 extra days allowed in the protocol for control subjects but this
would still ensure that the biopsies were within the window of implantation.
Whereas most of the endometrial biopsies were conducted in the middle of the
window of implantation (confirmed on histological dating), the extra days were
allowed in the protocol so that as many women as possible could be included. The
accuracy of endometrial dating was confirmed not only by serum progesterone
levels but also by histological examination of the endometrium.
There are limited data relating to sex steroid receptor expression in mid-luteal
phase endometrium. The one study by Simon and colleagues did not find any
significant changes in PR and ER expression at LH+7 after treatment with
Ganirelix when compared to mid-luteal (LH+7) untreated controls (also referred to
above). The same study did not find any difference in gene expression between
natural cycle and Ganirelix treated endometrium at LH+7 (Simon C et al., 2005).
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Figure 4.1 Diagram depicting the timing of endometrial biopsy in the study and










































































Endometrial tissue from a subset of five parous women was available for QRT-
PCR studies. In these women, the LMP, endometrial histology and serum
progesterone levels were all consistent with mid-luteal phase of the cycle. This
subset was chosen on the basis of mRNA quality. Although the mean age
difference between women in the two groups was substantial, since the aim of this
part of the study was quantitative analysis rather than qualitative analysis, it was
decided to include these women in this part of the study. To my knowledge, there
are no data to suggest that there are any quantitative mRNA changes in the
endometrium of women at different ages. Hence, accepting the limitations of
interpreting results in the background of a substantial difference in ages of these
women, in the absence of evidence to the contrary, for the current study, it was
assumed that as long as it was ensured that the endometrium was in the mid-luteal
stage, the quantitative data should be valid.
Endometrial tissue was fixed in 4% paraformaldehyde then embedded in paraffin
for immunohistochemical analysis. In addition, endometrium was also frozen at the
point of tissue collection in liquid nitrogen and stored at -70°C. RNA was extracted
from frozen endometrial tissue.
4.2.2 Immunohistochemistry
The expression of PR, ERa, ERji and AR and enzyme expression of 3PHSD and
17PHSD5 were studied with immunohistochemistry. The 3PHSD antibody
recognizes both human 3PHSD1 and 3PHSD2 enzymes. No documented antibodies
were available for 17PHSD2 enzyme and hence no immunochemistry was
performed for this enzyme.
The general immunohistochemistry protocol followed is described in section 3.2.1.
Table 4.3 summarises the incubation conditions for immunolocalisation of each of
the epitopes studied. Commercially available antibodies were used for
immunolocalisation of endometrial PR, ERa, ERP and AR. The 3PHSD rabbit
polyclonal antibody was raised against recombinant human 3PHSD2 and with
similar affinity recognizes both human 3PHSD1 and 3PHSD2 (McDonald SE,
Mason JI, Critchley HOD, unpublished observations). A mouse monoclonal
antibody against human 17HSD5 (Lin et al., 2004) was a generous gift from Dr
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Trevor Penning (University of Pennsylvania, Philadelphia, USA). Neither a mouse
monoclonal antibody against human 170HSD2 which was used in an earlier study
(Burton et al., 2003), nor any commercial 17HSD2 antibody were currently
available and hence no immunochemistry was performed for this enzyme.
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(Lin et al., 2004)
Mouse Immunoglobulin
G, Sigma, Dorset UK,
1:300 in NHS/PBS/BSA
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4.2.3 RNA extraction and RT-PCR
Frozen samples of endometrium stored at -70°C were homogenized and then total
RNA was extracted using Trizol (Invitrogen Life Technologies Ltd, UK) according
to the manufacturer's instructions. The genomic DNA was removed by subjecting
the RNA to DNAse treatment. After extraction the concentration and quality of
RNA were assessed using an Agilent bioanalyzer (Agilent Technologies, South
Queensferry, West Lothian, UK). The RT-PCR reaction was performed as
described before (Section 3.3; Henderson et al., 2003; McDonald et al., 2006). In
brief, a 10 pi volume of reaction solution containing the following: lxTaqman RT
buffer, magnesium chloride, deoxyNTPs, random hexamers, Multiscribe reverse
transcriptase, RNase inhibitor and nuclease-free water (reagents from Applied
Biosystems, Cheshire, UK) was used. 200 ng of template RNA was added. The RT
reaction was conducted at 25 °C for 60 min, 48 °C for 45 min and 95 °C for 5 min
for one cycle. RT-negative control had template RNA but no multiscribe enzyme
included, and an RT H2O had template RNA replaced by nuclease free water.
Negative controls were included in every run. The samples were then stored at
-20 °C.
4.2.4 Quantitative real-time PCR (QRT-PCR)
The primer/probe sets were designed using the Primer Express program (PE
Applied Biosystems) as described before (Section 3.3; Henderson et al., 2003) or
purchased from PE Applied Biosystems' Assay on Demand service. Where
possible these were chosen to span an intron to further reduce the chance of
spurious readings due to genomic DNA contamination. The sequences of the
primer/probe sets and their location within the specified cDNAs are given in Table
4.4. The 18S primers and probe were purchased from PE Applied Biosystems. A
Taqman real-time PCR mix was then prepared containing final concentrations of
Taqman universal PCR master mix (lx), ribosomal 18S forward and reverse
primers, and probe (50 nM; PE Applied Biosystems), forward and reverse primers
(300 nM), and probe for sequence of interest (200 nM; PE Applied Biosystems).
Wells were sealed with optical caps and the PCR was run on the Perkin-Elmer ABI
Prism 7900 (PE Applied Biosystems) using standard conditions.
Ill
The PR, ERa, ER(3 and AR mRNA and 3(3HSD types 1 and 2 and 17PHSD types 2
and 5 mRNA levels were studied with QRT-PCR. Taqman QRT-PCR was carried
out with primers and probes specific for the PR, ERa, ERp, AR, 3PHSD types 1
and 2 and 17PHSD types 2 and 5. The validated primers and probes for 3PHSD1,
3PHSD2 and 17PHSD5 were 'Assay on Demand' products supplied by PE Applied
Biosystems and these primers were intron-spanning.
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Table 4.4 Steroid receptor primer and probe sequences used for amplification by
real time QRT-PCR
Primer/probe Sequence Position Accession
no.
ERpi forward CCTGGCTAACCTCCTGATGCT 1459-
1480
AB006590
ERpi reverse CCACATTTTTGCACTTCATGTTG 1529-
1552 (r)
AB006590
ERpi probe AGATGTTCCATGCCCTTGTTACTCGCA 1499-
1525 (r)
AB006590
ERa forward TGATTGGTCTCGTCTGGCG 1523-
1541
NM_000125
ERa reverse CATGCCCTCTACACATTTTCCC 1602-
1624 (r)
NM 000125
ERa probe TGCTCCTAACTTGCTCTTGGACAGGAACC 1572-
1600
NM_000125
PR forward CAGTGGGCGTTCCAAATGA 2151
2170
NM_000926








AR forward GTACCCTGGCGGCATGGT 951-
1016
L29496
AR reverse CCCATTTCGCTTTTGACACA 951-
1016
L29496
AR probe AGCAGAGTGCCCTATCCCAGTCCCA 951-
1016
L29496
17PHSD-2 forward TGTCAGCAGCATGGGAGGA 731-803 LI 1708
17pHSD-2 reverse GGTCACAGCCGCCTTTGAT 731-803 LI 1708
17PHSD-2 probe CCCCAATGGAAAGGCTGGCATCTT 731-803 LI 1708
3pHSDl Assay on demand Hs00426435
ml
3PHSD2 Assay on demand Hs00605123
ml
17PHSD5(AKR1C3) Assay on demand Hs00366267
ml
The positions of the sequences are given within the cDNA, identified by the
accession number; r denotes reverse strand.
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4.2.5 Scoring, data presentation and statistical analysis of immunoreactivity.
The immunostaining intensity of epitopes in all tissue sections was assessed in a
semi-quantitative manner on a 4 point scale: 0 = no staining; 1 = mild/minimal
immunostaining; 2 = moderate immunostaining; 3 = intense immunostaining. All
tissue sections were scored blind by at least 2 observers. The semi-quantitative
immunohistochemistry data were analysed using the Mann-Whitney test. The





In patients treated with a rFSH-GnRH antagonist, almost all biopsies with
adequate tissue showed histological features consistent with mid-secretory phase of
the cycle. In one biopsy, there were features suggestive of advancement of the
dates and this was reported to be consistent with early to mid-secretory phase
endometrium. One endometrial biopsy sample submitted for histology was
unsatisfactory and hence histology on that sample could not be analysed (Table
4.5).
Immunoexpression of PR, ERa, ER|3, AR, 3(IHSD and 17pHSD5 at five cellular
locations, i.e. endometrial glands, stroma, surface epithelium, vascular endothelium
and perivascular cells, was studied. The mRNA transcripts of PR, ERa, ERp, AR,
3PHSD1, 3PHSD2, 17PHSD2 and 17PHSD5 were evaluated.
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Table 4.5 Histological analysis (dating) of endometrial biopsies of women treated
with a rFSH-GnRH antagonist
Biopsy number Histology report
1 Mid-secretory phase endometrium
2 Mid-secretory phase endometrium
3 Mid-secretory phase endometrium






PR immunoexpression (Table 4.6, Figures 4.2 and 4.3)
Compared with endometrium from untreated women, endometrium exposed to
Gonal-F® and Cetrorelix showed significantly reduced immunoexpression in
stroma (P < 0.05) and surface epithelium (P < 0.05). Conversely, PR
immunoreactivity was significantly increased in the perivascular cells (P < 0.05).
The difference in PR immunoexpression in the glands was significant (P < 0.05),
but we observed a marked variability in expression among the biopsies in the
control group.
ERa immunoexpression (Table 4.6, Figures 4.2 and 4.3)
Mild immunoexpression of ERa was observed at most cellular locations. No ERa
immunoexpression was observed in the vascular endothelium. No significant
differences were observed in endometrial ERa immunostaining between the two
groups of women.
ERp immunoexpression (Table 4.6, Figures 4.2 and 4.3)
ER(3 immunoexpression at most cellular locations was consistently strong with or
without treatment with GnRH antagonist and rFSH. Stromal expression was less
intense, but overall no significant differences were observed in endometrial ERp
immunoexpression between the two groups of subjects.
AR immunoexpression (Table 4.6, Figure 4.2)
AR immunoexpression was negligible in the glandular epithelium with or without
COH treatment. Stromal immunoexpression of AR was moderate, but overall no
significant differences were observed in endometrial AR immunostaining between
the two groups of subjects.
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Mean scores ± SD
Study (n=5)
Mean scores ± SD
p value
Glands 1.88 ±0.83 0±0 0.003*
Stroma 3 ± 0 2.2 ±0.45 0.019*







Perivascular cells 0.38 ±0.52 1.4 ±0.55 0.023*
*p < 0.05 denotes statistical significance (1Vlann-Whitney test)




Mean scores ± SD
Study (n=5)
Mean scores ± SD
p value
Glands 1.13 ±0.35 0.4 ±0.55 0.057
Stroma 1.63 ±0.74 1 ±0.71 0.213







Perivascular cells 1.5 ±0.53 1.6 ±0.55 0.769
p < 0.05 denotes statistical significance (Vlann-Whitney test)




Mean scores ± SD
Study (n=5)
Mean scores ± SD
p value
Glands 2.38 ±0.52 2.2 ± 0.45 0.523
Stroma 1.25 ±0.46 1.8 ± 0.45 0.063
Surface Epithelium 2 ±0.93 1.8 ±0.45 0.694
Vascular
Endothelium
1.88 ±0.35 1.6 ±0.55 0.271
Perivascular cells 1.63 ±0.52 1.4 ±0.55 0.446





Mean scores ± SD
Study (n=5)
Mean scores ± SD
p value
Glands 0.5 ±0.53 0.2 ±0.45 0.379
Stroma 2 ±0.76 1.6 ±0.55 0.379
Surface Epithelium 0.13 ±0.35 0.2 ±0.45 0.826
Vascular
Endothelium
0.25 ± 0.46 0±0 0.464
Perivascular cells 0.75 ±0.71 1 ±0 0.464
p < 0.05 denotes statistical significance (M ann-Whitney test)
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Figure 4.2 Immunoreactivity scores in different endometrial cellular
compartments. Note decreased PR in endometrial stroma (P=0.019)*, surface
epithelium (P=0.019)* and glands (P=0.003)* and increased PR in perivascular
cells (P=0.023)*. Box-and-whisker plots: box represents the 25th and 75th
percentiles, whiskers represent the 10th and 90th percentiles and the heavy bar
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Figure 4.3 Immunohistochemical localisation of steroid receptors in human
endometrium of women in the mid-luteal phase of cycle (control group) and in
women who have received COH and a GnRHantag (study group). (A) PR
immunostaining in endometrium from untreated women in mid-luteal phase -
intense stromal(S) and surface epithelial (SE) immunoreactivity (A) Inset - note
low level of perivascular immunostaining (arrow). (B) PR immunostaining in the
endometrium from women treated with GnRHantag and rFSH - reduced stromal
and surface epithelial immunostaining. (B) Inset - more intense perivascular cell
immunostaining (arrow). (C) ERa immunostaining in endometrium from women
treated with rFSH and GnRHantag - mild immunostaining at all cellular locations.
(C) Inset - absent immunostaining in the vascular endothelium (arrow). (D) ER0
immunostaining in endometrium from women treated with rFSH and GnRHantag.
- strong immunoreactivity in all cell types. (D) Inset - strong ERP immunostaining




3pHSD immunoexpression (Table 4.7, Figures 4.2 and 4.4)
Irrespective of COH, expression of 3J3HSD in the glands, surface epithelium and
endothelium was at a low level. No immunoexpression was seen in stroma or in
perivascular cells. No significant differences were observed in endometrial 3PHSD
immunostaining between the two groups of subjects.
17PHSD5 immunoexpression (Table 4.7, Figures 4.2 and 4.4)
Moderate to intense 17PHSD5 immunoexpression was observed in the endometrial
glands, and surface epithelium with or without treatment. No immunoexpression
was observed in stroma, however, negligible immunoexpression was observed in
perivascular cells. Moderate immunoexpression was observed in the vascular
endothelium. No significant differences were observed in endometrial 17PHSD5
immunostaining between the two groups of subjects.
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Table 4.7 Immunohistochemical semi-quantitative scoring results - Steroid
metabolizing enzyme expression data




Mean scores ± SD
Study (n=5)
Mean scores ± SD
p value





Surface Epithelium 0.83 ±0.98 0.4 ±0.55 J). 522
Vascular
Endothelium
0.33 ±0.52 0±0 0.361




p < 0.05 denotes statistical significance (Mlann-Whitney test)




Mean scores ± SD
Study (n=5)
Mean scores ± SD
p value





Surface Epithelium 2.17 ±0.75 1.8 ±0.45 0.411
Vascular
Endothelium






p < 0.05 denotes statistical significance (IVlann-Whitney test)
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Figure 4.4 Immunohistochemical localisation of selected steroid metabolising
enzymes in human endometrium of women in the mid-luteal phase of cycle
(control group) and in women who have received COH and a GnRHantag (study
group). (A) 3PHSD immunostaining in endometrium from untreated women in
mid-secretory phase - low level immunostaining at most cellular locations. (A)
Inset: low level immunostaining in vascular endothelium (arrow). (B) 3pHSD
immunostaining in the endometrium from women treated with rFSH and
GnRHantag. - low level immunostaining at most cellular locations. (B) Inset:
3PHSD negative - no immunostaining (C) 17pHSD5 immunostaining in
endometrium from untreated women in mid-secretory phase - moderate
immunostaining in glands (G) and surface epithelium (SE). No immunostaining in
stroma (S). (C) Inset: Moderate immunostaining in vascular endothelium (arrow).
(D) 17PHSD5 immunostaining in endometrium from women treated with rFSH and
GnRHantag. - moderate immunostaining in glands and surface epithelium. No
immunostaining in stroma. (D) Inset: 17PHSD5 negative - no immunostaining.
Scale Bar = 20 microns.
G = Glands, S = Stroma, SE = Surface Epithelium
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4.3.3 Quantitative real-time PCR (Table 4.8, Figure 4.5)
Sex-steroid receptors
QRT-PCR demonstrated a statistically significant reduction in the amount of
endometrial ERa mRNA (P = 0.02) and AR mRNA (P = 0.01) in COH treated
women compared with the controls. Although the level of PR mRNA was reduced
in the COH group, the difference was not significant (P = 0.12). No significant
differences were observed in the amount of ER(3 mRNA (P = 0.96) between the
two groups.
Steroid metabolizing enzymes
The 3pHSDl mRNA (P = 0.01) and 17pHSD2 mRNA (P = 0.02) levels were
significantly reduced in the COH group. In relation to 3pHSD2 and 17pHSD5
QRT-PCR, sufficient RNA was only available in 1 and 2 study samples,
respectively. Hence in these cases, the sample size was too small for analysis.
However, expression of adrenal/gonadal-specific 3pHSD2 transcripts is predicted
to be minimal in endometrium and the relative 3PHSD1/3PHSD2 transcript ratio
observed in the one sample is supportive of a minimal 3PHSD2 contribution to
endometrial 3PHSD.
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Table 4.8 Sex steroid receptors and steroid metabolizing enzymes quantitative
mRNA expression results
Sex steroid receptor mRNA expression
Control (n=5)
Mean 2AACT values ± SD
Study (n=4)
Mean 2AAcf ± SD
p value
PR 1.39 ±0.74 0.55 ±0.14 0.12
ERa 1.44 ±0.94 0.34 ±0.14 0.02*
ERB 0.35 ±0.37 0.18 ± 0.17 0.96
AR 0.72 ±0.35 0.16 ±0.05 0.01*
*p < 0.05 denotes statistical significance (t-test after log transformation)
Steroid metabolizing enzyme mRNA ex pression
Control (n=4)
Mean 2AACT values ± SD
Study (n=3)
Mean 2AAC values ±
SD
p value
33HSD1 2.11 ± 1.76 0.16 ±0.07 0.012*
17(3HSD2 2.13 ±2.15 0.06 ±0 0.028*
3(3HSD2 Sample size too small for analysis
173HSD5 Sample size too small for analysis
*p < 0.05 denotes statistical significance (t-test after log transformation)
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Figure 4.5 Quantitative evaluations of sex-steroid receptors and steroid receptor
metabolising enzymes mRNA expression of women in the mid-luteal phase of
cycle (control group) and in women who have received COH and a GnRHantag
(study group). (A) PR (PR), (B) ERa (ERa), (C) ERp (ERp), (D) AR (AR), (E)
3PHSD1 enzyme and (F) 17PHSD2 enzyme. All endometrial tissue samples were
compared with an internal control (comparator) obtained during the mid-luteal
phase of the menstrual cycle. ERa mRNA (P=0.02) and AR mRNA (P=0.01)
levels were significantly reduced in endometrial tissue from women treated with
GnRHantag and rFSH. 3pHSDl mRNA (P=0.01) and 17pHSD2 mRNA (P=0.02)
levels were significantly reduced in the endometrial samples from women treated
with GnRHantag and rFSH. Note scale (Y axis) in E and F differs from A-D














































The use of rFSH and a GnRH antagonist is an effective and reliable regime for
controlled ovarian stimulation as a part of IVF/ICSI treatment cycles. However, its
effects on the endometrium especially in relation to embryo implantation have not
been evaluated in detail. Although histological advancement of the chronological
stage of the endometrium has been observed at the time of oocyte retrieval
(Kolibianakis et al., 2002), the endometrial sex-steroid receptor protein and mRNA
expression levels during the putative window of implantation with the use of these
agents have not been reported. Furthermore no reports have been identified
describing expression of steroid metabolizing enzymes and their mRNA transcripts
during the window of implantation in the mid-luteal phase of the cycle with this
treatment regimen.
These studies have described a significant difference in PR protein expression in
women treated with rFSH and GnRH antagonist. Significant down-regulation of
PR protein expression in the endometrial stroma and surface epithelium was
observed. A significant up-regulation was observed in the perivascular cells in
women treated with cetrorelix and Gonal-F®. PR immunoexpression in the
endometrial glands was reduced in the treatment group, although the expression in
the controls was variable. No significant differences were observed in the protein
expression of ERa, ERp, AR, 3pHSD or 17pHSD5. Quantitatively, there was a
significant reduction in the levels ofERa mRNA, AR mRNA, 3PHSD1 mRNA and
17PHSD2 mRNA in the treatment group. No significant difference was observed in
the amount of ERp mRNA transcripts between the two groups of women, and
although PR mRNA was reduced in the treatment group, the difference was also
not significant.
Healthy fertile women were recruited as the control group. Women undergoing
assisted conception are a different group with alterations in physiological steroid
levels and possibly in the endometrium. Hence, recruiting untreated parous women
as a control group may not be the ideal equivalent comparison. However, the aim
was to try and understand the differences between the physiological state of
embryo implantation, which occurs in the mid-luteal phase in a natural ovulatory
cycle, and in rFSH and a GnRH antagonist treated endometrium. Hence, it was
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appropriate to include untreated fertile ovulatory women in the control group. In
the subjects in the control group, an LH surge was detected using an alternate day
urinary LH protocol. Urinary LH measurement may not be the most accurate way
of checking the timing of ovulation. However, it is possible to identify the window
of implantation on the basis of an alternate day urinary LH dating protocol. First,
the window of implantation is thought to extend over Days 5-10 after the LH
surge. Hence, even with urinary LH dating, it is possible to identify the putative
window of implantation. Second, it is theoretically possible that the difference of 1
or 2 days could influence the result. The endometrium has been dated not only by
LH dating, but also by histological dating and mid-luteal serum progesterone
concentration at the time of sampling.
There are no data to suggest that a difference of 1 or 2 days is likely to have a
major impact on the sex-steroid receptor expression. Indeed with the exception of
one study looking at the PR and ER expression at LH+7 after treatment with
ganirelix (Simon et al., 2005), where no alteration in the steroid receptor
expression was reported, data describing the steroid receptor expression in the mid-
luteal phase after treatment with rFSH and a GnRH antagonist has not been
previously reported. Luteal phase progesterone supplementation was administered
to the oocyte donors (study group) to mimic an actual treatment cycle. Evidence
exists to support the use of luteal phase progestogens after any form of down-
regulation in an IVF/ICSI treatment cycle (Beckers et al., 2003) and most centres
now offer this routinely. Administering progesterone supplementation in one group
(study) and not in another (control) may add an element of bias. However, the aim
was to compare the differences in the mid-luteal phase endometrium from fertile
untreated subjects, i.e. the physiological state with the mid-luteal endometrium of
women routinely treated with a GnRH antagonist and rFSH.
This study has shown that under the effect of a GnRH antagonist and rFSH with
luteal phase progesterone supplementation, there is a significant down-regulation
of PR in the surface epithelium. The observation of PR down-regulation in the
surface epithelium is in agreement with other studies evaluating PR content in the
secretory phase of a normal menstrual cycle. It has been suggested that under the
influence of progesterone, PR declines in the epithelium at the beginning of the
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window of implantation (Lessey et al., 1996). It therefore appears that any
hormonal fluctuations that may result in the serum due to treatment with cetrorelix
and Gonal-F® have little impact on intracellular PR in surface epithelium. In the
secretory phase of a normal menstrual cycle, significant PR expression has been
detected in the endometrial stroma (Lessey et al., 1988). However, under the effect
of a GnRH antagonist and rFSH and with progesterone supplementation, a
significant down-regulation of PR in endometrial stroma was noted. Several genes
have been localized to the endometrial stroma and significant proportions are
expressed during the secretory phase (Yanaihara et al., 2004). Studies have also
shown an important role for progesterone in the endometrial stromal cell in
induction of extracellular matrix in relation to implantation (Nakamoto et al.,
2005). A significant down-regulation of stromal PR could thus influence gene
expression during the secretory phase and adversely impact endometrial
receptivity.
PR protein has not been identified in the vascular endothelium (Krikun et al.,
2005), but PR are abundantly expressed in the perivascular cells throughout the
menstrual cycle (Perrot-Applanat et al., 1988; Critchley et al., 2001). In this study,
PR was significantly up-regulated in the perivascular cells of women treated with
cetrorelix and Gonal-F®. Progesterone acting on the perivascular cells has been
implicated in the modulation of endometrial blood flow. Furthermore, cytokine
control in the perivascular cells is thought to be controlled by progesterone (Kelly
et al., 2002). These factors may well be important in the process of embryo
implantation, and alterations of PR expression could influence these processes.
PR expression in the glands of untreated women was variable. In regular cycling
women, in the secretory phase, significant PR content was maintained in the
stroma, but diminished in the glandular epithelium (Lessey et al., 1988). In this
study, in some control biopsies, moderate glandular PR expression was maintained
however, as evident in the box and whisker plot, there was marked variability in
expression between biopsies. The number of women included in this study was
small and this may have contributed to the apparent trend towards an increased
mid-secretory PR expression in glands in untreated women. Furthermore, the
women included in the control group were different from those who provided the
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study biopsies in the treatment group. Whereas it would have been ideal to recruit
the same oocyte donors as controls to further reduce the bias, practically it was
only reasonable to seek an endometrial biopsy from an altruistic oocyte donor on a
single occasion. In the control group, the mid-luteal phase was confirmed through
consistency of reported LMP, circulating serum progesterone levels and
histological dating. It is interesting to note that with rFSH and a GnRH antagonist
treatment, glandular PR immunoexpression declined. This observation would be
consistent with PR expression in the secretory phase of an untreated cycle.
PR mRNA levels are known to vary during the human menstrual cycle. In the late
proliferative phase, glandular PR mRNA levels are significantly higher but it
reduced in the secretory phase. In the stroma, PR mRNA remains unchanged (Lau
et al., 1996). Although there was some reduction in PR mRNA levels in the
treatment group compared with the controls, the difference was not significant.
However, PR changes in whole biopsies may not reflect the subtle changes in
steroid receptor expression that exist between individual cell types.
In regular cycling women, ERa and ER(1 have been identified in the endometrial
epithelium, stroma, glands and perivascular cells (Saunders and Critchley, 2002).
Only ERp and not ERa is expressed in the vascular endothelium (Critchley et al.,
2001). No significant differences were observed in immunoexpression of either
ERa or ER|3 in treated women. Controlled ovarian stimulation is known to lead to
supraphysiological levels of E2 and progesterone. These are thought to affect the
endometrial receptivity through the predominantly progestational effects of
endometrial phase advancement and premature luteinization (Kolb and Paulson,
1997). Hence, it appears that ER-mediated signalling appears to be of less
importance in relation to implantation compared with PR mediated effects on the
endometrium. It is interesting to note however that quantitative RT-PCR showed
significantly reduced ERa mRNA levels in the treatment group.
AR expression is influenced by levels of circulating estrogens and androgens.
Epithelial AR is up-regulated by estrogens and androgens and is inhibited by
progestins (Slayden et al., 2001b; Apparao et al., 2002). AR is expressed in the
endometrial stromal cells. The intensity of expression declines from proliferative
phase to mid-secretory phase. In late secretory phase, AR expression is diminished
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in all cell types (Mertens et al., 2001). No significant difference in protein
expression of AR was observed in women treated with rFSH and a GnRH
antagonist, however, QRT-PCR showed significantly reduced AR mRNA levels in
the group of women treated with a GnRH antagonist and rFSH. So far, there are
very limited data on effects of AR and AR-induced gene expression in humans.
Studies in pigs show AR in the pig endometrium during the window of
implantation and demonstrate the functional, albeit complex, interactions of
androgens and estrogens in the regulation of uterine endometrial gene expression
and cell growth in vitro (Kowalski et al., 2004). Further studies are needed to
evaluate AR-induced gene expression in humans and the potential impact on
embryo implantation.
The 3PHSD is weakly expressed in the glandular epithelium of the proliferative
phase and moderately expressed in the glandular epithelium of secretory phase of
the endometrium (Rhee et al., 2003). In this study, irrespective of presence or
absence of treatment, immunoexpression of 3PHSD in the glands, surface
epithelium and endothelium was at a low level. No immunoexpression was seen in
stroma and perivascular cells. No significant difference was observed in
endometrial 3PHSD immunoexpression between the two groups of subjects. This
suggests that the pre-ovulatory supraphysiological levels of estrogen and
progestogen that result from COH and use of GnRH antagonists do not lead to any
significant alteration in the levels of 3pHSD protein during the window of
implantation. The currently available antibody against 3pHSD recognizes both
forms of human 3pHSD enzymes, types 1 and 2. Hence it is not possible to
comment on changes in the amounts of 3PHSD1 protein. However, RNA studies
indicate that 3PHSD1 mRNA transcripts may be changing. A significant reduction
in 3pHSDl mRNA was observed in women treated with a GnRH antagonist and
rFSH. The 3pHSDl is responsible for the conversion of inactive pregnenolone to
active progesterone and of dehydroepiandrosterone to androstenedione. A
reduction in 3PHSD1 transcripts will ultimately lead to a reduction of intracellular
progesterone. In the presence of altered PR expression, as observed with
immunohistochemistry, it is likely that the reduced ligand availability for binding
to PR leads to a disturbance in the dynamics of ligand-receptor interaction. This
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may affect progesterone mediated signalling pathways including alterations in gene
expression profiles thereby affecting the receptivity of the endometrium.
The 17PHSD5 transforms androstenedione to testosterone and also progesterone to
the inactive 20-hydroxyprogesterone, and in the endometrium its
immunoexpression has been localized to the surface epithelium and the vascular
endothelium (Pelletier et al., 1999). The findings in this study are in agreement
with previous reports. There was a moderate to intense 17pHSD5
immunoexpression in endometrial surface epithelium and vascular endothelium.
However, in this study, moderate 17pHSD5 immunoexpression was evident in the
endometrial glands. No immunoexpression was observed in stroma and negligible
immunoexpression was observed in the perivascular cells. No significant difference
was observed in the 17PHSD5 immunoexpression between the two groups of
subjects. A significant reduction of 17PHSD2 mRNA was demonstrated in women
treated with rFSH and a GnRH antagonist. Since 17PHSD2 is involved in the
inactivation of E2 to estrone and converting androgens to less potent forms, it is
likely that higher levels of intracellular E2 and androgens persist thereby further
disturbing the balance between estrogen, progesterone and androgens. This may
further affect the endometrial development leading to suboptimal endometrial
receptivity.
One previous report compared the effects of a GnRH antagonist treatment on mid-
luteal phase endometrium to the state of the mid-luteal endometrium in a natural
ovulatory cycle (Simon et al., 2005). That study only examined ER and PR
expression 7 days after an LH surge. The GnRH antagonist used in that study was
ganirelix. In the current study, cetrorelix was used and to my knowledge this is the
first report describing the ER, PR and AR expression as well as the steroid
metabolizing enzymes expression in a GnRH antagonist treated mid-luteal phase
endometrium.
The reason, why so few studies have addressed the mechanisms of endometrial
receptivity in IVF/ICSI cycles during the window of implantation is due to the
difficulty in obtaining, for detailed studies, endometrial biopsies at this phase of the




In summary, these are novel data describing the effects of a GnRH antagonist and
rFSH on sex-steroid receptor and steroid metabolizing enzymes expression in mid-
secretory phase endometrium. This study has shown that under the effect of rFSH
and a GnRH antagonist with progesterone supplementation, significant alterations
occur in endometrial intracrinology at a time when the endometrium would be
expected to be most receptive for implantation. The changes observed and the
putative alterations that might occur as a result of these changes are summarised in
Tables 4.9 (a), (b) & (c). The impact of these observations on embryo-endometrial
interaction requires further evaluation.
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Table 4.9 Summary of alterations in the endometrium after exposure to cetrorelix,
Gonal-F® and progesterone.
(a) Changes in protein expression
Endometrial compartment Changes observed
Surface Epithelium Decrease in PR
Glandular Epithelium Decrease in PR
Stroma Decrease in PR
Perivascular Cell Increase in PR
(b) Changes in mRNA expression
Endometrial compartment Changes observed
Endometrial cell Decrease in AR mRNA expression
Decrease in ERa mRNA expression
(c) Putative alterations in intracellular hormone concentrations as a result of
observed changes
Endometrial compartment Putative changes
Endometrial cell Decrease in progesterone concentration
Increase in estradiol concentration
Increase in androgen concentration
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CHAPTER 5
Endometrial expression of steroid receptors in




Hormone replacement therapy (HRT) is used by peri and postmenopausal women
for the relief of menopausal symptoms and the prevention of osteoporotic fractures.
The main therapeutic benefit is derived from estrogen but progestogen is necessary
to prevent endometrial hyperplasia and adenocarcinoma. The majority of
postmenopausal women take a continuous combined estrogen plus progestogen
therapy that aims to avoid any vaginal bleeding. However, unpredictable and
unscheduled vaginal bleeding or spotting is a common side effect described by up
to 60% of HRT users (al-Azzawi and Habiba, 1994), leading to discontinuation of
therapy in up to one in three users (Limouzin-Lamothe, 1996). Over 30% of cyclic
HRT users and nearly half of all continuous combined HRT users make at least one
visit to their gynaecologist with irregular bleeding (Ettinger et al., 1998). In the
majority of cases no pathology is found (Elliott et al., 2003). In the Women's
Health Initiative study, a prospective double-blinded trial to assess the major health
benefits and risks of the most commonly used combined hormone preparations in
the USA, irregular bleeding was responsible for un-blinding in almost 40% of
women assigned to receive estrogen plus progestogen therapy (Rossouw et al.,
2002).
Irregular vaginal bleeding tends to settle with prolonged use, but since many
national guidelines now advise restricting use of HRT to less than 5 years,
unscheduled bleeding is likely to continue to be a clinical problem. There are no
established ways of predicting, avoiding or treating unscheduled bleeding on HRT
(Mossa et al., 2003; North American Menopause Society, 2003). Few studies have
addressed the potential mechanisms of HRT-induced bleeding and the underlying
mechanisms are poorly understood. Changes have been reported in endometrial
vascular density and perivascular support as well as increased numbers of stromal
natural killer cells and an altered balance of matrix metalloproteinases to their
tissue inhibitors, which may contribute to vascular breakdown and unscheduled
bleeding in some HRT users (Hickey et al., 2005; Hickey et al., 2008; Hickey et
al., 2006). Human endometrium is a target for steroid hormones. Endometrial
shedding and repair are considered inflammatory processes and sex steroids and
glucocorticoids, acting via their receptors, are thought to play a vital role in the
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processes involved (Jabbour et al., 2006). Sex steroid receptor expression
undergoes significant changes in regular cycling women, after treatment with
exogenous estrogens and progestogens and in the presence or absence of
breakthrough bleeding (Jabbour et al., 2006; Milling-Smith and Critchley, 2005).
Both endometrial estrogen and progesterone receptors (ER and PR) are up-
regulated in stromal and glandular cells during the proliferative phase and
subsequently downregulated in the glandular compartment during the secretory
phase (Chauchereau et al., 1992). PR expression persists in the stromal cells in the
secretory phase. PR protein has not been identified in the endometrial vascular
endothelium (Krikun et al., 2005). Progesterone receptors are, however, abundantly
expressed in the perivascular endometrial cells throughout the cycle (Perrot-
Applanat et al., 1988; Critchley et al., 2001). Both forms of the ER are expressed
in the perivascular cells, but only ER(t is present in endometrial endothelial cells
(Critchley et al., 2001). Endometrial stromal and endothelial cells express the GR
(Bamberger et al., 2001; Henderson et al., 2003). During the menstrual cycle, the
AR is expressed in endometrial stromal cells and intensity of AR immunostaining
is greater during the proliferative as compared to the secretory phase (Mertens et
al., 2001; Burton et al., 2003; Slayden et al., 2001b).
The aim of this study was to investigate whether a relationship exists between
endometrial steroid receptor expression and bleeding patterns in HRT users.
5.2 Methods
The women included in this study represent a subset from a larger study of
bleeding mechanisms on HRT from the Menopause Clinic at King Edward
Memorial Hospital (KEMH, Perth, Western Australia) between 2003 and 2005
(Hickey et al., 2005; Hickey et al., 2006). The study was approved by the
institutional ethics committee of King Edward Memorial Hospital, WA, Australia
and all subjects provided informed consent. The endometrial samples for this study
were obtained in the Menopause clinic at King Edward Memorial Hospital, Perth,
Western Australia. Endometrial biopsies obtained with the Pipelle* endometrial
sampling device (Pipelle de Cornier, Laboratoire CCD, Paris, France) were used.
Biopsies were fixed immediately in 10% formalin for 18 hours and tissue was then
138
embedded in paraffin. Sections were cut at 5 pm. The sections were dried at 37°C
overnight. All biopsies had a standard haematoxylin and eosin section submitted to
an experienced histopathologist for classification according to Noyes criteria
(Noyes et al., 1950) and for identification of any pathological features. The
immunohistochemical analysis of these biopsies was carried out in the Centre for
Reproductive Biology, University of Edinburgh, UK.
Thirty-eight endometrial biopsies were obtained from 21 postmenopausal women.
Biopsies were obtained from seven postmenopausal women with at least 12 months
of amenorrhoea who had not been exposed to any hormonal treatments in the
previous 90 days. These latter postmenopausal subjects, not receiving HRT, were
included as controls for comparative purposes of the effects of HRT exposure on
the postmenopausal endometrium. A further 31 biopsies were obtained from 14
postmenopausal women using continuous combined HRT. Eleven women gave
multiple biopsies (Table 5.1). Multiple biopsies were obtained in order to compare
sex steroid receptor expression during and outside a bleeding episode in the same
subject.
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Table 5.1 Detailed breakdown of numbers of biopsies provided by all women
taking part in this study












Biopsies with adequate tissue for analysis were selected to represent the clinical
categories of no HRT use (Group 1), HRT use with no bleeding (Group 2), HRT
use with irregular bleeding (Group 3) and HRT use with irregular bleeding
biopsied during a bleeding episode (Group 4) (Table 5.2). One endometrial biopsy
was excluded as this was reported to be a benign polyp. A detailed medical history
including bleeding patterns and current and previous HRT use was obtained from
all the women. Bleeding diaries were prospectively completed over a 90-day
reference period and bleeding patterns classified as either 'no bleeding' or 'irregular
bleeding'. Irregular bleeding was defined as any vaginal bleeding occurring in
postmenopausal continuous combined HRT users after at least 3 months of HRT
use. The study was restricted to those women using oral or transdermal HRT and
the range of products used are documented in Tables 5.3 and 5.4. Women were
excluded if they were taking any herbal or other therapy that might alter
endometrial histology.
Compliance with the HRT medication was monitored during this period and
women were excluded if they did not take their HRT preparation strictly according
to the manufacturer's instructions (daily for oral preparations or twice-weekly for
transdermal preparations). Those with irregular bleeding were asked to contact the
research nurse during bleeding episodes so that biopsies could be obtained both
during and outside bleeding episodes. Irregular bleeding in HRT users was
investigated according to standard hospital protocols. In brief, a Pap smear was
obtained and transvaginal pelvic ultrasound arranged. If the endometrial thickness
was <6 mm, an endometrial biopsy was obtained to assess histology. If the
endometrium was >6 mm, hysteroscopy and endometrial biopsy were performed.
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Table 5.2 Group numbers and definitions











1 7 No No No 7
2 8 Yes No No 9
3 9 Yes Yes No 12
4 9 Yes Yes Yes 10
Total 38
Table 5.3 Estrogen and progestogen components of hormone replacement therapy
(HRT) preparations used
Estrogen Biopsies (rt) Progestogen Biopsies (n)
Oral estradiol lmg 11 Duphaston 10 mg 4








Premarin 0.625 mg 3 Provera 5mg 11
Premarin 1.25 mg 2 Provera 10 mg 1













Group 1 Women in Group 1 were not using HRT at the time ofbiopsy
Group 2 Women using HRT with no history of bleeding
LYCA Transdermal Estradiol 50gg Norethisterone 250gg
MAJO Transdermal Estradiol 50gg Norethisterone 250gg
HIYO Oral Estradiol 2mg Cyproterone acetate
5mg
JABO Oral Estradiol lmg MPA 5mg
JUTO Transdermal Estradiol 50pg Norethisterone 250gg
ANFA Oral Estradiol lmg MPA 5mg




Group 3 Women using HRT with a history of bleeding, Endometrial
biopsy conducted out with a bleeding episode
LYCA Transdermal Estradiol 50gg Norethisterone 250gg




MAAN Transdermal Estradiol 50pg Norethisterone 250gg




LAEL Oral Estradiol lmg Dydrogesteronel Omg
MAPA Oral Estradiol lmg Dydrogesterone 1 Omg
DOBA Oral Estradiol 2mg MPA 5mg
Group 4 Women using HRT with a history ofbleeding, Endometrial
biopsy conducted during a bleeding episode
SASI Transdermal Estradiol 50gg Norethisterone 250gg
LYCA Transdermal Estradiol 50pg Norethisterone 250gg




MAAN Transdermal Estradiol 50gg Norethisterone 250pg




DOBA Oral Estradiol 2mg MPA 5mg
MAPA Oral Estradiol lmg Dydrogesterone 1 Omg
MPA - Medroxyprogesterone acetate
143
5.2.1 Immunohistochemistry
Immunostaining for the tissue localisation of each steroid receptor was performed
separately. Standard immunohistochemistry protocols were used as described in
section 3. Paraffin-embedded tissue sections were dewaxed, rehydrated and an
antigen retrieval step performed to expose the epitope (steroid receptor protein)
under study. The sections were transferred into a Bond® automated
immunohistochemistry staining system (Vision BioSystems, Newcastle upon Tyne,
UK). The immunostaining procedures were performed as described previously
(Henderson et al., 2003; Burton et al., 2003). The antigen-antibody complex was
detected using a high-contrast polymer that included diaminobenzidine to identify
positive immunoreactivity as indicated by presence of brown staining on tissue
sections. Table 5.5 summarises the conditions for immunolocalisation of each of
the epitopes studied.
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Scoring and analysis of immunoreactivity
The immunostaining intensity of epitopes in all tissue sections was assessed in a
standard semi-quantitative manner on a four-point scale: 0 = no immunostaining, 1
= mild immunostaining, 2 = moderate immunostaining and 3 = intense
immunostaining. All tissue sections were scored blind by two observers. This
scoring system has been previously validated in a subset of tissue sections in which
immunoreactivity was measured with a computerized image analysis system and a
strong correlation between quantitative data derived from image analysis and
subjective scores by a trained observer was obtained (Wang et al., 1998).
Statistics
Multiple measurements on the same subjects in the same group were averaged
before analysis. Wilcoxon signed-ranks tests were used for comparisons between
Groups 3 and 4 for which the measurements were made on biopsies from the same
subjects, while the other five pair-wise comparisons of groups (i.e. Group 1 vs
Group 2, Group 1 vs Group 3, etc.) were made using Mann-Whitney tests since all
subjects in Groups 1 and 2 differed from all those in Groups 3 and 4. Two subjects
contributed data to both Groups 1 and 2, and their measurements were excluded
from the comparison of these two groups. Dunn's multiple comparison correction
was then applied to the p values from each set of six tests.
5.3 Results
Endometrial biopsies were separated into four groups on the basis of bleeding
patterns. Of the 38 biopsies analysed, seven were from postmenopausal women not
using HRT (18%, Group 1), nine were from continuous combined HRT users with
no bleeding in the previous 3 months (24%, Group 2), 12 were from continuous
combined HRT users with a history of irregular bleeding in the previous 3 months
(31%, Group 3) and 10 were from HRT users with irregular bleeding biopsied
during a bleeding episode (26%, Group 4) (Table 5.2). The median age of women
not using HRT was 52 years (interquartile range (IQR) 45-57, range 47-67 years).
The median age of women on HRT was 54 years (IQR 53-57, range 42-62 years)
and the median duration of HRT use was 34 months. There were no statistically
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significant differences between the ages of HRT users and non-users (p = 0.445),
time since menopause or body mass index of women between the groups. All HRT
users were taking continuous combined HRT but as in normal clinical practice they
were using a range of products (Table 5.4).
5.3.1 Endometrial histology
Of the 38 biopsies examined, 22/38 (58%) were classified as weakly proliferative,
14/38 (37%) were classified as atrophic, one appeared decidual and one appeared
secretory. No relationship was observed between the histological appearance and
bleeding patterns or to the type of estrogen or progestogen in the HRT used.
5.3.2 Immunohistochemistry
Immunoexpression of PR, GR, AR, ERa and ERJ3 at five cellular locations (i.e. in
the endometrial glands, stroma, surface epithelium, vascular endothelium and in
perivascular cells) was examined.
PR immunoexpression (Figures 5.1,5.2(a), Table 5.6)
No PR expression was observed in the vascular endothelium and perivascular cells
in any of the biopsies.
In the absence of HRT: moderate to intense PR expression was seen in the
endometrial glands, stroma and surface epithelium.
In the HRT-treated endometrium: in all endometrial biopsies performed outside a
bleeding episode, strong immunoexpression was observed in the endometrial
glands, stroma and surface epithelium. The least amount of glandular PR
expression was observed in women where the endometrial biopsy was taken during
a bleeding episode. In comparison to biopsies from women with no bleeding,
biopsies performed during a bleeding episode showed a strong trend (non¬
significant) towards down-regulation of endometrial glandular PR expression (p =
0.064). The surface and glandular epithelia showed identical trends, while the
stroma showed no differences between groups.
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Figure 5.1 Semi-quantitative immunoreactivity scores in endometrial cellular
compartments in 4 groups of women. Box-and-whisker plots: box represents the
25th and 75th percentiles, whiskers represent the 10th and 90th percentiles and the
heavy bar represents the median. NB: The n numbers represent the total number of
biopsies studied in each group. The n numbers vary because in some biopsies that
particular cell type was not reliably identified.
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Figure 5.2(a) Immunohistochemical localisation of steroid receptors in human
menopausal endometrium. Positive immunoreactivity showing localisation of
steroid receptor protein is indicated by brown staining. (A) PR immunostaining in
endometrium from women on HRT with no bleeding (Group 2). Note high level of
glandular immunoreactivity. (A) Inset: PR negative control - no immunoreactivity.
(B) PR immunostaining in endometrium from women on HRT with bleeding,
biopsy conducted during a bleeding episode (Group 4) demonstrating decreased
glandular immunoreactivity. (C) GR immunostaining in endometrium from women
on HRT with no bleeding (Group 2) illustrating down-regulation of glandular
immunoreactivity. (C) Inset: GR negative control - no immunoreactivity. (D) GR
immunostaining in endometrium from women on HRT with bleeding, biopsy
conducted during a bleeding episode (Group 4) displaying increased glandular
immunoreactivity. Note positive immunostaining in endothelial cells (arrow).
Scale Bar = 50 microns. G=Glands, S=Stroma, SE=Surface Epithelium
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Figure 5.2(b) Immunohistochemical localisation of steroid receptors in human
menopausal endometrium. Positive immunoreactivity showing localisation of
steroid receptor protein is indicated by brown staining. (A) AR immunostaining in
endometrium from women not on HRT with no bleeding (Group 1). Note low level
of immunoreactivity in glands and stroma. (A) Inset: AR negative control - no
immunoreactivity. (B) AR immunostaining in endometrium from women on HRT
with bleeding, biopsy conducted during a bleeding episode (Group 4) illustrating
low immunoreactivity in glands, stroma and surface epithelium.
Scale Bar = 50 microns. G=Glands, S^Stroma, SE=Surface Epithelium
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Table 5.6 Values ofp from the 90 statistical tests performed3
Tissue Comparison PR GR AR ERa ERp
Glandular 1 v 2 0.90 1.00 0.29 1.00 0.69
1 v3 0.86 0.94 0.39 0.53 0.76
1 v4 0.44 0.28 0.46 0.33 0.47
2 v 3 0.54 0.47 0.68 0.47 0.96
2 v 4 0.064* 0.087* 0.68 0.30 0.81
3 v 4 0.256* 0.10 0.93 0.70 0.70
Stroma 1 v 2 0.34 0.20 0.89 0.73 0.66
1 v3 0.36 0.90 0.46 0.90 0.92
1 v4 0.61 0.62 0.95 0.61 0.76
2 v 3 0.95 0.27 0.69 0.84 0.74
2 v 4 0.69 0.57 0.95 0.76 0.81
3 v 4 0.47 0.58 0.52 0.46 0.18
Surface
Epithelium
1 v2 0.41 0.73 0.90 1.00 1.00
1 v3 0.44 0.90 0.09 0.35 0.84
1 v 4 0.11 0.22 0.18 0.21 0.84
2 v 3 0.68 0.76 0.11 0.35 0.84
2 v 4 0.06 0.12 0.14 0.21 0.76
3 v 4 0.12 0.17 0.74 0.76 0.32
aFigures shown are uncorrected P-values from Mann-Whitney or Wilcoxon rank
sum tests comparing each pair of study groups except for those asterisked (*) for
which Dunn's correction was applied because the uncorrected p values were
significant.
AR, androgen receptor; ERa, estrogen receptor a; ERfi estrogen receptor fi; GR,
glucocorticoid receptor; PR, progesterone receptor
152
GR immunoexpression (Figures 5.1, 5.2(a), Table 5.6)
In the absence of HRT: GR expression in the endometrial glands was negligible.
Mild to moderate GR immunoreactivity was observed in the stroma, endothelium
and surface epithelium.
In the HRT-treated endometrium: In biopsies obtained during a bleeding episode,
a non-significant trend towards greater GR expression was observed in the
endometrial glands compared to subjects with no bleeding (p = 0.087). The stromal
expression of GR was variable. The immunoexpression in surface epithelium was
mild to moderate in all groups of women, and more intense in the endothelium.
Presence or absence of HRT, vaginal bleeding and the timing of the biopsy had no
impact on the GR immunoexpression in the vascular endothelium and surface
epithelium.
AR immunoexpression (Figures 5.1,5.2(b), Table 5.6)
In all the biopsies, AR expression in the endometrial perivascular cells and vascular
endothelium was negligible.
In the absence of HRT: mild AR expression was observed in the endometrial
glands and stroma. AR expression in the surface epithelium was moderate.
In the HRT-treated endometrium: AR expression in the endometrial glandular
epithelium and stroma in all groups of women was consistently at a low level.
Estrogen receptor a and {J expression (Figures 5.1, Table 5.6)
In the absence of HRT: moderate to intense immunoreactivity for ERa and ERp
was observed in the endometrial glands, stroma, perivascular cells and surface
epithelium. Only ER|3 immunostaining was present in vascular endothelial cells.
In the HRT-treated endometrium: In all the groups of women, consistently strong
ERa and ERp. expression was observed in the endometrial glandular epithelium,
stroma and the surface epithelium.
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5.4 Discussion
This study provides a detailed description of PR, GR, AR, ERa and ERp. receptor
protein expression in endometrial cell components (glands, stroma, surface
epithelium, perivascular and endothelial cells) of postmenopausal HRT users.
Steroid receptor expression has been described in the context of bleeding patterns
reported by subjects. No significant differences in steroid receptor expression in
endometrium of women using HRT who report unscheduled bleeding episodes
were demonstrated. Interesting trends (non-significant) in endometrial expression
of glandular PR (decrease) and GR (increase) in postmenopausal HRT users who
report unscheduled bleeding have however been observed. These patterns of steroid
receptor expression in HRT users (with and without unscheduled bleeding) differ
from those seen in premenopausal women using progestogen-only contraception,
with bleeding from an apparently 'atrophic' endometrium. Different mechanisms
are therefore likely to underlie abnormal bleeding in postmenopausal HRT users.
Perhaps because of technical difficulties in obtaining endometrial samples in the
menopause, is there a paucity of data on steroid receptor expression in
postmenopausal endometrium. Comparatively, pre-menopausal endometrium has
been better characterized. Ideally it would not be appropriate to compare pre¬
menopausal endometrium with postmenopausal endometrium due to a
fundamentally different hormonal milieu. However, in the absence of
postmenopausal data, the only comparisons that can be made are in situations
where the postmenopausal hormonal manipulation is likely to lead to an equivalent
pre-menopausal state. There are data to suggest that continuous combined HRT use
leads to a predominantly progestogenic effect on the endometrium (Wells et al.,
2002). The equivalent pre-menopausal endometrial phase would be the secretory
phase.
All HRT users in this study were using continuous combined HRT. Therefore, it
would be expected to find similar steroid receptor changes as those in the secretory
phase of the normal menstrual cycle. In the latter, there is a down-regulation of
ERa in the glands and stromal cells and of PR in glandular epithelium (Critchley et
al., 2001). The endogenous and exogenous hormonal milieu in postmenopausal
HRT users is, however, quite different from that seen in the secretory phase in
154
premenopausal women where the specific sequential pattern of ovarian steroid
production is tightly regulated. An interesting, albeit non-significant, observation
was that with HRT, strong immunoexpression of PR in endometrial glands was
maintained but in the presence of reported unscheduled bleeding glandular PR
expression declined. Unlike the premenopausal state, in the postmenopausal
untreated endometrium, strong glandular PR expression is maintained. In the
absence of significant circulating levels of progestogens, the progestogenic
stimulus to the endometrium is negligible. In regular cycling women, PR is down-
regulated in the glandular compartment during the secretory phase by progesterone
acting at both the transcriptional and post-transcriptional level (Jabbour et al.,
2006; Chauchereau et al., 1992). Since these were observational studies, it is not
possible to confirm whether the reduction in PR was a cause or a result of
unscheduled bleeding, or if present whether the PR is functional. In premenopausal
women using long-acting progestogen-only contraceptives (POC), a decrease in PR
is observed even after short-term use of progestogen but this has not been shown to
relate to bleeding patterns (Critchley et al., 1998b; Hurskainen et al., 2000). In
depot medroxyprogesterone acetate users, stromal PR is reported to be reduced in
those with irregular bleeding (Chotnopparatpattara et al., 2003). Another
interesting observation was the absence of PR expression in the perivascular cells
in all studied biopsies. No perivascular PR expression was observed irrespective of
the presence or absence of HRT and with or without bleeding. This observation
appears to be a feature of postmenopausal endometrium in contrast to
premenopausal endometrium since, in the premenopausal state, at least in women
with regular cycles, progesterone receptors are abundantly expressed in the
perivascular endometrial cells throughout the cycle (Perrot-Applanat et al., 1988;
Critchley et al., 2001).
The mechanisms of bleeding with both POC and HRT are not fully understood but
the endometrial changes associated with bleeding in HRT users appear to show
some differences to those seen in younger women with progestogen-related
irregular bleeding, suggesting that different mechanisms may be involved (Hickey
et al., 2006; Hickey et al., 2003). Dahmoun and colleagues have reported that PR
expression in the epithelium and stroma is unchanged before and during HRT
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administration in subjects with no bleeding (Dahmoun et al., 2004). The findings in
the present study are in agreement with this report, with an added advantage of
samples from subjects with irregular bleeding patterns and also biopsies
specifically obtained during a bleeding episode. The results from the present study
thus add to the body of knowledge that bleeding episodes in HRT users are
associated with distinct endometrial changes. Changes have previously been
reported in endometrial leukocyte populations during bleeding in HRT users with
an increase in uterine natural killer cells (Hickey et al., 2005) and changes in
stromal expression of matrix metalloproteinases and their tissue inhibitors (Hickey
et al., 2006; Hickey et al., 2001).
GR expression in endometrium is normally localised to stromal and endothelial
cells (Bamberger et al., 2001; Henderson et al., 2003). The role for GR and
glucocorticoids in human endometrium has not been defined. Increased GR
expression may potentiate effects of endogenous/locally derived Cortisol thus
suppressing angiogenesis (Narvekar et al., 2006; Small et al., 2005) and
aggravating potential for unscheduled bleeding. Augmented local Cortisol action
may also disturb local endometrial prostaglandin production. Prostaglandins play
an important role in endometrial bleeding (Baird et al., 1996). Disturbance in the
balance of local factors maintaining endometrial blood vessel integrity and stability
could be another possible mechanism responsible for unscheduled bleeding.
In postmenopausal endometrium studied here there were no differences in AR or
ER (a and p) expression, irrespective of presence or absence of HRT and bleeding
pattern. In postmenopausal untreated endometrium, Dahmoun and colleagues
observed high levels of ERa expression in glandular epithelium but with HRT
treatment a decrease in expression was seen (Dahmoun et al., 2004). In the present
study, no down-regulation of expression of ERa or ERp. in either glandular or
stromal cells was observed after HRT exposure. Presence or absence of bleeding
also did not make any significant difference to endometrial ER (ERa or ERP)
expression. Dahmoun and colleagues used only two preparations of HRT in their
study (Dahmoun et al., 2004). Five different continuous combined HRT
preparations were used as a part of this study. This may have contributed to the
differences in these findings. Alternatively it may suggest variable functional
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alterations of ER and PR in the postmenopausal endometrium during exposure to
differing hormonal preparations.
It is acknowledged that the sample size in this present study is small. A reason why
so few studies have addressed the mechanisms of irregular bleeding in HRT users
is that adequate endometrial samples from postmenopausal women with no
endometrial pathology and a thin endometrium can be extremely difficult to obtain.
Furthermore, obtaining samples during a bleeding episode requires particular
vigilance and a high level of compliance amongst postmenopausal women.
A variety of HRT preparations were used by the women taking part in this study.
This may have influenced the endometrial cellular response. Nevertheless, irregular
bleeding is common to all HRT preparations and hence it is reasonable to work on
the assumption that common mechanisms may underlie these phenomena.
Conclusions
The present study of endometrial steroid receptor expression and bleeding patterns
in HRT users has failed to demonstrate significant differences in steroid receptor
protein expression in those women who report unscheduled bleeding episodes.
These observations differ from the endometrial steroid receptor expression
observed with normal menstruation and long-term progestogen-only
administration, suggesting that different local mechanisms are involved in HRT-
related bleedings. Interesting trends (non-significant) however have been observed
in endometrial expression of glandular PR (decrease) and GR (increase) in
postmenopausal HRT users who report unscheduled bleeding. These observations
warrant further investigation among a larger group of HRT users with an
endometrial biopsy during a bleeding episode to explore the mechanisms
underlying problematic unscheduled bleeding. It is unlikely that effective strategies
for the treatment or prevention of abnormal bleeding on HRT will be developed
unless the underlying local mechanisms are understood.
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CHAPTER 6
Intrauterine release of progesterone antagonist ZK230211




Unscheduled breakthrough bleeding (BTB) associated with the use of progestin-
only contraception remains a major problem, often resulting in poor compliance
and discontinuation of progestin-only contraceptive methods (Dugoff et al., 1995;
Kovacs, 1996). Intrauterine release of levonorgestrel (LNG) by means of the LNG-
releasing -intrauterine system (LNG-IUS) is highly effective for contraception as
well as for the treatment of heavy menstrual bleeding (monorrhagia) (Andersson et
al., 1994; Luukkainen and Toivonen, 1995; Hurskainen et al., 2004). However,
initiation of LNG-IUS treatment is associated with a high incidence of BTB, which
typically resolves following the first few months of LNG-IUS use (Andersson et
al., 1994; Hurskainen et al., 2004).
The effects on the endometrium of continuous administration of progesterone
antagonists (PAs) such as mifepristone and ZK137316 have been evaluated both in
women (Baird et al., 2003a; Brown et al., 2002; Narvekar et al., 2004) and in non-
human primates (Wolf et al., 1989; Slayden and Brenner, 1994; Slayden et al.,
1998; Slayden et al., 2001; Chwalisz et al., 2000). In humans, daily administration
of mifepristone in the doses of 2mg and 5mg was shown to induce amenorrhoea in
majority of women taking part in the study over a period of 120 days. Ovulation
was also suppressed in the majority of women however follicular activity was
maintained (Brown et al., 2002). Endometrial histology in the women taking part in
this study showed inactive proliferative or cystic changes with dense stroma. There
was a significant decrease in markers of proliferation, i.e. mitotic index and Ki67
staining (Baird et al., 2003a). In a related study there was a significant decrease in
the expression of H3 mitosis marker and progesterone receptor in endometrial
glands and stroma by day 60 of treatment with 2mg and 5mg doses of mifepristone.
In contrast, the expression of androgen receptor increased in glands, surface
epithelium, and stroma compared with the pre-treatment endometrium. These
changes were maintained at 120 days of treatment. The expression of estrogen
receptor was unchanged in stroma and surface epithelium; however, there was a
significant decrease in expression after 120 days of treatment. As androgens can
antagonize estrogen action, enhanced glandular androgen receptor expression
induced by mifepristone could play a role in its anti-proliferative effects (Narvekar
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et al., 2004). Treatment with ZK137316 upregulated the PR expression.
Furthermore, ZK137316, in the presence or absence of E2, reduces VEGF release
in fibroblast cell culture but it showed no significant effects in epithelial cell
culture. The different results for the epithelial cells and fibroblasts indicate that the
pharmacological effects of progesterone antagonists may be cell specific and
depend on the presence or absence of partial progestogenic agonistic activities
(Classen-Linke et al., 2000).
In non-human primates, PAs inhibit endometrial proliferation and induce
amenorrhoea (Wolf et al., 1989; Slayden et al., 1998; Slayden et al., 2001). When
administered chronically at relatively low doses, PAs block the mitotic activity of
endometrial epithelium and induce stromal compaction in a dose-dependent
manner in both spayed and intact monkeys (Wolf et al., 1989; Slayden and
Brenner, 1994; Slayden et al., 1998; Slayden et al., 2001; Heikinheimo et al.,
1996). As follicular development is not suppressed during PA administration
(Heikinheimo et al., 1995; Slayden et al., 2001), endometrial suppression is not
associated with a decrease in circulating levels of estradiol. Thus the mechanism of
action of endometrial suppression remains somewhat enigmatic; atrophy of the
uterine spiral arteries being a likely explanation (Chwalisz et al., 2000).
The PA ZK230211 is a highly potent PA with no progestogenic effects (Fuhrmann
et al., 2000; Slayden et al., 2001). Systemic daily administration of ZK230211 at
doses of >16 pg/kg to cynomolgus monkeys suppresses ovulation and menstruation
(Slayden et al., 2001). Similarly, intrauterine release of 3-4 pg and 26-30 pg of
ZK230211/24 h had an antiproliferative effect on primate endometrium (Nayak et
al., 2000). Thus intrauterine release ofPAs, especially ZK230211, may make them
useful in both contraception and hormone therapy for various gynaecological
indications. Specifically, endometrial suppression by means of PA-releasing IUS
might be effective in the treatment of heavy or prolonged uterine bleeding.
Moreover, a PA-IUS is likely to convert the endometrium into a non-receptive
state, which may be utilized in the development of novel contraceptive strategies.
In the present randomized, single-blinded, prospective proof-of-concept trial, the
bleeding patterns and endometrial effects of intrauterine release of the PA
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ZK230211 versus progestin LNG were evaluated in women scheduled for
hysterectomy owing to heavy or painful menstruation.
6.2 Methods
The study subjects were identified among women on waiting list for hysterectomy
at the Department of Obstetrics and Gynaecology, Helsinki University Central
Hospital. The endometrial tissue samples were obtained from women at the time of
a hysterectomy. Women scheduled for hysterectomy owing to idiopathic heavy
menstrual bleeding (menorrhagia) or painful menstruation (dysmenorrhoea)
participated in the study. The numbers of days of bleeding (requiring protection)
and spotting (no protection required) during 30-day periods preceding insertion of
the IUS, and preceding hysterectomy, were assessed from bleeding diaries. Prior to
participation, each woman signed an informed consent document. The study
protocol was approved by the Institutional Review Board of Helsinki University
Central Hospital and the Finnish National Agency for Medicines. Figure 6.1 shows
the flow of the subjects through the study.
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The criteria for inclusion in the study were written informed consent, age 30-^18
years, regular menstrual periods with cycle length between 21-35 days, length of
the uterine cavity between 6 and 10 cm and good general health. The exclusion
criteria were: endometrial polyps or hyperplasia, submucosal myoma or intramural
myoma exceeding 4 cm in greatest diameter or myoma distorting the uterine cavity,
an ovarian cyst exceeding 4 cm, epithelial cell atypia in the Pap smear, concomitant
use of an intrauterine device, history of climacteric symptoms and systemic use of
sex steroids within the last 3 months.
The experimental IUS's releasing ZK230211 (ZK-1US) at rates of 1, 4 and 8 pg/24
h were provided by Schering Ag (Berlin, Germany). The LNG-releasing IUS (20
pg/24 h; MIRENA, Schering Oy, Turku, Finland) was used as a comparator.
Similarly as for
LNG-IUS, the ZK-IUS consisted of a polyethylene body in the shape of T with a
mixture of ZK230211 and polydimethyl siloxane mounted around the vertical arm.
The dimensions of the ZK-IUS and LNG-IUS were similar (32 x 32 mm).
The women were randomized using SAS/PLAN by Schering Oy to any of the three
experimental ZK-IUS's or LNG-IUS. Investigators had a separate stock of
identically packaged IUS's and randomization numbers. However, the nature of the
IUS became apparent to the study personnel following opening of the packaging.
The IUS's were inserted between 4 and 8 weeks prior to scheduled hysterectomy.
The duration of the trial was based on previous toxicological data obtained from
non-human primates, with the drug regulatory agency permitting the study to last
up to 8 weeks. Insertion was performed between days 1 and 7 of the menstrual
cycle. Following insertion, fundal location of the IUS was verified by means of
pelvic ultrasonography.
Of the 42 women randomized, 11 women (acting as controls) were randomized to
receive LNG-IUS. Of these 2 women were excluded and hence 9 women provided
endometrial tissue for the study. Of the women randomized to receive ZK230211-
IUS, women using ZK230211-IUS lpg (n=10), ZK230211-IUS 4pg (n=ll) and
ZK230211-IUS 8pg (n=10) provided samples for the study. On the morning of
hysterectomy, the location of the IUS was again verified by means of pelvic
ultrasonography.
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The following specimens were collected just before and immediately after removal
of the uterus at hysterectomy.
1. Just prior to the surgery, a venous blood sample was collected for
determination of serum ZK230211 concentration.
2. Following surgery and collection of specimens for routine pathological
examination, separate samples of endometrium were collected from the
fundal, mid-corpus and isthmic areas of the uterus for haematoxylin and
eosin staining and immunohistochemistry (IHC).
3. Thereafter, separate samples of endometrium and myometrium were taken
for determination of ZK230211 levels. All the remaining endometrial tissue
(after the histological samples were taken) was separated and collected for these
measurements.
The primary outcome measure was assessment of endometrial morphology during
the use of ZK-IUS in comparison to that of LNG-IUS. The secondary objectives
included assessment of bleeding patterns, determination of uterine and serum
concentration of ZK230211 and evaluation of the effect of ZK-IUS versus LNG-
IUS on selected endometrial markers.
Serum and uterine tissue measurements of ZK230211
The samples were pre-prepared and sent for analysis to the analytical laboratory of
Schering AG, Berlin, Germany. A liquid chromatography mass spectrometer/mass
spectrometer method was used for the measurement of ZK230211 concentrations.
A peripheral venous blood sample was obtained prior to surgery. The lowest limit
of quantification in human serum samples was 50 pg/ml, and in the uterine tissue
samples (endometrial and myometrial), it was 10-25 ng/g.
Endometrial morphology
Endometrial morphology was assessed from haematoxylin and eosin stained tissues
taken from the fundus, corpus or isthmus. In addition to routine diagnostic analysis,
estrogenic (E) and progestogenic (P) activities were evaluated by means of the
following criteria: E0, atrophic glands; El, small single-layered glands with rare
mitosis; E2, moderately sized glands with two or three cell layers and occasional
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mitoses; E3, tortuous glands, several cell layers, easily detectable mitotic activity;
PO, no signs of a progestogenic effect; PI, basal vacuolization in most cells; P2,
dilated glands with secretory activity; P3, stromal decidualization. The combined E
and P score was assigned to one of the three categories: fully active = E2-3P0;
partially suppressed = E2-3P1-3 or E1P0-3; or fully suppressed = EO. The samples
were assessed independently by two pathologists. In cases of disagreement, a third
pathologist was included. If the hormonal effect varied between anatomical
locations, the overall result from two of the three locations (fundus, corpus or
isthmus) was taken as the consensus score.
Immunohistochemistry
Standard immunohistochemistry protocols, as described in section 3.2.1, were
followed. Tissue expression of androgen receptor (AR), progesterone receptor (PR)
and estrogen receptors alpha and beta (ERa and ERp) was assessed as described
previously (Critchley et al., 2001; Slayden el al., 2001; Henderson et al., 2003).
The proliferation markers Ki-67 and phosphorylated histone H3 (PH3) were
evaluated as described by Brenner et al. (Brenner et al., 2003) and Narvekar et al.
(Narvekar et al., 2004). Finally, insulin-like growth factor-binding protein-1
(IGFBP-1) was evaluated according to Pekonen et al. (Pekonen et al., 1992). The
antigen retrieval methods, primary antibodies and negative controls used in the
immunohistochemical analyses are summarized in Table 6.1. The amounts of the
above-mentioned epitopes were assessed by two blinded observers in a semi
quantitative manner on a 4-point scale: 0, no staining; 1, mild/minimal staining; 2,
moderate immunostaining and 3, intense immunostaining.
Statistical analysis
Statistical analyses were performed using the chi-square test, the Fisher's exact
test, the Mann-Whitney U-test or the Kruskal- Wallis test, as appropriate. A two-
tailed P-value lower than 0.05 was considered statistically significant. The
calculations were performed with StatView statistical software (SAS Institute Inc.,
Cary, NC, USA).
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Table 6.1 Summary of the antigen retrieval methods, primary antibodies and
negative controls used in various immunohistochemical analyses






















































































Two women dropped out of the study, one because of endometritis following
insertion of an LNG-IUS and another one because of epithelial cell atypia in the
Pap smear collected prior to insertion of an IUS. Thus 40 subjects completed the
study; their demographic details are shown in Table 6.2. The four groups did not
differ from each other as regards age, body mass index or uterine weight. Most
(93%) of the subjects were parous. Hysterectomy was performed abdominally in




















































































The primary outcome measure was comparison of endometrial morphology. Figure
6.2 illustrates endometrial morphology after treatment with an IUS releasing 8 pg
of ZK230211/24 h, or LNG (20 pg/24 h). Endometrial morphology differed in
relation to ZK230211 and LNG treatment. In LNG-treated endometrium, marked
stromal decidualization was seen and the morphology of the glands varied from
inactive to secretory. On the other hand, stromal decidualization was not observed
after ZK230211 treatment. The glands, in contrast, were often dilated and the
epithelial cells showed little proliferative activity and a secretory morphology.
Endometrial morphology was judged to reflect partial suppression in >2 of the 3
locations (fundus, corpus and isthmus) in 30%, 9% and 10% of women with ZK-
IUS's releasing 1, 4 and 8 pg/24 h, respectively, and in 67% of women with an
LNG-IUS. The difference in endometrial morphology was statistically significant
between the groups of women using the LNG-IUS versus ZK-IUS's releasing 4
and 8 pg/24 h (P<0.01 and P<0.02, respectively). The difference between women
with an LNG-IUS versus a ZK-IUS releasing lpg/ 24 h approached significance (P
= 0.11). A high degree of morphologically estrogenic effects (grade 3 in 60-82%)
were seen following the use of ZK-IUS's, whereas only 11% of the endometrial
specimens collected following use of an LNG-IUS displayed grade 3 estrogenic
effects. Moreover, the distribution of morphologically estrogenic effects (grade 1-2
versus 3) differed significantly between subjects using an LNG-IUS versus IUS's
releasing 1, 4 and 8 pg of ZK230211/24 h (P<0.05, P<0.002 and P<0.005,
respectively). However, morphologically progestogenic effects (grade 0-2 versus
3, or grade 0-1 versus 2-3) were not significantly different between the
endometrial specimens exposed to an LNG-IUS or any of the ZK-IUS's.
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Figure 6.2 Haematoxylin and eosin-stained human endometrium following
treatment with an IUS releasing 8 pg of ZK230211/24 h (panels on the left), and
treatment with an LNG-IUS (panels on the right). Note the stromal compaction and
non-functional secretory morphology in the glands (Non-functional secretory
morphology refers to the situation where the glands have a tortuous appearance
similar to that seen in the secretory stage but lack the functional ability of secreting
glandular secretions, as is evident particularly in the Top left figure) following
ZK230211 treatment. In LNG-treated endometrium, marked stromal




The secondary objectives included assessment of bleeding patterns, determination
of uterine and serum concentrations of ZK230211 and evaluation of the effect of
ZK-IUS versus LNG-IUS on selected endometrial markers. Figure 6.3 shows the
numbers of days of bleeding and spotting (mean + SD) during the 30-day periods
immediately preceding insertion of the IUS's, and hysterectomy. The number of
days with bleeding and spotting increased significantly in the group randomized to
the LNG-IUS (PO.Ol), whereas non-significant changes were observed in the
three groups randomized to ZK-IUS's.
6.3.3 Uterine tissue and serum concentrations of ZK230211
ZK230211 was measurable in all endometrial specimens. The mean (+SD)
endometrial concentrations of ZK230211 (per gram of tissue wet weight) were
83.7+40.6, 83.8+39.5 and 166.9+134.6 ng/g in the groups using ZK-IUS's
releasing 1, 4 and 8 pg of ZK230211/24 h, respectively. Only four subjects (one in
each group using a ZK-IUS releasing 1 and 4 mg of ZK230211, and two in the
group using an IUS releasing 8 mg of ZK230211) had measurable levels of
ZK230211 in the myometrium. The individual concentrations varied from 8.4 to
47.7 ng/g of myometrial-wet weight. However, serum concentrations of ZK230211
were below the quantification limit of the assay in all samples analysed (n = 31)
(Table 6.3).
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Figure 6.3 Days of bleeding and spotting (mean + SD) during a 30-day period
preceding (B) insertion of a ZK230211-IUS or an LNG-IUS, and preceding
hysterectomy (D) in the four experimental groups. The number of days of spotting
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6.3.4 Immunohistochemistry
Figures 6.4 and 6.5 show a summary of the various immunohistochemical analyses
performed. Staining for sex steroid receptors PR, ERa, ER(3 and AR was analysed
in endometrial glands, stroma and surface epithelium. In addition, staining for
proliferation markers phosphorylated Histone 3 and Ki-67 and decidualisation
marker IGFBP-1 was analysed separately.
Sex steroid receptors
Immunostaining for PR in endometria exposed to intrauterine ZK230211 and LNG
is illustrated in Fig. 6.4A and 6.4B, respectively. PR was not detectable in the
surface epithelium following exposure to intrauterine LNG. It was, however,
detectable in the surface epithelium following exposure to ZK230211; the
difference was significant between the groups exposed to LNG and all three doses
of ZK230211 (PO.Ol - <0.05). In endometrial glands and stroma, intense
immunoreactivity for PR was observed after intrauterine administration of
ZK230211. Immunostaining for PR in endometrial stroma differed significantly
(P<0.05) between the groups exposed to LNG and to ZK230211 at 4 pg/24 h.
Staining for ERa in both endometrial glands and stroma was similar following
intrauterine exposure to LNG and all the three doses of ZK230211 Figs. 6.4C and
6.4D. In general, immunostaining for ER(3 was more intense than for ERa.
Immunolocalization ER(S in endometria following intrauterine treatment with
ZK230211 and LNG is shown in Fig. 6.4E and F, respectively. Staining for ERfl
was intense in surface epithelium, glands and stroma following exposure to both
LNG and all three doses of ZK230211. No statistically significant differences in
ER(3 staining emerged between the endometria exposed to LNG and ZK230211.
Minimal staining for AR was detectable in the endometrial epithelium following
exposure to intrauterine LNG. No immunoreactivity for AR was detectable in
endometrial epithelium following ZK230211 (P<0.05 between groups exposed to
LNG versus ZK230211). The endometrial stroma displayed moderate




Tissue expression of the proliferation markers PH3 (Fig. 6.5C and D) and Ki-67
was weak in endometrial glands and stroma exposed to either ZK230211 or LNG.
Staining for Ki-67 and PH3 was similar irrespective of the dose of ZK230211.
When analysed semi quantitatively, the median values varied between 0 and 1, and
did not differ between the different groups.
Decidualisation marker - IGFBP-1
Figures 6.5E and 6.5F depict the results of IGFBP-1 IHC in endometria following
treatment with intrauterine ZK230211 and LNG, respectively. No immunostaining
for IGFBP-1 was observed in endometria exposed to intrauterine ZK230211.
However, IGFBP-1 was detectable in all but one of the endometrial specimens
following intrauterine LNG administration (P<0.0001).
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Figure 6.4 Immunohistochemical localization of PR, ERa and ER0 in human
endometrium. (A) PR immunostaining in endometria from women treated with
IUS's releasing 4 gg of ZK230211/24 h. Note the high level of stromal (S)
immunoreactivity (P < 0.05) and increased immunostaining in glands (G). (B) PR
immunostaining in endometria from women treated with LNG-IUS, demonstrating
low levels of stromal and glandular PR immunoreactivity. ERa immunostaining in
endometria from women treated with ZK230211 IUS releasing 4 gg of
ZK230211/24 h (C). (D) ERa immunostaining in endometria from women treated
with LNG-IUS. Staining for ERa was similar in endometrial glands and stroma
after exposure to both, ZK230211 IUS and LNG-IUS. ERp immunostaining in
endometria from women treated with IUS's releasing 8 gg of ZK230211/24 h (E),
and LNG-IUS (F). Note the high level of immunostaining at all cellular locations
following use of both ZK- and LNG-IUS. Scale bar = 10 microns.







Figure 6.5 Immunohistochemical localization of AR, PH3 and IGFBP-1 in human
endometrium. AR-stained endometrium following treatment with 8 pg of
ZK230211/24 h (A), and treatment with an LNG-IUS (B). Note moderate staining
in the stroma irrespective of the type of stimulation. PH3-stained endometrium
following treatment with 4 pg of ZK230211/24 h (C), and treatment with an LNG-
IUS (D). Note the sparse staining for PH3 and lack of proliferation. (E) IGFBP-1
immunostaining in endometria from women treated with an IUS releasing 8 pg of
ZK230211/24 h. Note no immunoreactivity at any cellular location. (F) IGFBP-1
immunostaining in endometria from women treated with LNG-IUS. Note intense
IGFBP-1 immunoreactivity in decidualized stromal cells. Scale bar = 10 microns
G = glands; S = stroma; SE = surface epithelium; En = endothelium
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The present study demonstrates that intrauterine release of the PA ZK230211 by
means of an IUS is feasible and that it results in significant endometrial levels of
ZK230211. Use of a ZK-IUS had no effect on the number of days of bleeding or
spotting, whereas an increase in uterine bleeding was noted during the short period
of exposure of the endometrium to LNG. When compared with the LNG-IUS, clear
signs of PA effects, such as maintenance of endometrial PR expression in the
glandular epithelium and lack of IGFBP-1 protein expression, were seen during the
short period of exposure to a ZK-IUS.
The present study was randomized and blinded in design. In addition, in contrast to
the majority of studies in which the endometrial effects of PA have been assessed,
the present work was performed in human subjects. A proof of concept study such
as this, with obvious restrictions as regards clinical work, can only be performed
among women presenting electively for hysterectomy. Thus a concern about
interpretation of the data is that the IUS's were tested in women presenting with
menstrual complaints and abnormal uteri. Furthermore, the study was of a
relatively short duration and some of the eventual endometrial effects associated
with both the LNG-IUS and ZK-IUS's may not be apparent until after a longer
period of exposure. Analysis of the uterine blood vessels was not included in the
present study. This is an interesting research question that should also be addressed
in future studies. As expected, the number of days of spotting and bleeding
increased following insertion of an LNG-IUS. However, the ZK-IUS's failed to
have an effect on uterine bleeding patterns reported by the women. Since
administration of PA to nonhuman primates results in a rapid induction of
amenorrhoea (Wolf et al., 1989; Slayden and Brenner, 1994; Slayden el al., 1998;
Slayden et al., 2001), the lack of an immediate effect of the ZK-IUS's on uterine
bleeding was an unexpected observation. In previous studies in which ZK230211
has been evaluated in non-human primates, ovulation and menstruation were
suppressed in a dose-dependent fashion (Slayden et al., 2001). The doses of
ZK230211 used in the present work may have been insufficient for induction of
amenorrhoea. However, in a preliminary study on non-human primates,
intrauterine release of ZK230211 at 3-4 pg/24 h resulted in marked endometrial
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suppression (Nayak et al., 2000). The difference in bleeding patterns during the use
of ZK-IUS's may be dose-related or the result of subtle differences between human
and non-human primate endometrium.
Several investigators have reported profound atrophy of the endometrial glands and
decidualization of stroma in women following use of an LNG-IUS for 3 months or
longer (Silverberg et al., 1986; Critchley et al., 1998a; Phillips et al., 2003). In the
present study, the endometrium was categorized as suppressed in two-thirds of the
LNG-IUS users. More profound suppression of the endometrium may have been
observed had the duration of intrauterine LNG administration been for a longer
period of time. Endometrial suppression, as evaluated morphologically, was weak
following administration of ZK230211. In contrast, clear morphological signs of an
estrogenic effect were evident in endometrial specimens collected following the
use of intrauterine ZK230211. This is in agreement with the results of a recent
study carried out by Baird et al. (Baird et al., 2003), in which prolonged
administration of low doses of oral mifepristone resulted in either a proliferative
condition or cystic dilatation in the majority of women. Data concerning the
morphological effects of PA, and more broadly those of selective PR modulators,
on human endometrium have only recently been reported (Chwalisz et al., 2005;
Williams et al., 2007). Categorization of the effect on the endometrium of
ZK230211 is problematic, and the nomenclature associated with morphological
events, such as estrogen or progestin-like, seen during the normal menstrual cycle,
may not be justified. Indeed, it has been recognized that use of PR modulators
leads to non-classical endometrial morphology, and new descriptions have been
developed (Williams et al., 2007).
In the present study, endometrial proliferation was assessed using IHC for both Ki-
67 and PH3. The PH3 antibody identifies chromosomes during mitosis in cultured
cells or whole mounts, thus providing accurate information about cellular
proliferation (Brenner et al., 2003). The immunoreactivity of these was negligible
in both endometrial epithelial and stromal cell compartments following intrauterine
delivery of LNG and ZK230211. Similarly, Hurskainen et al. (Hurskainen et al.,
2000) reported that endometrial staining for Ki-67 was weak during the use of an
LNG-IUS. Previous studies concerning the effects of administration of PAs on
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endometrial expression of Ki-67 have also been reported. Low levels of Ki-67
immunostaining were seen during administration of mifepristone at doses of 2 or 5
mg for 120 days in female volunteers (Baird et al., 2003). In non-human primate
endometrium, however, Ki-67 levels comparable to those seen in proliferative
phase endometrium were detected following systemic administration of ZK230211
in cynomolgous monkeys undergoing artificial cycles (Slayden et al., 2001). As
regards PH3 immunolabelling, a significant decrease in the expression of PH3 has
been reported in human endometrium following chronic low dose administration of
mifepristone (Narvekar et al., 2004).
Down-regulation of endometrial ER and PR is a well characterized progestin
effect, and is observed with intrauterine administration of LNG (Critchley et al.,
1998b; Hurskainen et al., 2000). In the present study, PR were down regulated both
in the surface epithelium and in the stroma of the endometria exposed to LNG
when compared with endometria exposed to ZK230211. As observed in nonhuman
primate endometrium, endometrial PR levels were maintained during PA
administration (Slayden et al., 1993). The present data on PR expression in
endometrium exposed to intrauterine PA are consistent with the PA nature of
ZK230211. Endometrial expression of both ERa and ERp was similar to the use of
either an LNG-IUS or a ZK-IUS. This contrasts with the effects of ZK230211 on
primate endometrium, in which systemic administration of ZK230211 counteracted
the effects of progesterone, resulting in up-regulation of ERa (Slayden et al.,
2001).
Expression of AR is down regulated in secretory phase human endometrium and in
endometria collected from women using an LNG-IUS (Burton et al., 2003). In
contrast, PA-induced suppression of endometrial growth is associated with up-
regulation of endometrial AR in non-human primates (Brenner and Slayden, 2005)
and in women (Narvekar et al., 2004). Furthermore, antagonism of androgen action
by co-administration of flutamide to PA-treated cynomolgous monkeys has been
reported to result in loss of endometrial suppression (Brenner et al., 2003). These
data suggest that androgen action in essential for the suppressive effects of PAs on
the endometrium. In the present study, expression of AR in the glandular
epithelium was minimal among the subjects exposed to intrauterine ZK230211
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administration. This lack of up-regulation of AR may explain in part the lack of
endometrial suppression following intrauterine delivery of ZK230211.
The endometrial content of IGFBP-1 is increased in human secretory phase and
decidualized endometrium (Rutanen et al., 1984a; Rutanen et al., 1984b).
Similarly, addition of progestins to cultures of human endometrial tissue explants
has been reported to increase the synthesis of IGFBP-1 (Bell et al., 1991; Gao et
al., 1994). Endometrial exposure to LNG results in strong expression of
endometrial IGFBP-1 (Pekonen et al., 1992). Thus, sequestration of IGF action as a
result of elevated tissue content of IGFBP-1 has been proposed as one of the
mechanisms explaining endometrial suppression during use of an LNG-IUS
(Rutanen et al., 1997). In the present study, strong expression of IGFBP-1 protein
was evident in the specimens collected from women treated with an LNG-IUS.
However, IGFBP-1 was not detectable in any of the endometrial specimens
collected from women using ZK-IUS's. It is possible that in the absence of IGFBP-
1, IGF actions on the endometrium are maintained, which may contribute to the
endometrial morphology observed during use of a ZK-IUS. Such data further
confirm the PA action of ZK230211 on the human endometrium.
Conclusions
This study demonstrates that the effects of intrauterine release of the PA,
ZK230211, and the progestin LNG, on the endometrium, differ. Endometrial
proliferation is a function of mitotic activity in the endometrial epithelium. In
general, progesterone antagonists, when administered chronically at relatively low
doses, have been found to block mitotic activity of endometrial epithelium and
induce stromal compaction thereby suppressing endometrial proliferation.
However, such endometrial suppression following administration of ZK230211
was negligible. In the current study, ZK230211 was administered for a relatively
short duration of time and this may be a contributory factor. Nonetheless, even
after relatively short term use, lack of proliferative activity was evident in
endometria from women exposed to ZK230211. A high level of endometrial PR
expression as well as lack of IGFBP-1 protein expression following intrauterine
administration of ZK230211 confirms the PA nature of ZK230211 action on the
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human endometrium. Since the LNG-IUS has also been demonstrated to have lack
of endometrial proliferative effects, it is likely that the clinical effects of
intrauterine delivery of ZK230211 and LNG, on the human endometrium are
probably mediated via different molecular and cellular mechanisms. The clinical






This thesis is based on three studies predominantly evaluating endometrial steroid
receptor expression after pharmacological exposure to three different but very
pertinent clinical scenarios. It provides further clarification on endometrial
characteristics at the time of embryo implantation in IVF/ICSI treatment cycles,
during break-through bleeding in postmenopausal HRT treated endometrium and
during treatment of premenopausal heavy menstrual bleeding. All studies were
carried out on endometrium from human subjects.
The indications for assisted conception technologies are broadening. The treatment
regimes commonly employ gonadotrophins, their analogues and antagonists to
achieve various effects. In the context of IVF treatment, recent data show reduced
pregnancy rates after treatment with a GnRH antagonist. The effects of GnRH
antagonists could be mediated directly through the GnRH receptor, which has been
localised in the endometrium or they may be mediated indirectly via the hormonal
fluctuations that may lead to alteration in the expression of steroid receptors or
indeed through an alteration in the intracrine modulation thereby affecting ligand
availability within the endometrial cell.
In the first study included in this thesis, it is demonstrated that, in endometrium
exposed to Gonal-F® (a recombinant - FSH preparation) and cetrorelix (a GnRH
antagonist), significant down-regulation of PR protein expression occurs in the
endometrial stroma and surface epithelium (Vani et al., 2007). PR down-regulation
in the surface epithelium is thought to be under the influence of progesterone and
PR is known to decline at the beginning of the window of implantation. It therefore
appears that any hormonal fluctuations that may result in the serum due to
treatment with cetrorelix and Gonal-F® have little impact on intracellular PR in
surface epithelium. In the secretory phase of a normal menstrual cycle, significant
PR expression has been detected in the endometrial stroma. Several genes have
been localized to the endometrial stroma and are expressed during the secretory
phase. Studies have also shown an important role for progesterone in the
endometrial stromal cell in induction of extracellular matrix in relation to
implantation. A significant down-regulation of stromal PR, as observed after
exposure to rFSH and a GnRH antagonist, could thus influence gene expression
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during the secretory phase or indeed have an influence on the modulation of
extracellular matrix.
After exposure to cetrorelix and Gonal-F®, PR was significantly up-regulated in the
perivascular cells (Vani et al., 2007). PR protein has not been identified in the
vascular endothelium, but they are abundantly expressed in the perivascular cells
throughout the menstrual cycle. Vascular proliferation and restructuring are
important functions of secretory phase endometrium and progesterone acting on the
perivascular cells has been implicated in the modulation of endometrial blood flow.
Furthermore, cytokine control in the perivascular cells is thought to be controlled
by progesterone.
Thus it is evident that there are significant alterations in PR expression after
exposure to a GnRH antagonist and rFSH. As described above, there are a variety
of possible mechanisms through which these factors could impact on the processes
of embryo implantation and on pregnancy rates in IVF cycles. No significant
differences were observed in the protein expression of ERa, ERJ3, AR, 3pHSD or
170HSD5 (Vani et al., 2007).
Flaving established the PR protein alterations under the effect of rFSH and GnRH
antagonist, it would be interesting to evaluate whether this translated into
transcriptional changes. Hence quantitative PCR studies were undertaken. The
results were disparate. Quantitatively, there was a significant reduction in the levels
of ERa mRNA and AR mRNA but no changes in the ERp mRNA transcripts. PR
mRNA was reduced after treatment but the difference was not significant (Vani et
al., 2007). PR mRNA levels are known to vary during the menstrual cycle. The
reason for the discrepancy between protein expression and mRNA expression is
unclear but this phenomenon has been reported by other researchers. Changes in
PR in whole biopsies may not reflect the subtle changes in steroid receptor
expression that exist between individual ceil types. Regarding ER, despite
controlled ovarian hyperstimulation that is known to lead to supraphysiological
levels of E2 and progesterone, no significant differences were observed in the
immunoexpression of ERa or ERP in treated women (Vani el al., 2007). Even ER
are thought to affect the endometrial receptivity through the predominantly
progestational effects of endometrial phase advancement and premature
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luteinization. Hence, it appears that ER-mediated signalling appears to be of less
importance in relation to implantation compared with PR mediated effects on the
endometrium. It is interesting to note however that quantitative RT-PCR showed
significantly reduced ERa mRNA levels in the treatment group (Vani et al., 2007).
AR is expressed in the endometrial stromal cells. The intensity of expression
declines from proliferative phase to mid-secretory phase. No significant differences
in protein expression of AR were observed in women treated with rFSH and a
GnRH antagonist. However, QRT-PCR showed significantly reduced AR mRNA
levels in the group of women treated with a GnRH antagonist and rFSH (Vani et
al., 2007). So far, there are very limited data on effects of AR and AR-induced
gene expression in humans. Studies in pigs show AR in the pig endometrium
during the window of implantation and demonstrate the functional, albeit complex,
interactions of androgens and estrogens in the regulation of uterine endometrial
gene expression and cell growth in vitro. Further studies are needed to evaluate
AR-induced gene expression in humans and the potential impact on embryo
implantation.
In summary, the protein and mRNA expression data thus far appear to show that
the endometrial effects are mediated through progesterone acting on the stromal
and peri-vascular PR with little influence of ER mediated signalling.
Having gathered data regarding the receptor expression and mRNA transcript
profile, it becomes important to understand the intracellular changes in ligand
availability. Endometrial intracrinology was studied by evaluating the 170
hydroxysteroid dehydrogenases and the 30 hydroxysteroid dehydrogenase
enzymes, well recognised members in the intracrine cascade. In this study,
irrespective of presence or absence of treatment, no significant differences were
observed in endometrial 30HSD immunoexpression between the two groups of
women (Vani et al., 2007). This suggests that the pre-ovulatory supraphysiological
levels of estrogen and progestogen that result from COH and use of GnRH
antagonists do not lead to any significant alteration in the levels of 30HSD protein
during the window of implantation. The currently available antibody against
30HSD recognizes both forms of human 30HSD enzymes, types 1 and 2. Hence it
is not possible to comment on changes in the amounts of 30HSD1 protein.
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However, RNA studies indicate that 30HSD1 mRNA transcripts may be changing.
A significant reduction in 3PHSD1 mRNA was observed in women treated with a
GnRH antagonist and rFSH (Vani et al., 2007). The 3|3HSD is responsible for the
conversion of inactive pregnenolone to active progesterone and of
dehydroepiandrosterone to androstenedione. A reduction in 3pHSDl transcripts
will ultimately lead to a reduction of intracellular progesterone. In the presence of
altered PR expression, as was observed with IHC, it is likely that the reduced
ligand availability for binding to PR leads to a disturbance in the dynamics of
ligand-receptor interaction. This may affect progesterone mediated signalling
pathways including alterations in gene expression profiles thereby affecting the
receptivity of the endometrium.
The 17pHSD enzymes are involved in the reactions catalyzing the activation and
inactivation of androgens and estrogens. The 17pHSD5 transforms androstenedione
to testosterone and also progesterone to the inactive 20-hydroxyprogesterone. The
17pHSD2 is involved in the inactivation of E2 to estrone and converting androgens
to less potent forms. A significant reduction of 17PHSD2 mRNA was observed in
women treated with rFSH and a GnRH antagonist (Vani et al., 2007). Since
17pHSD2 is involved in the inactivation of E2 to estrone and converting androgens
to less potent forms, it is likely that higher levels of intracellular E2 and androgens
persist thereby further disturbing the balance between estrogen, progesterone and
androgens. This may further affect the endometrial development leading to
suboptimal endometrial receptivity.
The first study included in this thesis has addressed one of the vital functions of the
endometrium, that of embryo implantation. Another important aspect of
endometrial function is its response to postmenopausal hormone therapy and this
has been a matter of great interest in the last several decades. Postmenopausal
hormone replacement therapy is widely used. However, breakthrough bleeding
(BTB) on HRT, causes of which are unknown, is a common problem in all HRT
users. It is recognised that altered endometrial blood vessels, MMP's and their
tissue inhibitors, changes in endometrial leucocyte populations and uterine natural
killer cells have a role in HRT related BTB. However the exact role of steroid
receptors in BTB is unclear. A detailed description of steroid receptors; PR, GR,
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AR, ERa. and ERp. receptor protein expression in endometrial cell components
(glands, stroma, surface epithelium, perivascular and endothelial cells) of
postmenopausal HRT users is vital to understand the causes of BTB and to develop
treatment strategies to prevent this unwanted side effect. In the second study
included in this thesis, steroid receptor expression has been described in the context
of bleeding patterns reported by subjects, with a particular advantage of inclusion
of endometrial biopsies obtained at the time of a bleeding episode.
All HRT users in the said study were using continuous combined HRT, which has a
predominantly progestogenic effect on the endometrium. Hence one would expect
to see progestational change in the endometrium, likely mimicking the secretory
phase of a normal menstrual cycle or changes similar to those seen in women using
progestogen only contraception. The endogenous and exogenous hormonal milieu
in postmenopausal HRT users is, however, quite different from that seen in the
secretory phase in premenopausal women where the specific sequential pattern of
ovarian steroid production is tightly regulated. Significant differences in steroid
receptor expression have not been observed in endometrium of women using HRT
who report unscheduled bleeding episodes. Interesting trends (non-significant)
were observed in endometrial expression of glandular PR (decrease) and GR
(increase) in postmenopausal HRT users who report unscheduled bleeding. There
were no differences in AR or ER (a and P) expression, irrespective of presence or
absence of HRT and bleeding pattern (Vani et al., 2008). These patterns of steroid
receptor expression in HRT users (with and without unscheduled bleeding) differ
from those seen in premenopausal women using progestogen-only contraception,
with bleeding from an apparently 'atrophic' endometrium. Absence of significant
differences assumes a special importance not least due to the dissimilarities noted
between what is expected and what was observed. Hence it seems likely that
different mechanisms underlie abnormal bleeding in postmenopausal HRT users.
An interesting, albeit non-significant, observation was that with HRT, strong
immunoexpression of PR in endometrial glands was maintained but in the presence
of reported unscheduled bleeding glandular PR expression declined. Unlike the
premenopausal state, in the postmenopausal untreated endometrium, strong
glandular PR expression is maintained (Vani et al., 2008). In regular cycling
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women, PR is down-regulated in the glandular compartment during the secretory
phase by progesterone.
Another interesting observation was the absence of PR expression in the
perivascular cells in all studied biopsies. No perivascular PR expression was
observed irrespective of the presence or absence of HRT and with or without
bleeding (Vani et al., 2008). This observation appears to be a feature of
postmenopausal endometrium in contrast to premenopausal endometrium since, in
the premenopausal state, at least in women with regular cycles, progesterone
receptors are abundantly expressed in the perivascular endometrial cells throughout
the cycle.
Inflammation has been proposed as a possible contributory factor in BTB with or
without exposure to HRT. With this in mind, GR expression was analysed in the
postmenopausal endometrium. Endometrium GR is normally localised to stromal
and vascular endothelial cells. Increased GR expression may potentiate effects of
endogenous/locally derived Cortisol thus suppressing angiogenesis and aggravating
potential for unscheduled bleeding. Augmented local Cortisol action may also
disturb local endometrial prostaglandin production. Disturbance in the balance of
local factors maintaining endometrial blood vessel integrity and stability could be
another possible mechanism responsible for unscheduled bleeding.
In the study included in this thesis, five different preparations of continuous
combined HRT preparations were used. This may have contributed to the
differences in these findings. Nevertheless, irregular bleeding is common to all
HRT preparations and hence it is reasonable to work on the assumption that
common mechanisms may underlie these phenomena. Alternatively it may suggest
variable functional alterations of ER and PR in the postmenopausal endometrium
during exposure to differing hormonal preparations.
Having dealt with the questions of steroid receptor expression in mid-luteal
endometrium in the context of embryo implantation and then postmenopausal
endometrium in the context of BTB, attention was directed to another vital
endometrial function; menstruation. Menstrual dysfunction is one of the
commonest complaints in gynaecology. Progestogens are commonly used for the
treatment of menstrual disorders but all progestogens have a common side effect -
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breakthrough vaginal bleeding. The levonorgestrel -IUS is no exception to this
annoying side effect and a significant proportion of users have the IUS removed as
a result of this problem. Progesterone antagonists (PA) have been proposed as
alternatives since, in animal studies, use of PA-IUS has resulted in complete
amenorrhoea with endometrial suppression without suppressing ovarian hormonal
activity.
The third study included in the thesis is a proof of concept study. Here, expression
of sex steroid receptors PR, ERa, ERp and AR; proliferation markers PH3 and Ki-
67 and decidualisation marker IGFBP-1 was evaluated. Intrauterine release of the
PA ZK230211 appears to be feasible and it results in significant endometrial levels
of ZK230211. When compared with the LNG-IUS, clear signs of PA effects, such
as maintenance of endometrial PR expression in the glandular epithelium and lack
of IGFBP-1 protein expression, were seen during the short period of exposure to a
ZK-IUS (Heikinheimo et al., 2007).
As expected, the number of days of spotting and bleeding increased following
insertion of an LNG-IUS. However, the ZK-IUS's failed to have an effect on
uterine bleeding patterns reported by the women (Heikinheimo et al., 2007). Since
administration of PA to nonhuman primates results in a rapid induction of
amenorrhoea, the lack of an immediate effect of the ZK-IUS's on uterine bleeding
was an unexpected observation. The doses of ZK230211 used in the present work
may have been insufficient for induction of amenorrhoea. The difference in
bleeding patterns during the use of ZK-IUS's may be dose-related or the result of
subtle differences between human and non-human primate endometrium.
In relation of steroid receptors, down-regulation of endometrial ER and PR is a
well characterized progestin effect and is observed with intrauterine administration
of LNG. In the present study, PR were down regulated both in the surface
epithelium and in the stroma of the endometria exposed to LNG when compared
with endometria exposed to ZK230211 (Heikinheimo et al., 2007). The present
data on PR expression in endometrium exposed to intrauterine PA are consistent
with the PA nature of ZK230211. Endometrial expression of both ERa and ERP
was similar to the use of either an LNG-IUS or a ZK-IUS (Heikinheimo et al.,
2007). This contrasts with the effects of ZK230211 on primate endometrium, in
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which systemic administration of ZK230211 counteracted the effects of
progesterone, resulting in up-regulation of ERa.
Previous studies assessing AR expression suggest that androgen action is essential
for the suppressive effects of PAs on the endometrium. In the present study,
expression of AR in the glandular epithelium was minimal among the subjects
exposed to intrauterine ZK230211 administration (Heikinheimo et al., 2007). This
lack of up-regulation of AR may explain in part the lack of endometrial
suppression following intrauterine delivery of ZK230211.
Endometrial proliferation was assessed using IHC for both Ki-67 and PH3. The
immunoreactivity of these was negligible in both endometrial epithelial and
stromal cell compartments following intrauterine delivery of LNG and ZK230211
(Heikinheimo et al., 2007). Previous studies in women have shown low levels of
Ki-67 immunostaining during administration of mifepristone however in non-
human primate endometrium, Ki-67 levels comparable to those seen in
proliferative phase endometrium were detected following systemic administration
of ZK230211. As regards PH3 immunolabelling, a significant decrease in the
expression of PH3 has been reported in human endometrium following chronic low
dose administration of mifepristone.
The endometrial content of IGFBP-1 is increased in human secretory phase and
decidualized endometrium. Endometrial exposure to LNG results in strong
expression of endometrial IGFBP-1. Thus, sequestration of IGF action as a result
of elevated tissue content of IGFBP-1 has been proposed as one of the mechanisms
explaining endometrial suppression during use of an LNG-IUS. In the present
study, strong expression of IGFBP-1 protein was evident in the specimens
collected from women treated with an LNG-IUS. However, IGFBP-1 was not
detectable in any of the endometrial specimens collected from women using ZK-
IUS (Heikinheimo et al., 2007). It is possible that in the absence of IGFBP-1, IGF
actions on the endometrium are maintained, which may contribute to the
endometrial morphology observed during use of a ZK-IUS. Such data further
confirm the PA action of ZK230211 on the human endometrium.
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Conclusions:
This thesis adds to our understanding of sex steroid receptor expression in relation
to three important clinical areas pertaining to the endometrium i.e. embryo
implantation, menstrual bleeding and postmenopausal hormone therapy related
breakthrough bleeding. All these clinical scenarios have, at the biological level,
involvement of sex steroid receptors and other factors in a complex cascade of
events. The above studies show that whilst steroid receptors have a role to play in
each situation, the interactions are complex. They also suggest that receptor activity
and effects may be species specific, may vary with age and the nature and duration
of pharmacological stimulus. To understand the functional significance of the
steroid receptors, specific questions will need to be addressed in focussed studies.
With further clarity of endometrial steroid receptor function, there is potential for
developing clinically effective interventions.
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7.2 Suggestions for future studies
This thesis encompasses 3 studies analysing the endometrium under the effects of
different pharmacological interventions. These are in relation to 3 clinical scenarios
however through these studies the hope was to gain further understanding of the
modulation of the local endometrial steroid milieu.
Endometrium in embryo implantation
In comparison to physiological mid-luteal endometrium, it has been demonstrated
that with exogenous administration of a GnRH antagonist and recombinant FSH,
there are alterations in the sex steroid receptor expression and in the intracellular
expression of steroid metabolizing enzymes. These changes may lead to alterations
in the activity and the intracellular availability of the ligands.
• This sample size in this study was small and in the first instance it would be
interesting to undertake a similar study on larger number of women to
confirm these findings.
• Alterations in the steroid receptor expression have been observed and it
would be interesting to see if these led to morphometric changes in the
various cellular compartments in the mid-luteal endometrium.
• In the recent past, in relation to embryo implantation, the focus of research
has shifted to gene array studies. It is recognised that sex steroids,
predominantly acting on the endometrial stromal cells, have a significant
influence on the gene profiles and an alteration of the ligand availability
may have a significant impact on the gene profile in the mid-luteal phase.
Gene micro-array studies would be useful to assess the impact of rFSH and
GnRH antagonist exposure on mid-luteal endometrium.
• Ultimately it would be interesting to analyse the impact of these
observations on embryo implantation and pregnancy rates in IVF cycles
Endometrium andpost-menopausal hormone replacement therapy
Hormone replacement therapy users frequently suffer from unscheduled
breakthrough bleeding. The mechanisms are unclear. Interesting trends, albeit non¬
significant in this small study, have been demonstrated in endometrial expression
of glandular PR and GR in postmenopausal HRT users who report unscheduled
bleeding. The steroid receptor expression observed in women on continuous
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combined HRT was dissimilar from women on long-term progestins. Hence it
appears that different mechanisms apply in HRT related unscheduled bleeding.
• The observed trends in the GR expression raise interesting questions about
a possible mechanism related to the inflammation pathway. If indeed the
GR expression findings are confirmed in a larger study then further studies
should be directed to evaluating the inflammatory markers in the
postmenopausal endometrium.
• Another interesting observation was the downward trend of PR in glands. It
is unclear whether this was a cause or effect of the breakthrough bleeding.
Quantitative evaluation of PR mRNA and intracrine studies might clarify
whether this observation is due to a reduction in transcription or as a result
of a fall in ligand availability.
• A very interesting feature in all postmenopausal endometrial samples was
the absence of PR expression in the perivascular cells. This raises
interesting questions about the vascular function of the putative 'atrophic'
endometrium.
Endometrium and Anti-Progestin Intrauterine System
This study has demonstrated that intrauterine release of ZK230211 is feasible.
• Perhaps due to the short time duration of the study, the use of ZK-IUS did
not show any effects on the number of days of bleeding or spotting. Hence
in the first instance, studies need to be carried out over a longer period of
time.
• In non-human primate studies, ZK-IUS, even at the doses used in this
study, showed a rapid induction of amenorrhoea. This was not seen in the
current study and one of the possible explanations is that the dose required
to achieve amenorrhoea in humans may be different. Having established
the feasibility of the use of a ZK-IUS, further studies need to identify the
optimum effective dose of the ZK-IUS in humans to achieve satisfactory
suppression of ovulation and menstruation without leading to a hypo-
estrogenic state.
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• In relation to the bleeding, analysis of the uterine blood vessels was not
included in the present study. This is an interesting research question that
should be addressed in future studies.
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Appendix I: Source of General Materials
Tissue Collection Supplier
Neutral Buffered Formalin (NBF) See Appendix: Recipes
Paraformaldehyde (PFA) See Appendix: Recipes
Pipelle Suction Curette Laboratoire CCD, Paris, France
TP 1050 Tissue Processor Leica Corp., UK
RNA Extraction Supplier




Chloroform Sigma, Poole, Dorset, UK
Isopropranolol Sigma, Poole, Dorset, UK
Ethanol (Molecular Biology Grade) BDH Laboratory Supplies, Poole, UK
RNA Storage Solution Ambion Inc., Austin, Texas, USA
Phase Lock Gel Tubes Eppendorf, Hamburg, Germany
Real Time QRT-PCR Supplier
DNAse Amplification Kit Invitrogen Life Tech, Paisley, UK
Taqman Reverse Transcription Reagents AB Applied Biosystems, Cheshire, UK
Taqman Master Mix Stratagene, Amsterdam, Netherlands
Ribosomal RNA Control Reagents AB Applied Biosystems, Cheshire, UK
Primers/ Probe Sets for Sequences Biosource, Nivelles, Belgium
ABI Prism 7700 AB Applied Biosystems, Cheshire, UK
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Immunohistochemistry Supplier
Histoclear Nat. Diagnostics, Atlanta, Georgia,
USA
Phosphate Buffered Saline (PBS) See Appendix II
PBS+Tween 20 See Appendix II
Tris Buffered Saline (TBS) See Appendix II
TBS+Tween 20 See Appendix II
Hydrogen Peroxide Solution 30% BDH Laboratory Supplies, Poole, UK
Sodium Citrate See Appendix II
Pressure Cooker Clipso, Tefal, Nottingham, UK
Avidin/Biotin Blocking Kit Vector Laboratories, Peterborough, UK
Non Immune Horse Serum (Vectastatin) Vector Laboratories, Peterborough, UK
Bovine Serum Albumin Sigma, Poole, UK
Biotinylated Horse anti-Mouse Antibody Vector Laboratories, Peterborough, UK
Avidin Biotin Peroxidase Complex Vector Laboratories, Peterborough, UK
3,3' Diaminobenzidine Dako, Cambridge, UK
Harris Haematoxylin Pioneer Research Chemicals,
Colchester, UK
Xylene BDH Laboratory Supplies, Poole, UK
Pertex Cellpath Pic, Hemel Hempstead, UK
Image Analysis System Improvision Inc., Lexington, MA, USA
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Appendix II: Recipes for Solutions
4% Paraformaldehyde (PFA)
Weight/Volume Chemical Name Supplier
4g Paraformaldehyde Sigma
100ml PBS (See Below) Sigma
Heat at 60°C
Store at 4°C and use within 7 days
4% Natural Buffered Formalin (NBF)
Weight/Volume Chemical Name Supplier
6.5g Na2HP04 BDH
4.5g Na2HP04.2H20 BDH
100ml 40% Formaldehyde BDH
900ml Distilled Water
0.01M Phosphate Buffered Saline (PBS) pH 7.4
Weight/Volume Chemical Name Supplier
5 Tablets PBS Sigma
1000ml Distilled Water
0.01M Phosphate Buffered Saline+Tween (PBST) pH 7.4
Weight/Volume Chemical Name Supplier
5 Tablets PBS Sigma
1000ml Distilled Water
8g NaCl BDH
lOOgl Tween 20 Sigma
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0.5M Tris Buffered Saline (TBS)
Weight/Volume Chemical Name Supplier
60.55g Trizma Base Sigma
700ml Distilled Water
pH to 7.4 and make up to 1000ml with Distilled Water
Dilute 1:10 for working 0.05 Solution and add 8.5g NaCl/litre
0.5M Tris Buffered Saline+Tween 20 (TBST)
Weight/Volume Chemical Name Supplier
60.55g Trizma Base Sigma
700ml Distilled Water
pH to 7.4 and make up to 1000ml with Distilled Water
Dilute 1:10 for working 0.05 Solution and add 8.5g NaCl/litre
Add lOOpl/L Tween 20
0.1M Sodium Citrate
Weight/Volume Chemical Name Supplier
29.41g Tri-Sodium Citrate BDH
O.lg Sodium Azide Sigma
700ml Distilled Water
pH to 6.0 and make up to 1000ml with Distilled Water
Dilute 1:10 for working 0.01M Solution
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